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Cardiovascular disease (CVD) encompasses all disorders associated with the heart 
and vascular system. It includes many serious disorders such as stroke, heart failure 
and myocardial infarction and as such is the leading cause of death globally1. Fur-
thermore, CVD also has a considerable financial burden in the Western society with 
for example a projected medical cost of 1.1 trillion dollar in the United States in 
20351. The vast majority of CVD deaths can be attributed to coronary artery disease 
and stroke of which atherosclerosis is the main underlying cause. Atherosclerosis 
is a multifactorial disease with a long list of known risk factors. While some of 
these risk factors are fixed (i.e. gender, genetics, age), other risk factors, including 
smoking, excessive alcohol use, an unhealthy diet and physical inactivity are largely 
lifestyle-dependent. Greater understanding and improved management of these risk 
factors has resulted in a strong decline in CVD mortality since the 1970s. Nonethe-
less, the decline is stagnating in the last few years and it has been shown that risk 
factor control does not eliminate CVD1,2. In fact, the most successful treatments 
so far have been plasma lipid lowering, which leads to a 30% reduction in relative 
risk of cardiovascular disease. In addition, it has been estimated that by 2035 ap-
proximately 45% of all United States adults will have some form of CVD due to the 
rapid increase in the number of old and obese people1. These data clearly indicate 
that there is an urgent need for novel strategies to improve the prevention and 
treatment of atherosclerosis.
Atherosclerosis
Atherosclerosis is primarily characterized by the build-up of fatty material in the 
innermost layer of vessel walls. This process of arterial wall thickening was long 
considered as a normal and non-pathological consequence of aging. However, in the 
early 20th century several cardinal studies introduced the concept of atherosclerosis 
and the essential role of cholesterol in driving atherosclerosis3. Since then, the 
research community has devoted large efforts in elucidating the pathophysiology of 
atherosclerosis. This has led to a much greater understanding of the molecular and 
cellular intricacies in atherosclerosis, however this extended knowledge has not yet 





Atherosclerosis is a chronic and slowly developing process. Lesion development 
often starts in an individual’s teenage years which is typically without any clinical 
manifestation4. The formation of early lesions is closely linked with endothelial 
dysfunction, which primarily occurs in areas with disturbed local blood flow5. For 
this reason, lesions are often found within inner curvatures of arteries, where there 
is minimal shear stress, or at bifurcations, where blood flows oscillatory. The com-
bination of local changes in blood flow with high levels of circulating cholesterol 
in the form of (very) low-density lipoproteins (VLDL and LDL) induces endothelial 
damage and/or activation6. This subsequently results in an increased permeability 
and expression of adhesion molecules on the endothelium. As a consequence, the 
presence of high amounts of plasma VLDL and LDL leads to passive diffusion of 
these lipoproteins through the now permeable endothelium7. In the vessel wall, 
lipoproteins undergo interactions with proteoglycans and are chemically modified8. 
The latter is considered a key step in the development of atherosclerosis, since 
modified LDL (e.g. oxidized LDL) further induces the endothelial cells to express 
adhesion molecules, chemokines and growth factors. The cumulative effect of the 
different processes is an increase of monocytes into the vessel wall9. In response to 
secreted growth factors, such as macrophage colony stimulating factor, monocytes 
Figure 1. Development of atherosclerosis. Following endothelial damage, lipoproteins accumulate in 
the subendothelial space. Monocytes and macrophages are recruited to this early lesion and take up 
large amounts of cholesterol giving rise to fatty streaks. After failed clearance of the accumulated cho-
lesterol and lipoproteins, more and more immune cells accumulate in the artery wall. Subsequently, 
smooth muscle cells are recruited which form a fibrous cap. The progression from an established le-
sion to a vulnerable plaque includes the thinning of the fibrous cap and the presence of large necrotic 
areas. Eventually, the cap can erode or rupture giving rise to a thrombus and the occurrence of acute 
clinical events. Adapted with permission from Moore KJ, Tabas I. Cell 2011;145:341–355.
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locally differentiate into macrophages and upregulate their expression of scavenging 
receptors. Predominantly via these receptors, macrophages are efficient phagocytes 
and start clearing the vessel wall of the fatty material. This results in one of the 
hallmarks of early stage atherosclerosis; the presence of foam cells. Through the 
uptake of cholesterol esters, macrophages acquire a “foamy” look under the elec-
tron microscope and are thus called foam cells. The initial accumulation of foam 
cells results in a low-grade inflammation and a thin intimal cell layer known as fatty 
streaks10. This early immune response initially protects against further accumulation 
of immune cells and cholesterol. In fact, when combined with sufficient cholesterol 
lowering, these early lesions can still fully regress11. Nonetheless, in most situations 
early lesions will eventually evolve into advanced lesions.
Advanced lesions
The formation of advanced lesions is primarily a result of an unrestrained immune 
response. Due to the constant accumulation of fatty material in the vessel wall, mac-
rophages are unable to cope with the increased burden. This results in apoptosis of 
macrophages, which is a programmed cell death response12. The effective removal 
of apoptotic cells by phagocytes occurs through a process called efferocytosis. 
Since macrophages are the predominant phagocytes in atherosclerotic lesions, the 
removal of apoptotic macrophages is largely dependent on the availability of vi-
able macrophages. Hence, there is a very delicate balance between the number of 
apoptotic macrophages and the number of efferocytosis-mediating macrophages13. 
During atherosclerosis development, this balance is eventually disturbed due to the 
cholesterol overload. The failure of effective efferocytosis results in an accumula-
tion of cellular debris, secondary necrosis and the leakage of cytoplasmic contents 
from dying macrophages, which all contributes to the formation of necrotic cores13. 
At this point, the ongoing lesional inflammation also results in the recruitment of 
other immune cells, such as neutrophils, dendritic cells and T cells, of which most of 
them perpetuate the ongoing inflammation. In addition, the local immune response 
also activates smooth muscle cells in the media, after which they migrate towards 
the intima. Smooth muscle cells produce extracellular matrix components such as 
collagen-rich fibers that stabilize the lesion14,15. Additionally, some smooth muscle 
cells rapidly proliferate and migrate towards the lumen side of the lesion to form a 
protective fibrous cap16,17. The combination of a thick fibrous cap and the presence 
of collagen is initially able to stabilize the lipid-rich necrotic areas and patients with 
well-stabilized lesions can be asymptomatic for years18. However, the next stage of 
atherosclerosis is destabilization of the lesion which is clinically the most important 
and obvious stage19. Several important aspects of lesion destabilization include 
thinning of the fibrous cap and lesion neovascularization. The precise mechanisms 
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behind thinning of the fibrous cap are not yet known, however it is believed that it is 
eventually due to increased apoptosis of the smooth muscle cells forming the cap18. 
The process of neovascularization is initiated due to the hypoxic areas in the lesion 
and destabilizes the lesion in several ways20. Firstly, more immune cells are able to 
infiltrate the lesion via the newly formed blood vessels21. Secondly, the microvessels 
are often poorly formed which can result in intraplaque hemorrhages19. This latter 
results in the rapid accumulation of lesional erythrocytes and appears to be a critical 
contribution to lesion destabilization19.
Clinical events
Unrestrained progression of a lesion will eventually result in clinical manifesta-
tions22. Due to increased lesion volume, arteries can become stenotic, obstructing 
normal blood flow. Depending on the site of lesion, this may manifest itself in 
different symptoms such as chest pain in coronary artery stenosis23. More acute 
cardiovascular events occur when unstable lesions erode or rupture, resulting in 
the formation of a thrombus. A thrombus can completely block blood flow and give 
rise to different cardiovascular complications, including stroke and heart attacks, 
depending on the tissue or organ affected23. For these advanced stages, several 
surgical strategies are available. For example, via an endarterectomy the complete 
lesion is surgically removed 24. Other options include a vascular bypass operation25 
and balloon angioplasty to restore normal blood flow26. However, all of these op-
tions have major drawbacks. The most prominent one is the increased possibility 
of restenosis due to the endothelial damage and local inflammation inflicted by 
the surgical procedures27. Hence, prevention of atherosclerosis and the associated 
clinical events remains the most favorable option, however effective therapeutic 
options to do so are still scarce.
Experimental models of atherosclerosis
Due to the multifactorial character of atherosclerosis, the current ex vivo and in vitro 
models are insufficiently able to mimic the full spectrum of the disease pathology. 
Hence, to unravel the complex nature of atherosclerosis and to find novel thera-
peutic targets, the use of experimental animal models is still absolutely necessary. 
While zebra fish, rats, rabbits and non-human primates have been used, the most 
commonly used animal species for atherosclerosis research is the mouse28. Mice are 
easy to genetically modify and breed, hence, they are ideally suited for experimental 
research. However, in contrast to humans, mice are very resilient against athero-
sclerosis and do not spontaneously develop this disease even when given a high 
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cholesterol diet. Thus two genetic knock-out models are now frequently used; apo-
lipoprotein E-deficient (ApoE-/-) mice and low-density lipoprotein receptor-deficient 
(Ldlr-/-) mice. Both ApoE-/- and Ldlr-/- mice have a deficiency in lipid metabolism, 
which renders them susceptible to atherosclerosis development. While ApoE-/- mice 
spontaneously develop lesions on a normal chow diet, Ldlr-/- mice need to be fed a 
Western-type diet, which is high in fat and cholesterol content. The resulting ath-
erosclerosis is relatively similar in these mice, however the nature of the atherogenic 
processes can substantially differ, which should be taken in consideration during 
experimental design29.
Another model uses perivascular collars and induces site-specific lesions in the 
carotid artery. Silastic tubes are placed around the common carotid arteries which 
induces turbulent blood flow proximal to the collar. This disturbance in blood flow 
induces rapid lesions in combination with a Western-type diet in both ApoE-/- and 
Ldlr-/- mice30.
A more novel approach is to use an adeno-associated virus with a gain-of-function 
for proprotein convertase subtilisin/kexin type 9 (PCSK9)31. Overexpression of 
PCSK9 effectively results in a largely similar phenotype as Ldlr-/- mice, since PCSK9 
targets the LDLR for degradation32. Since this requires only a single injection of 
virus, this novel method might eliminate the need for laborious breeding schemes 
to generate double knock-out mice.
Lipids in atherosclerosis
It is not surprising that the two most extensively used animal models are based on 
deficiencies in lipid metabolism, mimicking human familial hypercholesteremia. As 
discussed, the influence of cholesterol on atherosclerosis was already clearly estab-
lished in the early 20th century. While cholesterol has an important physiological 
function in cell membrane structure33 and steroid hormone production34, excessive 
plasma levels have a strong correlation with atherosclerosis35,36. Circulating levels 
of cholesterol originate in part from dietary cholesterol, however the great major-
ity of cholesterol is endogenously produced in the liver37. Since cholesterol is only 
minimally soluble in water, it is mainly transported by lipoproteins. Thus after it is 
released by the liver, cholesterol is mostly associated with VLDL. However, VLDL is 
also rich in triglycerides and its main function is to transfer triglycerides to tissues 
through the action of lipoprotein lipase. VLDL that is stripped of its triglycerides 
is a more dense particle (IDL) and is converted by hepatic lipase into LDL. Cells 
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obtain cholesterol through the LDLR, which binds circulating LDL and internalizes it 
through endocytosis. Subsequently, the cholesterol will be released internally and 
the LDLR is recycled and migrates back towards the cell surface. Circulating levels 
of lipoproteins are under strict control of hepatic expression of lipoprotein receptors 
(i.e. LDLR) which can bind both to ApoE in VLDL and to ApoB in LDL. Hence, genetic 
deficiency in either ApoE or LDLR results in unregulated levels of LDL and VLDL as 
seen in the experimental mouse models. Interestingly, while both VLDL and LDL are 
considered “bad cholesterol”, a third lipoprotein, HDL, is often considered as “good” 
cholesterol38. HDL is involved in the reverse cholesterol transport from peripheral 
tissue to the liver. Not surprisingly, high plasma levels of HDL have been associated 
with decreased cardiovascular risks39. Given the well-defined associations of VLDL/
LDL and HDL with CVD, the lipid metabolism pathway has been an extensively 
investigated therapeutic target. Indeed, reducing VLDL/LDL by inhibition of hepatic 
cholesterol synthesis by statins has proven to significantly reduce cardiovascular 
risks. In contrast, therapeutic strategies to increase HDL have not been very suc-
cessful. Quite recently, a next generation of lipid-lowering drugs that target PCSK9 
have entered the market. As discussed, PCSK9 binds to the LDLR and targets it for 
degradation32. PCSK9 inhibitors effectively prevent this process, which results in 
higher numbers of hepatic LDLR, which enables them to clear more circulating cho-
lesterol. Several phase III clinical trials have recently been performed demonstrating 
that PCSK9 inhibitors indeed decrease the serum cholesterol levels and the risk of 
cardiovascular events40. Nonetheless, statins have been widely available for the last 
decades and we have seen a cardiovascular relative risk reduction of approximately 
30%. The additional value of PCSK9 inhibitors has to be evaluated in the coming 
years, but it is clear that other processes than lipid metabolism contribute to ath-
erosclerosis and CVD.
The immune system and atherosclerosis
In general, the immune system can be divided into two main arms; the innate and 
adaptive immune system. Cells of the innate immunity include neutrophils, mono-
cytes, macrophages and dendritic cells. These cells quickly respond to pathogens 
and danger signals and act as a first-line of defense. Recognition of non-self antigens 
happens through pattern recognition receptors which recognize a broad range of 
antigens. Macrophages and dendritic cells are able to internalize and present these 
antigens to cells of the adaptive immune system; B and T cells. The adaptive immune 
system response is slower, however, the reaction is antigen-specific and results 
in immunological memory formation, which can result in long-lasting protection 
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against pathogens. This concept of memory formation is effectively harnessed in 
modern-day vaccination strategies.
The notion that the immune system is involved in atherosclerosis is not new. Rudolf 
Virchow already observed the inflammatory nature of atherosclerotic plaques in 
the 19th century41. His modern vision, however, was mostly ignored after the role 
of cholesterol and lipids was clearly established. For almost a century, atheroscle-
rosis was mainly regarded as an entirely lipid-driven disease41. In the meantime, 
the general understanding of the immune system strongly increased and since the 
1990s the contribution of the immune system to atherosclerosis gained a lot more 
attention. Nowadays, atherosclerosis is termed as a chronic inflammatory disease42 
and the recently finished CANTOS trial unmistakably demonstrated that therapeu-
tic intervention in the immune response can result in cardiovascular protection43. 
However, there is a large variation in the individual contribution of immune cell 
subsets with both pro- and anti-atherogenic effects. Although the role of neutro-
phils44, mast cells45, eosinophils46, NKT cells47, NK cells48, MDSCs49 and ILCs50 is 
outside the scope of this thesis, it should be noted that all of these cells influence 
atherosclerosis development. The role of monocytes, macrophages, dendritic cells, 
T cells and B cells will be further outlined below.
Monocytes
Monocytes are innate immune cells that develop in the bone marrow before be-
ing released into the circulation. They are relatively short-lived and either re-enter 
the bone-marrow or migrate into inflamed tissues after several days. Based on 
the expression pattern of CD14 and CD16, three human monocyte subsets have 
been determined; classical (CD14++CD16–), non-classical (CD14+CD16+) and inter-
mediate monocytes (CD14++CD16+)51. Classical monocytes are the most abundant 
monocytes, infiltrate inflamed tissues and can differentiate into non-classical and 
intermediate monocytes52. Non-classical monocytes patrol healthy endothelium 
and rapidly respond to tissue injury53. The intermediate monocytes represent the 
smallest population of monocytes and can secrete large amounts of TNF-α54. The 
gene expression profile of intermediate monocytes overlaps largely with that of 
classical monocytes and both can predict cardiovascular events55,56. In mice two 
monocyte subsets have been identified, Ly-6Chi and Ly-6Clo which are similar to 
classical/intermediate monocytes and non-classical monocytes respectively57. In 
general, it is believed that circulating monocytes represent a general population by 
which inflamed tissue are rapidly infiltrated58. It has been shown that in response to 
high cholesterol levels, the number of monocytes strongly increases59. This is due 
to both an increase in monocyte generation from precursors in the bone marrow as 
Chapter 1
16
well as increased recruitment of monocytes from the bone marrow60. Additionally, 
in atherosclerosis the activated endothelium results in a rapid infiltration of Ly-6Chi 
inflammatory monocytes into the vessel wall59. Interestingly, this is one of the cru-
cial steps in the initiation of atherosclerosis, while its contribution to established 
atherosclerosis seems minimal61. Nonetheless, the constant recruitment of Ly-6Chi 
monocytes from the bone marrow and deposition into the lesion has been shown 
to greatly influence lesion size62. Particularly since the majority of these Ly-6Chi 
monocytes differentiate into macrophages in the lesion59.
Macrophages
As mentioned, macrophages are crucial in the development of atherosclerosis. 
Multiple studies have shown that the absence of macrophages significantly reduces 
atherosclerosis severity61,63,64. However, the classical concept of macrophages as 
passive lipid collectors in the lesion has certainly been changed41. We now know 
that macrophages are very versatile immune cells that display a large degree of 
plasticity65. Naïve macrophages (M0) are very sensitive for local inflammatory 
mediators and can polarize into a number of subsets. This is not a terminal dif-
ferentiation, since changes in the micro-environment can stimulate macrophages 
to repolarize66,67. This makes it difficult to describe the effects of each subset on 
atherosclerosis, since the macrophage phenotype is continuously shifting. Adding 
to the complexity, lesional macrophages share many markers with dendritic cells 
and smooth muscle cells68,69. Nevertheless, mainly based on in vitro experiments, 
different classifications of macrophages have been made65. In experimental sys-
tems, M1 macrophages can be generated by stimulation with LPS and IFN-γ. These 
macrophages initiate a strong pro-inflammatory response with the secretion of 
IL-1β, IL-12 and TNF-α. Additionally they produce chemokines, such as MCP-1, to 
further increase the recruitment of monocytes. Hence, these M1 macrophages have 
a markedly pro-inflammatory response in order to kill pathogens upon infection 
and are thus termed classical macrophages. Non-classical macrophages include M2 
macrophages, which can be polarized from M0 macrophages by IL-4 and IL-13. The 
immune response of M2 macrophages is in stark contrast to M1 macrophages, with 
the secretion of inflammation-resolving cytokines such as IL-10 and TGF-β. Pure 
M1 and M2 macrophage subsets might not be present in atherosclerotic lesions, 
but this classification has given a lot more insight in the differential function of 
macrophages in atherosclerosis65. For instance, it is believed that in early lesions the 
majority of macrophages has a M2 phenotype which switches towards M1 during 
disease progression66. In addition, M2 macrophages are found more frequently in 
plaques of asymptomatic patients, while M1 macrophages are more abundant in 
plaques from patients that suffered an acute ischemic attack70. In functional assays, 
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M1 macrophages indeed have shown to secrete matrix metalloproteases which sig-
nificantly add to the vulnerability of a lesion by breaking down extracellular matrix 
proteins71. They have also shown increased uptake of oxLDL and a debilitated ability 
for efferocytosis71. Hence, M1 macrophages seem to have a clear pro-atherogenic 
function. Contrary, M2 macrophages are superior phagocytes and have shown 
enhanced capability to clear apoptotic debris72,73. Similar to M1 macrophages, 
M2 macrophages are found in lesions of mice68 and humans, however, due to the 
production of anti-inflammatory cytokines M2 macrophages are believed to be ath-
eroprotective. Also evidenced by the fact that polarization of macrophages towards 
a M2 phenotype by Schistoma mansoni infection reduces atherosclerosis74. Besides 
M1 and M2 macrophages, other macrophages subsets, including M475 and Mox76, 
with distinct functions have been described and the M1/M2 paradigm is now under 
debate77. Indeed due to the plastic nature of macrophages, lesional macrophages 
can best be viewed as a dynamic range of phenotypes and functions65. Despite the 
difficult nomenclature, the importance of macrophages in the pathophysiology of 
atherosclerosis is unmistakable.
Dendritic cells
A close relative of macrophages in terms of extracellular markers is the dendritic cell 
(DC). Since dendritic cells are professional antigen presenting cells (APCs) they func-
tion at the interface between the innate and adaptive immune system78. They are 
present in all lymphoid and almost all non-lymphoid tissues. Similar to macrophages 
the distinction of different DC subsets has given rise to some debate79,80. However, 
it is now understood that both conventional (cDC) and plasmacytoid (pDC) DCs are 
derived from a common DC progenitor while monocytes give rise to a different sub-
set (moDCs)80. The immature precursors patrol the periphery and lymphoid tissue in 
search for antigens. They pick up and process antigens in inflamed tissues while they 
differentiate into mature DCs. This is accompanied by a switch from a phagocytic 
phenotype towards an antigen-presenting phenotype with increased expression 
of costimulatory receptors such as CD80 and CD86 and CCR7. Subsequently they 
migrate and present antigens in nearby lymph nodes. The resulting antigen-specific 
immune response is largely dependent on the co-receptor and cytokine expression 
of the mature DC. DCs have the remarkable ability to skew an immune reaction 
towards both anti- and pro-inflammatory responses. The functional role of DCs 
in the pathogenesis of atherosclerosis is not fully clear81. They are present in the 
adventitia82, accumulate lipids and depletion of DCs in Ldlr-/- mice has shown to 
attenuate atherosclerosis83. In contrast, prolonged survival of DCs in either Ldlr-/- or 
apoE-/- mice did not result in accelerated atherosclerosis due to an atheroprotective 
decrease in serum cholesterol levels84. Additionally, it has been demonstrated that 
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ex vivo oxLDL-pulsed DCs can be used to decrease lesion size85. Due to the versatile 
nature of DCs it is difficult to pinpoint specific pro- or anti-atherosclerotic effects 
to different DC subsets81. Nonetheless, given their central role in the activation of 
T cells it remains of great interest to further dissect the effects of DC subsets in 
atherosclerosis.
CD8+ T cells
T cells originate from lymphoid progenitor cells in the bone marrow which undergo 
further development in the thymus. There they mature in either CD4+ or CD8+ 
T cells and leave the thymus for the periphery. CD8+ T cells or cytotoxic T cells 
recognize antigen on MHC-I molecules which is expressed on all nucleated cells. 
Under normal circumstances, cells continuously display cytosolic self-antigens in 
MHC-I molecules, which usually does not elicit an immune response. In an infected 
cell, however, non-self antigens are presented and recognized by CD8+ T cells. For 
an effective CD8+ T cell response cross-presentation of the non-self antigen by an 
APC is usually necessary86, after which the CD8+ T cell kills the infected target cell. 
They also secrete large amounts of IFN-γ and TNF-α which further increases the 
local inflammation87. The contribution of CD8+ T cells to atherosclerosis in humans 
appears primarily of atherogenic nature. They represent the majority of lesional 
lymphocytes88 and a strong correlation between CD8+ T cells and coronary artery 
disease has been found previously89,90. In contrast, the results in experimental mouse 
models do not fully support such a definitive conclusion. It was shown that CD8+ 
T cells strongly respond to a high fat diet as measured by their IFN-γ production91. In 
line with an proatherogenic contribution, it was further demonstrated that depletion 
of CD8+ T cells resulted in attenuated atherosclerosis while the adoptive transfer 
exacerbated disease severity92. On the other hand, mice lacking MHC-I molecules 
are unable to mount effective CD8+ T cell responses and show increased atheroscle-
rosis93. Other evidence supporting a protective role came from vaccination studies 
with an ApoB-100 epitope, which induced CD8+ T cell-mediated atheroprotection94. 
An explanation for these discrepancies might lie in the presence of multiple distinct 
CD8+ T cell subsets95. For instance, regulatory CD8+ T cells have recently been 
identified that specifically interacts with cells expressing the non-classical MHC-I 
molecule Qa-196. These regulatory CD8+ T cells have recently been demonstrated to 
inhibit specific CD4+ T cell response during atherosclerosis development which re-
sulted in decreased lesion size97. Others also showed that CD25+CD8+ T cells could 
confer atheroprotection98. However the heterogeneity of CD8+ T cells includes more 
subsets than regulatory CD8+ T cells which have not yet been elucidated95. Given 
their strong presence in human lesions, shedding more light on the contribution of 




In contrast to cytotoxic CD8+ T cells that require antigen to presented on MHC-I 
molecules, CD4+ T helper cells recognize antigen presented by MHC-II molecules. 
Professional APCs such as DCs constitutively express MHC-II and it can also be 
induced on other cell types such as endothelial cells. CD4+ T cells regress from the 
thymus and migrate to secondary lymphoid organs, where they further mature into 
naïve CD4+ T cells. Besides antigen recognition, activation of a naïve CD4+ T cell 
requires the association with a stimulatory immune checkpoint protein. This drives 
autocrine IL-2 stimulation which induces T cell proliferation. Depending on the local 
inflammatory environment, unpolarized T helper (Th0) cells will differentiate into 
a specific Th cell subset. They are named Th cells since they help the activation or 
suppression of other immune cells. Each Th cell subset carries out a specific immune 
function and different Th cell subsets are often required in response to different 
pathogens. The influence of CD4+ T cells is therefore largely dependent on the Th 
subset.
Figure 2. CD4+ T cell subsets and their key effector functions in atherosclerosis. Th1 cells primarily 
promote inflammation, while Th2 cells can have both pro- and anti-inflammatory responses. The role 
of Th17 cells is still controversial. Tregs dampen inflammation and have a well-defined protective ef-




Th1 cells are induced in response to intracellular pathogens. They are induced by 
IFNγ, IL-12 and IL-18 which drives the expression of T-bet in CD4+ T cells. T-bet is 
the master regulator of Th1 cells and induces the production of pro-inflammatory 
cytokines such as IFNγ and TNFα. Th1 cells mainly activate macrophages, CD8+ 
T cells and the production of IgG2c by B cells, which aid the immune response 
against intracellular invaders. However, in atherosclerosis Th1 cells have a well-
defined proatherogenic response. They are abundantly found in both murine and 
human lesions99–101. Functional studies revealed that T-bet102 or IFNγ deficiency103 
resulted in markedly decreased atherosclerosis. Additionally, both IL-12 and IL-18 
have prominent atherogenic roles via the induction of Th1 cells.
A second major CD4+ T cell subset is the Th2 cell. Th2 cells are the host immune 
defense in case of extracellular pathogens and their differentiation is promoted by 
IL-4 and IL-33. The key transcription factor in Th2 cells is Gata-3104, which promotes 
IL-4, IL-5 and IL-13 expression105. This results in the activation and degranulation of 
eosinophils106 and mast cells107 and the proliferation of B cells108. Hence, Th2 cells 
mount an effective humoral immune response to battle extracellular pathogens. 
Their effect in the pathogenesis of atherosclerosis is, however, not so clear-cut. 
IL-5 has been shown to promote an atheroprotective B cell response109 and IL-13 
also reduced lesion size by skewing the macrophages towards a M2 phenotype110. 
However, IL-4 has been regarded as the hallmark Th2 cytokine and has demon-
strated contradictory results. It has shown to strongly reduce the differentiation of 
Th1 cells111, however it has no influence on atherosclerosis when administered112. In 
fact, deficiency of IL-4 decreased lesion development, which is in line with a proath-
erogenic role113. Since IL-4, IL-5 and IL-13 are not exclusively produced by Th2 cells, 
it remains difficult to determine the exact contribution of Th2 cells to atherosclerosis 
without cell-specific KO models. Nonetheless, an imbalance between Th1 and Th2 
cells seems to be associated with coronary artery disease114,115.
A third subset is that of Th17 cells which seem to be important against certain fun-
gal infections and are primarily characterized by their expression of RORγt116. This 
expression is induced by stimulation with TGFβ and IL-6 and results primarily in the 
secretion of IL-17 and to a lesser extent of IL-21 and IL-22. Contradictory data of 
Th17 cells and IL-17 have been reported. Antibody-mediated inhibition of IL-17117 or 
IL-17 deficiency reduce lesion development118. Others also demonstrated that IL-17 
deficiency did not affect atherosclerosis119. Additionally, it has been demonstrated 
that depletion of B cells resulted in an IL-17-mediated atheroprotection120.
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T follicular helper cells (Tfh) are a relatively new subset that have received a lot of at-
tention in the last few years121. While Th1, Th2 and Th17 cells usually exit lymphoid 
tissues to migrate towards the site of inflammation, Tfh cells travel towards the B 
cell border to provide help for B cells121. They are characterized by expression of 
several markers such as Bcl-6, PD-1, CXCR5 and ICOS. They further mainly secrete 
IL-21 and IL-4 which strongly activates nearby B cells. The interaction between T 
and B cells in germinal centers will be discussed more thoroughly below. Nonethe-
less, several reports have investigated the effects of Tfh cells on atherosclerosis and 
for now have exclusively found an atherogenic effect97,122,123.
A unique subset of CD4+ T cells that mainly inhibits other immune cells is the regula-
tory T cell (Treg). The importance of this subset mainly lies in the ability to maintain 
self-tolerance and to resolve inflammatory responses. TGFβ plays an important role 
in the differentiation of Tregs124, however weak interactions with the T cell recep-
tor can also induce Tregs125. Tregs can be identified by high expression of CD25 
and FoxP3. CD25 is the IL-2 receptor and some of the immunosuppressive effects 
of Tregs are mediated through CD25126. Moreover, FoxP3 directs the expression 
and secretion of IL-10 and TGFβ which are strong anti-inflammatory cytokines127. 
Given that most immune cells have a detrimental contribution to atherosclerosis, it 
is not surprising that the immune regulation of Tregs is clearly atheroprotective128. 
Depletion of Tregs results in increased disease severity129,130, whereas expansion 
of Tregs via an IL-2/anti-IL-2 complex or adoptive transfer of Tregs decrease lesion 
development131,132. Given that low numbers of Tregs are associated with CVD and 
their well-defined effects in experimental models, they are a very promising target 
for the treatment of atherosclerosis (reviewed in128).
B cells
Besides T cells, the other major component of the adaptive immune system is rep-
resented by B cells. In general there are two main populations of B cells that are 
distinct in origin and function, B1 and B2 cells.
B2 cells
B2 cells develop in the bone marrow from a common lymphoid progenitor which 
happens in sequential stages (Fig. 3). Early stages of B2 cell development involve 
the rearrangement of the heavy and light chain locus and once B cells express cell 
surface IgM they are considered as immature B cells (Fig. 3). Immature B cells are 
tested for self-reactivity and B cells with no strong reactivity are allowed to further 
mature in the blood and secondary lymphoid tissues. Immature B cells are also re-
ferred to as transitional B cells and it has been proposed that the maturation process 
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involves two consecutive stages with transitional type 1 and type 2 B cells133. These 
transitional B cells can mature into either marginal zone (MZ) B cells or follicular 
(FO) B cells. The precise requirements and conditions for the differentiation into 
one of these subsets remain unknown. In fact, it is still under debate if this final 
selection happens in the periphery or is already predetermined during development 
in the bone marrow134.
FO B cells represent the large majority of B cells and are characterized by high levels 
of IgD and CD23135. They respond to T cell-dependent antigens and activation of FO 
B cells is initiated when it recognizes an antigen with its surface immunoglobulin. 
This initiates the upregulation of CCR7 which drives migration of the B cell towards 
the T-cell zones in lymphoid tissues. Subsequently the antigen is internalized and 
presented on MHC-II molecules to cognate CD4+ T cells. This triggers the activation 
of the CD4+ T cell to express extracellular markers and cytokines to further stimu-
late the B cell. This includes CD40 ligand expression which is a particular important 
CD4+ T cell effector molecule which binds to CD40 on the B cell. This interaction 
is important for almost all phases in B cell activation, including proliferation, class-
switching and somatic hypermutation136. After several rounds of proliferation, some 
Figure 3. General overview of different the development of different B cell lineages and subsets. 




B cells differentiate into antibody-producing plasmablasts. These cells are often 
considered as immature plasma cells and secrete antibodies for some days after 
which they either die or further differentiate into plasma cells. The generation of 
most plasma cells, however, is through a longer route in germinal centers. Proliferat-
ing B cells represent the majority of immune cells in the germinal center, but Tfh 
cells and follicular dendritic cells are also crucial components. In the germinal center, 
B cells receive stimuli from Tfh cells to undergo isotype switching, which is a process 
that changes the constant-region of the immunoglobulin heavy-chain. This process 
is highly dependent on the cytokine production by T cells and follicular dendritic 
cells. For instance, Th2 cells are potent B cell activators and primarily induce IgG1 
and IgE production. On the other hand, Th1 cells only minimally activate B cells but 
skew antibody production towards an IgG2 isotype137. Subsequently, they undergo 
somatic hypermutation which introduces point-mutations in the variable immuno-
globulin region which enables affinity maturation. In this process, B cells compete 
for survival signals from Tfh cells which promotes clones with increased antigen-
affinity. Finally, B cells receive an as of yet unknown terminal differentiation signal 
which induces BLIMP-1 expression. BLIMP-1 effectively suppresses proliferation 
and drives the generation of plasma cells138. Plasma cells secrete large amounts of 
antibodies and downregulate CXCR5 and CCR7 which permits them to leave the 
germinal center and migrate towards peripheral tissue139. Other B cells turn into 
memory B cells which remain dormant until antigen is reintroduced. The current 
vision on this germinal center reaction and follicular B2 cells mainly portrays an 
atherogenic role which will be further discussed in further chapters.
The second major B2 cell subset is that of MZ B cells, which follow a completely 
different activation pathway. They are easily distinguished from FO B cells due to 
their high expression of CD21 and IgM and low levels of CD23. MZ B cells are 
uniquely located at the blood interface in the spleen and rapidly respond to blood-
borne pathogens140. Although they are able to form germinal centers in response 
to T cell-dependent antigens, these are often poorly organized141. In contrast, they 
usually recognize T cell-independent antigens after which they rapidly produce 
polyreactive IgM antibodies. It has recently been shown that MZ B cells accumulate 
during atherosclerosis development. However, removal of MZ B cell aggravated 
atherosclerosis suggesting that the increase in MZ B is a protective response123.
B1 cells
B1 cells are a distinct subset of B cells that are derived from precursors in the fetal 
liver142. In adult life, B1 cells mainly reside in the peritoneal cavity and their popula-
tion is primarily dependent on self-renewal instead of recruitment of new cells from 
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the bone marrow. Although they are derived from a different origin, B1 cells share 
many similarities with MZ B cells. Together with MZ B cells, the B1 cells can be re-
garded as innate-like B cells that are placed at the interface between the innate and 
adaptive immune response143. B1 cells can quickly respond to T cell-independent 
antigens by production of IgM. Additionally, they also spontaneously secrete IgM 
antibodies in absence of antigen with a broad specificity. These natural IgM antibod-
ies play a crucial role as a first line of defense in the humoral immunity144. B1 cells 
are able to protect against atherosclerosis, which will be further described in the 
next chapter.
Thesis outline
It is clear from all provided evidence that the immune system has a considerable 
impact on atherosclerosis. While the contribution of most immune cells has been in-
vestigated comprehensively in the last decade, the number of reports on B cells and 
atherosclerosis is still limited. More specifically, B cells have long been exclusively 
regarded as antibody-producing cells. However, we nowadays know that B cells are 
very versatile and dynamic immune cells with a broad range of actions. The resulting 
effect of these actions on atherosclerosis are only minimally investigated. Hence, 
the overall aim of this thesis is to modulate the B cell response in atherosclerosis 
and gain more insight into the antibody-independent roles of B cells during athero-
sclerosis. In Chapter 2 we reviewed the addition of novel subsets to the B cell family 
and their known roles in atherosclerosis. We have described that besides B1 and B2 
cells, more and more B cell subsets have been identified which are minimally inves-
tigated in the context of atherosclerosis. In Chapter 3 we aimed to elucidate the role 
of IL-10-secreting B cells in atherosclerosis. We show that these regulatory B cells 
potently inhibit the immune system during atherosclerosis development. However, 
we also show a hitherto unknown effect of B cell adoptive transfer on cholesterol 
homeostasis which could have masked the effects of IL-10 producing B cells on 
atherosclerosis. We further investigated IL-10 producing B cells using mice deficient 
in TIM-1 signaling (TIM-1Δmucin) in Chapter 4. We show that these mice are deficient 
in IL-10+ B cells and display increased lesion development compared to wild-type 
mice. Furthermore, these mice showed a specific reduction in the Th2 response, 
which potentially contributed to the increased lesion development in TIM-1Δmucin 
mice. In Chapter 5 we have described a different regulatory B cell subset expressing 
high levels of PD-L1. We effectively generated this subset by ex vivo stimulation of 
B cells with IFN-γ. We further show that this subset is able to inhibit Tfh cells in vitro 
and in vivo. Additionally, adoptive transfer of these IFNγ-stimulated B cells resulted 
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in decreased lesion formation. Chapter 6 describes role of the immune-checkpoint 
inhibitor BTLA in atherosclerosis. We first demonstrate that BTLA is mainly ex-
pressed on B cells in tissue from atherosclerotic patients and Ldlr-/- mice. Next, 
with the use of an agonistic antibody for BTLA in atherosclerosis, we demonstrate 
that this antibody selectively reduced follicular B cells, while other B cells remained 
unaffected. This resulted in diminished CD4+ T cell activation and an increase in 
the number of Tregs. We further revealed that treatment with the BTLA antibody 
reduced lesion development, besides also inducing lesion stabilization in established 
lesions. Concluding remarks and future perspectives on all results described in this 
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The number of deaths associated with cardiovascular disease remains high, despite 
great advances in treating the associated high levels of cholesterol. The main under-
lying pathology of cardiovascular disease is atherosclerosis, which is recognized as 
a chronic autoimmune-like inflammatory disease. Hence, there is a pressing need 
to shed light on the immune pathways associated with atherosclerosis. B cells have 
long been thought to have a general protective effect in atherosclerosis. However, 
findings in the last decade have challenged this paradigm, showing that it is crucial 
to differentiate between the various B cell subsets when assessing their effect on 
atherosclerosis.
Recent findings
It has become increasingly recognized that B cells can have significant effects on 
the immune system independent of antibody production. The understanding that 
B cells form a major source of cytokines and can directly influence T cell responses 
via surface markers, have led to the identification of novel B cell subsets. These 
subsets are important modulators of auto-immune disorders but have not yet been 
fully investigated in atherosclerosis.
Summary
Here we review the current known roles of B cell subsets and the putative effects of 
recently identified B cells on atherosclerosis.
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Introduction
Atherosclerosis has long been established as a chronic autoimmune-like inflamma-
tory disease. Substantial work in the last years has identified a broad spectrum of 
immune cells and immunomodulatory checkpoints that can have a significant con-
tribution to the onset and/or progression of atherosclerosis. Immune cells such as 
macrophages, monocytes, neutrophils, dendritic cells and T cells have been exten-
sively investigated and as such their impact on atherosclerosis has been illuminated 
to a great extent.
In addition, already in 2002 it was shown that B cells can also have a substantial im-
pact on the pathophysiology of atherosclerosis1,2. Two independent studies showed 
a general atheroprotective effect on atherosclerosis. Since then, the number of 
studies on B cells in atherosclerosis has somewhat waned compared to the number 
of papers examining T cells. However, the discovery that different B cell subsets can 
have opposing effects on atherosclerosis has led to a resurge in interest in B cells 
and atherosclerosis in recent years. As a result, the two main B cell lineages and 
their effects on atherosclerosis are now understood to a certain extent. In contrast, 
novel B cell subsets have been recently identified which could have great potential 
in atherosclerosis and have not yet been fully explored.
In this review we briefly discuss the current understanding of the role of classical 
B cells and the putative contribution of novel B cell subtypes to atherosclerosis.
B1 and B2 and antibody production
Broadly, B cells can be divided into two lineages that differ greatly in ontogeny, 
function, location and surface marker expression: B1 and B2 cells (Fig. 1). B1 cells 
are the dominant type of B cell in neonates and originate mainly from fetal liver 
and omentum. In adult life, they reside mostly in pleural and peritoneal cavities and 
respond to self- and T-independent antigens by secreting polyreactive natural IgM 
antibodies. Based on the expression of the surface marker CD5, B1 cells can be 
further subdivided in B1a and B1b cells. Alternatively, the large majority of B cells in 
the adult is comprised of B2 cells that include the conventional follicular B cells and 
marginal zone B cells. The latter are often considered as part of the innate immune 
system, since they rapidly respond to blood-borne antigens, including bacterial cell 
wall components and self-antigens, with polyreactive antibodies. However, the larg-
est population of splenic B cells consists of follicular B cells that undergo isotype 
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switching in germinal centers in response to T-cell dependent antigens and either 
give rise to memory B cells or antibody secreting plasma cells.
In 2002, two groups provided the first compelling evidence on the modulatory prop-
erties of B cells in atherosclerosis1,2. Initially, these two corroborating studies led to 
the idea of B cells having an overall atheroprotective effect. However, later studies 
Figure 1. Overview of the main B cell lineages and novel B cell subtypes with their known and puta-
tive effects on atherosclerosis. B cells can be divided into two main lineages; B1 and B2 cells. B1 cells 
can be further divided into B1b and B1a B cells that both attenuate atherosclerosis by the secretion 
of natural IgM antibodies (IgM NAbs). IRA B cells are derived from B1a cells and are characterized by 
GM-CSF production by which they promote inflammation in the spleen, which results in increased 
atherosclerosis. Conventional B2 cells, including marginal zone (MZ) and follicular (FO) B cells, are 
generally believed to have an atherogenic effect, which may be caused by their IgG secretion. Regula-
tory B cells (Bregs) negatively influence the immune response and hence could have potential athero-
protective effects. They share markers with many other B cell subsets and it remains unknown if they 
develop from a specific type of B cell or if all B cells can become regulatory when provided with the 
right immunological context. The majority of Bregs are dependent on IL10 production and many dif-
ferent markers have been ascribed to these cells, such as CD1dhiCD5+, TIM-1+, CD9+, CD138+ and 
CD21hiCD23hiCD24hi B cells. Only the latter have already been reported to protect against athero-
sclerosis. Killer B cells can induce apoptosis in TH cells by their expression of FASL. B cells expressing 
CD39 and CD73 can drive the purinergic response from the ATP to ADP and adenosine that is associ-
ated with atheroprotection. B cells expressing high levels of PD-L1 can inhibit the TFH-germinal center 
axis and decrease the secretion of high-affinity IgG antibodies. *Dotted lines/arrows depict not yet 
determined roles in atherosclerosis.
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challenged this paradigm by pointing out major differences between B1 and B2 cells 
in modulating atherosclerosis3–5. Currently, the evidence for a protective function 
of B1a cells is firmly established5–8. There is a widespread agreement that B1 cells 
protect against atherosclerosis due to the production of natural IgM antibodies that 
induce the clearance of oxidized low-density lipoproteins (oxLDL) and apoptotic 
cells9–11. In addition, it was recently shown that B1b cells contain similar atheropro-
tective characteristics by secreting natural antibodies12. On the other hand, there 
is an abundance of data claiming an atherogenic effect of B2 cells3,4,13,14. The most 
important evidence for this statement is provided by depletion studies, which show 
that selective depletion of B2 cells limits the development of atherosclerosis3,4,13,14. 
One reason for this is that the antibodies secreted by B2 cells are usually of the 
IgG isotype which are, in contrast to IgM antibodies, often associated with aggra-
vated atherosclerosis. However, the understanding about the effects of different 
isoforms of IgG is still very limited15. In addition, the exact influence of B2 cells on 
atherosclerosis remains debatable, since conflicting evidence shows that adoptively 
transferred B2 cells can also reduce lesion size16,17. The main difference between 
these apparent contradictory studies is the number and genotype of adoptively 
transferred B cells, 5x106 B cells from C57BL/6J (BL/6) mice versus 30x106 B cells 
from apolipoprotein E knockout (apoE-/-) mice4,16. This discrepancy points out the 
importance of taking into consideration that not all B2 cells are similar and that the 
source and number of cells used can have a major influence on the development of 
atherosclerosis.
In recent years, it has been shown that within the B1 and B2 lineages additional B 
cell subsets can be identified (Fig. 1). While most papers discussing B1 and B2 cells 
often emphasize their antibody producing capacities, the majority of these novel B 
cell subsets are either identified based on secretion of specific cytokines or surface 
marker expression. These B cells can modulate immune responses by altering the 
cytokine network or directly altering T cell responses via co-receptor expression. 
These emerging concepts play major roles in auto-immune disorders, but are not yet 
fully appreciated in the context of atherosclerosis.
IL-10 dependent regulatory B cells
One major group of B cells that has seen a lot of attention in the last decade is that of 
regulatory B cells (Bregs, Fig. 1). In general, B cells that negatively modulate the immune 
response are considered Bregs and the majority of these B cells depend in one way or 
another on the secretion of interleukin-10 (IL-10)18. IL-10 is an extensively studied 
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anti-inflammatory cytokine with well-known anti-atherogenic properties19–21. It is 
primarily secreted by macrophages and T cells and protects against atherosclerosis 
in several ways, including inhibition of macrophage and T cell activation but it also 
has impact on lipid metabolism21,22. It is now known that B cells are also capable in 
regulating auto-immune disorders via secretion of IL-1023, but this concept has only 
recently been investigated in atherosclerosis24,25. Using a chimeric system to gener-
ate Ldlr-/- mice with a B cell specific deficiency in IL-10, Sage et al. showed that a loss 
of B cell-derived IL10 unexpectedly did not result in a significant effect on plaque 
size24. A second study, however, showed that B-cell derived IL-10 is actually capable 
of reducing atherosclerosis development in apoE-/- mice25. Strom et al. reported a 
significant increase in IL10+ B cells in the lymph nodes of female apoE-/- mice com-
pared to BL/6 mice. Subsequent adoptive transfer of these lymph node B cells into 
apoE-/- mice protected them against collar-induced neo-intima formation. This effect 
was IL10-dependent since concurrent injection with an IL-10 neutralizing antibody 
abrogated the effects. Similarly, adoptive transfer of IL-10-/- B cells failed to protect 
against atherosclerosis25. The apparent discrepancy between these two studies can 
in part be explained by their different experimental approaches (e.g. apoE-/- vs. Ldlr-/- 
or chow diet vs. high-fat diet). However, another possibility is that IL10-producing 
B cells or the CD21hiCD23hiCD24hi B cell population as used by Strom et al. does 
not exclusively secrete IL-10. Two recent papers elegantly show that IL-35 is able 
to induce IL-10-producing B cells which in turn also secrete large amounts of IL-35 
that can suppress autoimmune disease26,27. As suggested by others, there could be 
a complex interplay between IL-35 and IL-10 in mediating immunosuppression28. 
Thus, silencing only one of these cytokines could lead to compensatory mechanisms 
resulting in upregulation of the cytokine by other cell types or the induction of 
other anti-inflammatory cytokines. For instance, in the aorta of mice deficient for B 
cell derived IL-10 a significant increase in IL-10 gene expression was found, while 
IL-35 or transforming growth factor β were not measured24. Moreover, the IL-10 
blocking antibody used by Strom et al. did not neutralize the decrease in lesional 
macrophages, again displaying only a partial response of IL-10-mediated immune 
suppression25.
Adding to the complexity is the lack of a unifying surface marker or transcription 
factor to identify IL-10 producing B cells. Currently, there is a growing collection 
of literature that identifies different B cell subsets in which IL10-producing B cells 
are enriched29–33. Many of these subsets are frequently used as biomarker for IL10-
producing B cells or for adoptive transfer experiments. Since these subsets differ 
largely in their surface marker expression and also in the actual number of IL-10 
producing B cells, the research into the exact contribution of B cell derived IL-10 to 
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atherosclerosis and other auto-immune disorders remains a challenge. It will thus 
be interesting to examine the effects of adoptive transfer studies using pure IL-10 
producing B cells. In addition, studies that shed light on the complex network of 
multiple immune-suppressive B cell derived cytokines are warranted to fully under-
stand the effects of IL-10 secreting B cells in atherosclerosis.
Other regulatory B cells
While typically regulatory B cells are associated with IL-10 producing B cells, the 
family of regulatory B cells has greatly expanded since the term was claimed18. It 
now also includes B cells expressing specific surface markers that can negatively 
regulate the immune response independent of IL-10 (Fig. 1).
For instance, Khan et al. identified a unique B cell subset that highly expresses 
programmed death ligand 1 (PD-L1)34. These PD-L1hi B cells are potent regulators 
of T cell responses both in vitro and in vivo. In particular the expansion of follicular 
helper T cells (TFH) that express the receptor for PD-L1 (PD-1) is negatively regulated 
by PD-L1hi B cells34. TFH cells are important modulators of the humoral immune 
response since they trigger and maintain the development of germinal centers. It 
has recently been demonstrated that this TFH-germinal center axis develops dur-
ing atherosclerosis, including isotype switching of antibodies from IgM to IgG35. 
Blockade or promotion of this axis results in attenuated or enhanced atherosclerosis 
in apoE-/- mice, respectively35. Since the PD-1/PD-L1 pathway has also shown its 
potential in modulating atherosclerosis, it will be very interesting to investigate the 
effects of the PD-L1hi B cells in this context 36–38.
Another B cell subtype that has been shown to negatively regulate T cell responses 
is the so called killer B cell39. This type of B cell expresses Fas ligand (FasL, CD178) 
which is usually found on cytotoxic CD8+ T cells and natural killer (NK) cells. Binding 
of FasL to its receptor Fas (CD95) leads to apoptosis in target cells. FasL+ B cells 
are mainly found within the splenic CD5+ population and can be induced by CD40 
stimulation and IL-540. Killer B cells are able to induce TH cell apoptosis and promote 
tolerance39,41, which are both crucial processes in treating atherosclerosis. In addi-
tion, soluble levels of FasL are clinically associated with a lower risk of cardiovascular 
disease42,43. Although it has not been directly shown that killer B cells secrete FasL, 




A third type of B cell that has been reported to exert immune suppression depends 
on the ectoenzymes CD39 and CD7344. Both enzymes work towards the removal of 
extracellular ATP and increasing the level of extracellular adenosine (ADO), which is 
associated with atheroprotection45. CD39 is expressed on all B cells, but the expres-
sion of CD73 is restricted to a specific subset of B1 cells. Sorting of CD73– and 
CD73+ B cells showed that only the latter were able to protect against experimental 
inflammatory colitis44. Ablation of CD73 results in increased neo-intima formation 
in a wire injury model46 and increased atherosclerosis in apoE-/- mice47. Since these 
studies used total knockouts of CD73, the role of CD73 and/or CD39 on B cells in 
atherosclerosis has not yet been elucidated.
Innate response activator (IRA) B cells
In contrast to Bregs, additional B cell subsets have been identified that predominantly 
exert pro-inflammatory functions (Fig. 1). IRA B cells were identified as a unique B 
cell subset regarding their ontology, development and function. They are particu-
larly characterized by the secretion of granulocyte macrophage colony stimulating 
factor (GM-CSF)48. GM-CSF is a pleiotropic cytokine that was first thought to be 
exclusively secreted by non-hematopoietic cells, macrophages and T cells. However, 
in response to LPS or sepsis a small population of peritoneal B1a cells is able to 
relocate to the spleen, secrete GM-CSF and hence protect against bacterial infec-
tion48. Several studies have been performed using total GM-CSF knockout mice on 
an apoE- or Ldlr-deficient background to examine the contribution of GM-CSF to 
atherosclerosis, but the results remain somewhat ambiguous. Gm-csf/apoE double 
knockout mice displayed an increase in atherosclerosis49, while gm-csf/Ldlr double 
knockout mice showed no difference50 or a sex-related reduction in plaque size 
(i.e. only in female mice)51. These conflicting results highlight the complex immune 
pathways of this cytokine and suggest that the context, timing and cellular source of 
GM-CSF might be important for the regulation of atherosclerosis.
Recently, it was shown by Hilgendorf et al. that during atherosclerosis progression, 
a small population of IRA B cells develops in the spleen52. Notably, they did not find 
any IRA B cells within the aorta, suggesting that B cells do not contribute to aortic 
GM-CSF and that they exert their effects indirectly. This was confirmed by show-
ing that an increased expression of GM-CSF in the spleen during atherosclerosis 
progression resulted in an expansion of conventional CD11c+ dendritic cells in the 
spleen. These in turn stimulated the proliferation of effector T cells and skewed 
them towards a Th1-dominant phenotype with a concomitant increase in antibodies 
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of the IgG2c isotype. This unfavorable immune response initiated by IRA B cells 
eventually culminated in an increase in atherosclerotic lesion size in Ldlr-/- mice52. 
Although this study elegantly showed that IRA B cells harbor atherogenic properties 
in the spleen of Ldlr-/- mice, it does not account for the differences found in the 
complete GM-CSF knock-out models between Ldlr-/- and apoE-/- mice. Since the 
increase in IRA B cells was most prominent in the apoE-/- mouse model, it would 
be expected that the contribution of B cells to the total levels of GM-CSF would 
be maximal in these mice. Along that line, gm-csf-/-apoE-/- mice would most likely 
demonstrate a decrease in lesion size, however the opposite has been reported49. 
On the other hand, it could be suggested that since women are better protected 
against sepsis than men53, they naturally contain more IRA B cells, which could at 
least partially explain the sex-difference found between females and males in gm-
csf-/- Ldlr-/- mice51.
Taken together, the study by Hilgendorf et al. was one of the first to report the 
effects of specific cytokine producing B cells on atherosclerosis, underscoring the 
immune-modulating effect B cells can have during atherosclerosis besides antibody 
production52.
Concluding remarks
B cells can have a tremendous impact on atherosclerosis, however it is crucial to 
differentiate between the different B cell subsets regarding their effects on athero-
sclerosis. The increased knowledge on other B cell subtypes than B1/B2 and the 
additional roles besides antibody production in recent years, has also improved the 
understanding of B cells in cardiovascular disease. However, one drawback is that 
most subsets share surface markers, proving it difficult to pinpoint the individual ef-
fects to a specific subtype of B cells. In terms of therapeutic potential, the frequently 
used option of global B cell depletion with CD20 antibodies might not be the most 
favorable option. Ideally, treatments that either selectively induce protective B cells 
or limit the effects of atherogenic B cells could offer more potential.
In conclusion, there still is a lot to gain in exploring and harvesting the potential of 
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Background and aims: Limiting the pro-inflammatory immune response is critical 
for the treatment of atherosclerosis. Regulatory B cells (Bregs) can modulate the 
immune response through interleukin-10 (IL-10). Current data regarding Bregs and 
atherosclerosis is scarce and conflicting.
Methods: In this study we investigated the frequency of IL-10+ B cells during the 
development of atherosclerosis in low-density lipoprotein receptor-deficient (Ldlr-/-) 
mice and studied the effect of adoptive transfer of IL-10+ B cells on atherosclerosis.
Results: We found a very strong inverse correlation between atherosclerosis sever-
ity and the frequency of IL-10+ B cells. This effect was cholesterol-independent and 
observed in spleen, draining lymph nodes and peritoneal cavity. To directly assess the 
effects of IL-10+ B cells on atherosclerosis, we expanded IL-10+ B cells ex vivo with 
anti-CD40 and selected pure and viable IL-10-secreting B cells and IL-10– B cells 
and adoptively transferred them to Ldlr-/- mice, respectively. Whereas IL-10– B cells 
were strongly atherogenic compared to control-treated mice, IL-10+ B cells did not 
affect lesion size. Adoptive transfer of IL-10+ B cells strongly reduced circulating 
leukocyte numbers and inflammatory monocytes. In addition, they decreased CD4+ 
T cell activation and increased IL-10+ CD4+ T cell numbers. Interestingly, both IL-10+ 
and IL-10– B cells exacerbated serum cholesterol levels and resulted in fatty livers, 
which potentially masked the beneficial effects of IL-10+ B cells on atherosclerosis.
Conclusions: These findings underscore the strong immune-regulating function of 
IL-10+ B cells and provide additional incentives to explore effective strategies that 
expand IL-10+ B cells in atherosclerosis.
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Introduction
Cardiovascular disease remains a major global health problem and is mainly caused 
by atherosclerosis. Atherosclerosis is characterized by the build-up of lipids in the 
vascular wall which initiates a strong immune response, hence its classification as 
an autoimmune-like disorder1. At present, most treatment options are aimed at lipid 
lowering and do not address the ongoing immune response which perpetuates the 
disease. The recent success of the CANTOS trial strongly encourages research into 
novel therapeutic strategies that limit the immune reaction2.
In the last decade, suppression of the immune reaction by regulatory B cells (Bregs) 
has received a lot of attention3. Bregs mediate the immune system primarily through 
interleukin-10 (IL-10) and it has been demonstrated that an imbalance in the num-
ber of Bregs strongly associates with multiple auto-immune disorders4,5, including 
coronary artery disease6. In experimental models of auto-immune disorders, cel-
lular therapy of Bregs have shown great potential, primarily via the induction of 
IL-10+ regulatory T cells7–9. Furthermore, it has been well-documented that IL-10 is 
protective in atherosclerosis10. However, there is a scarcity of research into Bregs 
and experimental atherosclerosis and the present data is conflicting11–15. While two 




using a mixed bone-marrow chimera model showed that B cell-derived IL-10 did not 
affect atherosclerosis12. These contradicting data clearly warrant more research into 
the contribution of Bregs to atherosclerosis.
A major hurdle in Breg research is the lack of a clearly defined immunophenotype. At 
present, there is a growing number of distinct Breg phenotypes defined by extracel-
lular markers7,16–21. Most research up to date has focused on these Breg subset. 
However, IL-10+ B cells are not limited to these subtypes and can be found within 
all B cell subsets, independent of their lineage or maturation and activation state22. 
Hence, IL-10 secretion is the primary mediator of immune suppression and remains 
the unique marker to classify Bregs. We thus aimed to determine in detail the role 
of IL-10+ B cells in atherosclerosis by studying the frequency and status of IL-10+ 
B cells during disease progression in low-density lipoprotein receptor-deficient mice 




Male Ldlr-/- mice were bred in house and were kept under standard laboratory condi-
tions. Mice were fed a normal chow diet or a Western-type diet (WTD) containing 
0.25% cholesterol and 15% cocoa butter (Special Diet Services, Witham, Essex, 
UK). Diet and water were provided ad libitum. All injections were administered i.v. 
to the lateral tail vein in a total volume of 100 µl. During the experiments, mice 
were weighed, and blood samples were obtained by tail vein bleeding. At the end 
of experiments, mice were anaesthetized by a subcutaneous injection of a cocktail 
containing ketamine (40 mg/mL), atropine (50 μg/mL), and sedazine (6.25 mg/mL). 
Mice were exsanguinated by femoral artery transection followed by perfusion with 
PBS through the left cardiac ventricle. All animal work was approved by the Leiden 
University Animal Ethics Committee and the animal experiments were performed 
conform the guidelines from Directive 2010/63/EU of the European Parliament on 
the protection of animals used for scientific purposes.
Isolation of IL-10+ B cells
Viable IL-10-secreting B cells were isolated from Ldlr-/- donor mice using a regu-
latory B cell isolation kit according to protocol (Miltenyi Biotec). In short, B cells 
were isolated from the spleens of donor mice by negative selection. Secondly, these 
B cells were stimulated for 72h with 5 µg/ml of an agonistic CD40 antibody (Enzo 
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Life Science, clone FGK45). To stimulate active IL-10-secretion, B cells were further 
stimulated with LPS (50 µg/ml, Escherichia coli serotype O111:B4), PMA (50 ng/
ml) and ionomycin (500 ng/ml) and labeled with an IL-10-catching antibody. Subse-
quently, the IL-10-secreting B cells were labelled with an IL-10 antibody conjugated 
to phycoerytrhin (PE) and finally isolated using magnetic PE-microbeads. The unla-
beled cell fraction was also collected and determined as IL-10– B cells. The isolated 
IL-10+ and IL-10– B cells were consistently of a ≥90% purity.
Cell culture and cytokine determination
Isolated IL-10– and IL-10+ B cells were cultured for 4 days with an agonistic CD40 
antibody (5 µg/ml) after which IL-10 was measured in culture supernatants. For 
the T and B cell co-culture, naïve CD4+ T cells were isolated by magnetic selection 
according to the provided protocol (Miltenyi Biotec). 1x105 CD4+ T cells were then 
plated in different ratios (1:2, 1:4, 1:8) with IL-10+ or IL-10– B cells and stimulated 
with 5 µg/ml of plate-bound anti-CD3. After 72h of culture, cells were harvested 
and analyzed by flow cytometry. Concentrations of IL-10 in culture supernatants 
were measured using standard ELISA protocols (BD Bioscience).
Real-time quantitative PCR
RNA was extracted from isolated B cells by using Trizol reagent according to manu-
facturer’s instructions (Invitrogen) after which cDNA was generated using RevertAid 
M-MuLV reverse transcriptase according to the instructions of the manufacturer 
(Thermo Scientific). Quantitative gene expression analysis was performed using 
Power SYBR Green Master Mix on a 7500 Fast Real-Time PCR system (Applied 
Biosystems). Gene expression of LIGHT (Forward: ATCTCACCAGGCCAACCCAGCA, 
Reverse: CCAGGCCAAGTCGTGTCTCCCATA) and lymphotoxin-alpha (Forward: 
CTGAAACCTGCTGCTCACCT, Reverse: ATGTCGGAGAAAGGCACGAT) was normal-
ized to housekeeping genes (hydroxymethylbilane synthase, ribosomal protein 37 
and glyceraldehyde 3-phosphate dehydrogenase).
Diet induced atherosclerosis
For the time-course experiment, age-matched (10-12 weeks old) Ldlr-/- mice were 
fed a WTD for 0, 3, 6 or 9 weeks (n=6/group). Mice were sacrificed at the same 
time-point after which the spleens were analyzed for the presence of IL-10+ B cells 
by flow cytometry. In a separate experiment, age-matched Ldlr-/- mice received a 
normal chow diet or WTD for 9 weeks (n=7/group). Multiple organs were harvested 
and processed for flow cytometry analysis. For the diet-switch experiment, Ldlr-/- 
mice were given either a WTD for 19 weeks, normal chow diet for 19 weeks or a 
WTD for 16 weeks and subsequently 3 weeks of normal chow diet (n=6/group). 
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These three weeks were determined by measuring the cholesterol levels during the 
switch to chow diet and the experiment was terminated when the cholesterol levels 
were normalized (data not shown). For the adoptive transfer experiment, at the start 
of WTD, 10-12 weeks old Ldlr-/- acceptor mice received 100 µl PBS or a cell suspen-
sion containing either 1x106 IL-10– or IL-10+ B cells (n=15/group). These injections 
were repeated at week 3 and 6 and mice were sacrificed after 9 weeks for analysis.
Flow cytometry
For the analysis of IL-10+ B cells, single cell suspensions were stimulated for 5 hours 
with LPS (50 µg/ml), PMA (50 ng/ml), ionomycin (500 ng/ml) and monensin (2 µM). 
For B10pro cells, B cells were first isolated with CD19-microbeads (Miltenyi Biotec) 
and subsequently stimulated for 48h with LPS (10 µg/ml) and/or an agonistic CD40 
antibody (5 µg/ml). Secretion of cytokines by T cells was induced with stimulation 
of PMA, ionomycin and brefeldin A (5 µg/ml). For flow cytometry analysis, Fc re-
ceptors were blocked (2.4G2) and samples were stained with a dead/live marker 
(Fixable Viablity Dye) and anti-mouse fluorochrome-conjugated antibodies against 
B220 (RA3-6B2), CD19 (1D3), IL-10 (JES-16E3), CD4 (RM4-5), CD86 (GL1), CD69 
(H1.2F3), CD25 (PC61.5), NK1.1 (PK136), CD11b (M1/70), Ly6-G (1A8), Ly-6C 
(HK1.4), CD62l (MEL-14), CD44 (IM7), IgM (Il/41), IgD (11-26c), CD21 (7E9), 
CD23 (B3B4), CD24 (M1/69), TIM-1 (RMT1-4), CD1d (1B1), CD5 (53-7.3) or TNFα 
(MP6-XT22). All antibodies were purchased from Thermo Fisher Scientific or Becton 
Dickinson. FACS analysis was performed on a FACSCanto II (Becton Dickinson), and 
the acquired data were analyzed using FlowJo software. Gates were set according to 
unstimulated controls (only treated with monensin or brefeldin A) or to isotype and 
fluorescence minus one controls.
Serum measurements
During the experiment, blood was collected from the tail vein. After euthanasia, 
orbital blood was collected in EDTA-coated tubes. Whole blood cell counts were 
analyzed using the XT-2000iV hematology analyzer (Sysmex Europe GMBH, Nor-
derstedt, Germany). Serum was acquired by centrifugation and stored at −20°C until 
further use. The total cholesterol levels in serum were determined using enzymatic 
colorimetric procedures (Roche/Hitachi, Mannheim, Germany). Precipath (Roche/
Hitachi) was used as an internal standard. Lipoprotein profiles were determined by 
fractionation of 50 µL samples of serum using a Superose 6 column (3.2×300 mm, 
Smart-System; Pharmacia, Uppsala, Sweden) after which total cholesterol levels 
were determined in each fraction.
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Liver lipid extraction and quantification
Triglycerides were extracted from liver tissue using Nonidet™ P 40 Substitute 
(Sigma-Aldrich Corp.). Liver tissue was homogenized with Nonidet™ P 40 Substi-
tute, heated until 90°C and chilled on ice. This procedure was repeated once and 
subsequently insoluble material was removed by centrifugation. Cholesterol was 
extracted from liver tissue by the Folch extraction method23. Triglycerides and cho-
lesterol concentration was determined by an enzymatic colorimetric assays.
Histology
To determine lesion size, cryosections (10 μm) of the aortic root were stained with 
Oil-Red-O and hematoxylin (Sigma-Aldrich). Sections with the largest lesion plus 
four flanking sections were analyzed for lesion size. Lipid content in liver sections 
was evaluated using the same Oil-Red-O staining. Collagen content in the lesion 
was assessed with a Masson’s trichrome staining according to the manufacturers 
protocol (Sigma-Aldrich). Corresponding sections on separate slides were also 
stained for monocyte/macrophage content using a monoclonal rat IgG2b antibody 
(MOMA-2, 1:1000, AbD Serotec) followed by a goat anti-rat IgG-horseradish per-
oxidase antibody (1:100, Sigma-Aldrich) and color development.
Statistics
All data are expressed as mean ± SEM. Data were tested for significance using a 
Student’s t-test for two normally distributed groups. Data from three groups or 
more were analyzed by an ordinary one-way ANOVA test followed by Tukey’s post 
hoc test. When data from multiple time-points were tested, a repeated measures 
ANOVA was performed instead. Probability values of p < 0.05 were considered 
significant. All statistical analysis was performed using GraphPad Prism 7.0.
Results
IL-10+ B cells are significantly reduced during atherosclerosis development 
in Ldlr-/- mice
To examine the frequency of IL-10+ B cells during the development of atheroscle-
rosis, we fed age-matched Ldlr-/- mice a Western type diet (WTD) for different time 
points (0, 3, 6 or 9 weeks) to induce various degrees of atherosclerosis. In general, 
two IL-10+ B cell types can be identified using flow cytometry; B10 and B10pro 
cells24,25. B10 cells readily secrete IL-10 after a short-term (5h) stimulation protocol 
(Fig. S1), while B10pro cells develop into IL-10-producing B cells after a long-term 
(48h) stimulation protocol with anti-CD40 and LPS. We found a gradual but sig-
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nificant decrease of B10 cells in the spleen when mice were fed a WTD diet for 
longer periods (Fig. 1A). To assess whether the loss of IL-10+ B cells correlated with 
disease severity, we measured the lesion size in aortic root sections and found a 
very significant inverse correlation between Bregs and atherosclerosis severity (Fig. 
1B). Similarly, we observed an even stronger decrease in B10pro cells with increas-
ing weeks of feeding the mice a WTD (Fig. 1C), which again highly correlated with 
increased atherosclerosis (Fig. 1D). In a separate experiment, we found that this 
effect was not spleen-specific but the loss of IL-10+ B cells was also observed in the 
mediastinal lymph nodes draining from the aortic root and in the peritoneal cavity 
(Fig. 1E). In contrast, B cells in non-draining lymph nodes and in the circulation were 
Figure 1. IL-10+ B cells are significantly reduced during atherosclerosis development in Ldlr‑/‑ mice. 
Age-matched Ldlr-/- mice were fed a Western type diet (WTD) or normal chow diet for varying periods 
and sacrificed at the same day. (A) IL-10+ B cells in splenocytes were determined with flow cytometry 
after a short-term (5h) stimulation with LPS (50 µg/ml), PMA (50 ng/ml), ionomycin (500 ng/ml) and 
monensin (2 µM) (LPIM) and (B) correlated with lesion size in aortic root sections. (C) IL-10+ B cells 
were determined after a long-term (48h) stimulation of isolated splenic B cells with LPS (50 µg/ml) 
and anti-CD40 (5 µg/ml) followed by LPIM stimulation and (D) correlated with lesion size in aortic 
root sections. (E) Ldlr-/- mice were fed a WTD or normal chow diet for 9 weeks after which IL-10+ 
B cells were determined using LPIM stimulation in the spleen, lymph node and peritoneal cavity. (F) 
Identification of IL-10+ B cells in mice fed a normal chow diet or a WTD for 9 weeks after stimulation 
of isolated splenic B cells with either LPS (50 µg/ml) or anti-CD40 (5 µg/ml) followed by LPIM stimula-
tion. (G) Ldlr-/- mice were fed a normal chow diet for 19 weeks, a WTD for 19 weeks or a WTD for 16 
weeks followed by a normal chow diet for 3 weeks (switch) to normalize cholesterol levels after which 
IL-10+ B cells were determined in the spleen with LPIM stimulation. Data are shown as mean ± SEM 
(*p<0.05, ** p<0.01, ***p<0.001, ****p<.00001).
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not affected by WTD-feeding (Fig. S2). We subsequently tested if a particular subset 
of regulatory B cells was affected during atherosclerosis development. This did not 
reveal a consistent reduction in specific subsets when we analyzed B cells in the 
spleen and lymph node (Fig. S3A-C). Along this line, we did not identify any differ-
ences in peritoneal subsets that pinpointed a particular B cell population that lost its 
IL-10 production after WTD diet feeding (Fig. S3D) We next wondered if the drastic 
reduction in B10pros was specifically a consequence of unresponsiveness to either 
LPS or anti-CD40. However, irrespective of the stimulus, flow cytometry revealed 
a highly significant decrease in the percentage of IL-10+ B cells in the spleen of 
WTD-fed mice compared to chow mice (Fig. 1F). Since Ldlr-/- mice fed a WTD have 
increased levels of serum cholesterol, we investigated whether this was directly 
affecting the number of IL-10+ B cells. Hence, we used a diet switch experiment by 
feeding Ldlr-/- mice either a normal chow diet, a WTD or a WTD followed by 3 weeks 
of a normal chow diet to normalize the cholesterol levels. We found that while the 
cholesterol levels in the diet-switched mice were fully normalized from 991 mg/dl to 
240 mg/dl (data no shown), the loss of IL-10+ B cells was not restored and remained 
significantly decreased compared to mice on a normal chow diet (Fig. 1G). Thus, 
IL-10+ B cells showed a strong inverse correlation with atherosclerosis severity, but 
this was not directly correlated to cholesterol serum levels.
Adoptive transfer of IL-10+ B cells leads to strong immune regulation
Given the strong decrease of IL-10+ B cells during atherosclerosis progression, we 
wanted to explore strategies to restore the immune-regulating function of B cells. 
However, the low frequency and availability of IL-10+ B cells severely limits the op-
tions of using them for cellular therapy. The practical difficulties can be overcome 
by either FACS-sorting Breg subpopulations based on extracellular markers11,17 or 
to expand Bregs ex vivo, for example using anti-CD40 stimulation8,26. The draw-
back is that both of these options at best result in a B cell population that is an 
enriched mixture of IL-10+ and IL-10– B cells. Since we found the greatest reduction 
in CD40-generated IL-10+ B cells during atherosclerosis progression (Fig. 1F), we 
hypothesized that adoptive transfer of these cells would be most beneficial in the 
context of atherosclerosis. To directly assess the function of IL-10+ B cells, we used 
a specialized kit to isolate viable IL-10-secreting B cells from anti-CD40 stimulated 
B cells that resulted in a 94.4% purity on average (Fig. S4). These IL-10+ B cells 
displayed an IgMhiIgDloCD21loCD24hiCD1dhiCD5+ phenotype compared to IL-10– 
B cells (Fig. 2A), which highly corresponds with previously described IL-10+ B cells 
from apolipoprotein E-deficient mice24. Furthermore, cytokine analysis revealed that 
while IL-10+ B cells readily secrete IL-10 after several days of culture, we failed to 
detect IL-10 in supernatants of IL-10– B cells (Fig. 2B). Another major determinant of 
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regulatory B cells is their effect on CD4+ T cell responses. In a co-culture experiment 
with CD4+ T cells, our isolated IL-10+ B cells significantly inhibited the development 
of TNFα+ CD4 T cells. This inhibition was dependent on the B to T cell ratio and 
correlated with IL-10 levels in culture supernatants (Fig. 2C). Taken together, these 
data indicate that our culture protocol and isolation resulted in a highly pure popula-
tion of IL-10+ B cells with a clear regulatory phenotype and function. We adoptively 
transferred these IL-10+ B cells to Ldlr-/- mice, which were subsequently fed a WTD 
for 9 weeks while PBS treatment and the negative fraction of the isolation (IL-10– 
B cells) were used as controls (Fig. S5).
Adoptive transfer of IL-10+ B cells led to a very marked reduction in all circulating 
leukocytes compared to mice receiving PBS or IL-10– B cells (Fig. 3A). Monocytes 
contribute significantly to lesion formation and IL-10 is known to inhibit monocyte 
adhesion and affect the monocyte polarization27,28. Hence, we used flow cytometry 
to measure the number of inflammatory monocytes and found that mice treated with 
IL-10+ B cells had a strong reduction in circulating inflammatory monocytes (Fig. 3B), 
indicating that adoptive transfer of IL-10+ B cells led to a less atherosclerosis-prone 
phenotype of monocytes. Moreover, it is well-known that Bregs have strong effects 
on CD4+ T cells22. Mice treated with IL-10+ B cells showed a very strong increase in cir-
culating IL-10+ CD4+ T cells compared to mice receiving PBS or IL-10– B cells (Fig. 3C). 
Similarly, we found that these circulating CD4+ T cells showed a more naïve phenotype 
in mice treated with IL-10+ B cells, while mice receiving IL-10– B cells demonstrated a 
Figure 2. Characterization of IL-10+ B cells. B cells were cultured with an agonistic CD40 antibody 
(5 µg/ml) for 72 hours after which they were stimulated with LPS (50 µg/ml), PMA (50 ng/ml) and 
ionomycin (500 ng/ml) to secrete IL-10. Subsequently IL-10– and IL-10+ B cells were isolated. (A) Char-
acterization of extracellular markers of IL-10– and IL-10+ B cells with flow cytometry). (B) IL-10– and 
IL-10+ B cells were cultured for 4 days with an agonistic CD40 antibody (5 µg/ml) after which IL-10 
was measured in culture supernatants (C) Different ratios of IL-10– and IL-10+ B cells were co-cultured 
with naïve CD4+ T cells and stimulated with anti-CD3 (5 µg/ml). After 72 hours, IL-10 was measured 
in cultured supernatants with ELISA and TNFα+ CD4 T cells were determined with flow cytometry.
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strong increase in effector memory CD4+ T cells (Fig 3D). We also measured CD4+ T 
cell activation in the lymph node draining from the aortic root and found a significant 
reduction in expression of CD69, CD25 and CD86 on CD4+ T cells in mice treated with 
IL-10+ B cells compared to mice receiving PBS or IL-10– B cells (Fig. 3E). This illustrated 
that the CD4+ T cells are less activated in mice receiving IL-10+ B cells compared to 
mice treated with PBS or IL-10– B cells. Taken together, these data clearly indicate that 
adoptive transfer of IL-10+ B cell resulted in significant immune regulation.
IL-10– B cells are strongly atherogenic while IL-10+ B cells do not affect 
lesion size
Considering the strong immune regulation after treatment with IL-10+ B cells, we 
wondered what their effect on atherosclerosis development was. Hence, we mea-
sured lesion size and composition in the aortic root. We found that while treatment 
of mice with IL-10– B cells led to a drastic increase in atherosclerosis, treatment of 
mice with IL-10+ B cells did not affect lesion size compared to PBS-treated mice (Fig. 
4A). Similarly, lesion composition in terms of collagen and macrophage content did 
not differ between mice treated with PBS or IL-10+ B cells. In contrast, lesions of 
mice that received IL-10– B cells showed a more advanced lesion phenotype with 
increased collagen and total macrophage area (Fig. 4B and 4C).
Figure 3. Adoptive transfer of IL-10+ B cells leads to strong immune regulation. Ldlr-/- mice were put 
on a Western type diet for 9 weeks and received either three i.v. injections of PBS, IL10+ or IL10– 
B cells (1x106 cells/injection). (A) Hematologic analysis of circulating white blood cells. Blood samples 
were analyzed with flow cytometry for (B) inflammatory monocytes (B220–NK1.1– CD11b+SSCloLy-
6GintLy-6Chi), (C) IL-10+CD4+ T cells and (D) naïve (CD62l+CD44–), effector memory (CD62l–CD44+) or 
central memory (CD62l+CD44+) CD4+ T cells. (E) Single cell suspensions of isolated lymph nodes were 
analyzed for activation markers on CD4+ T cells with flow cytometry. Data are shown as mean ± SEM 
(*p<0.05, ** p<0.01, ***p<0.001, ****p<.00001).
Chapter 3
60
Adoptive transfer of both IL-10– and IL-10+ B cells leads to exacerbated 
serum cholesterol levels
Given the strong evidence for an anti-atherogenic immune regulatory effect of IL-
10+ B cells, we were surprised to find that adoptive transfer of IL-10+ B cells did 
not alter lesion size or composition. To explain this discrepancy, we explored other 
parameters, which could have masked the anti-atherogenic effects of IL-10+ B cells 
on the immune system. Considering the strong correlation of serum cholesterol 
levels with lesion size, we determined whether the cellular therapy had resulted 
in altered lipid levels. Indeed, we found differences in body weight (Fig. 5A) and an 
unexpected increase in total serum cholesterol levels in mice receiving IL-10+ as well 
as IL-10– B cells (Fig. 5B), which was primarily caused by an increase in the levels 
of very-low density lipoprotein (Fig. 5C). We determined significant correlations of 
serum cholesterol levels and lesion size for mice treated with PBS or IL-10– B cells, 
but this correlation was abolished in mice that received IL-10+ B cells (Fig. 5D). Since 
cholesterol is a key determinant for lesion development, this suggests that lipid-
independent mechanisms interfered during the development of atherosclerosis. We 
further investigated the livers of mice treated with IL-10+ or IL-10– B cells and found 
that these displayed increased Oil Red O staining compared to the PBS-treated mice 
(Fig. 5E). Moreover, we analyzed the lipid content of the livers and found a remark-
Figure 4. IL-10– B cells are strongly atherogenic while IL-10+ B cells do not affect lesion size. Ldlr-/- 
mice were put on a Western type diet for 9 weeks and received either three i.v. injections of PBS, 
IL10+ or IL10– B cells (1x106 cells/injection). Representative pictures and quantification of aortic-root 
sections stained with (A) Oil Red O (B) Masson’s trichrome staining and (C) MOMA-2. Data are shown 
as mean ± SEM (*p<0.05, ** p<0.01).
61
Bidirectional effects of IL-10+ regulatory B cells in Ldlr-/- mice
able increase in both cholesterol (Fig. 5F) and triglycerides (Fig. 5G) in mice that 
received B cell adoptive transfers compared to PBS-treated mice. Given the strong 
immune regulation in mice receiving IL-10+ B cells we believe that these effects 
have negated the atherogenic effects of increased cholesterol levels. In an effort to 
shed some light on the increased cholesterol levels, we measured the expression of 
lymphotoxin-alpha (LTα) and LIGHT on B cells after CD40-stimulation, since these 
molecules have previously been shown to regulate cholesterol levels in Ldlr-/- mice29. 
We found that CD40-stimulation of B cells significantly enhanced the expression 
of both LIGHT (Fig. S6A) and LTα (Fig. S6B). Our isolation protocol further required 
B cells to be stimulated with LPS, PMA and ionomycin and after this additional 
stimulus, expression of LIGHT and LTα remained high on B cells (Fig. S6A-B). Subse-
quently, we separated IL-10– and IL-10+ B cells and measured the gene expression of 
LIGHT and LTα by qPCR and did not find any significant differences between IL-10– 
and IL-10+ B cells (Fig. S6C). These findings might explain the increased cholesterol 
levels found in mice that received an adoptive transfer with IL-10– or IL-10+ B cells.
Discussion
Since the role of Bregs in cardiovascular disease is currently under debate11–13, we 
aimed to investigate the contribution of IL-10+ B cells to diet-induced atherosclero-
sis. IL-10+ B cells were drastically reduced during atherosclerosis development and 
Figure 5. Adoptive transfer of both IL-10– and IL-10+ B cells leads to exacerbated serum cholesterol 
levels. Ldlr-/- mice were put on a Western type diet for 9 weeks and received either three i.v. injec-
tions of PBS, IL10+ or IL10– B cells (1x106 cells/injection). (A) Body weight was assessed during the 
experiment. (B) Quantification of total serum cholesterol levels. (C) Characterization of the serum li-
poprotein profile. (D) Correlations between serum cholesterol levels and plaque size in the aortic root. 
(E) Sections of liver tissue were stained with Oil-Red-O. (F) Quantification of extracted cholesterol 
content in the liver. (G) Quantification of extracted cholesterol content in the liver. Data are shown as 
mean ± SEM (*p<0.05, ** p<0.01, ***p<0.001, ****p<.00001).
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adoptive transfer of pure IL-10+ B cells limited the immune reaction. However, this 
was also associated with increased serum cholesterol levels and a fatty liver and this 
bidirectional effect prevented amelioration of atherosclerosis.
The increase in serum cholesterol levels after adoptive B cell transfer was a major 
unexpected finding of this study. There is a paucity of data examining the relation 
between immune cells and plasma cholesterol levels. While effects of dendritic 
cells30 and T cells29 have been described previously, a direct contribution of B cells to 
cholesterol homeostasis has not been recognized before. However, it has previously 
been shown that expression of LTα and LIGHT on CD4+ T cells is able to increase 
serum cholesterol levels29. Since it has also been shown that CD40-activation of 
B cells increases the expression of lymphotoxin on B cells31,32, we measured the 
expression of LTα and LIGHT on B cells in our experiments. We found that our 
ex vivo stimulation protocol led to a considerable increase in extracellular expres-
sion of both proteins, which could potentially explain the exacerbated lipid levels 
found in this study. Despite the lack of a defined causal mechanism, these findings 
underscore that the immune response and plasma lipid levels are more interrelated 
in atherosclerosis than frequently thought. Additionally, the increased plasma lipids 
have undoubtedly influenced the atherosclerosis development in our study and 
could have masked the beneficial effects of IL-10+ B cells on atherosclerosis.
We did however find a strong atherogenic effect of IL-10– B cells, which was not 
found using IL-10+ B cells. It is well-known that splenic B2 cells increase lesion 
size33,34, in line with our findings using IL-10– B cells, however we show here that 
pure splenic IL-10 producing B cells do not contain these atherogenic properties. 
Moreover, they limited the immune response and increased numbers of IL-10+ 
T cells. These findings corroborate with earlier data of an adoptive transfer study 
using CD21hiCD23hiCD24hi B cells that both induced IL-10+ T cells and exerted 
vascular protection11. In contrast, another study investigating the role of B cell-
derived IL-10 did not find any effect on atherosclerosis12. The authors used a mixed 
bone-marrow chimera model to establish a B cell-specific loss of IL-10, which did 
not influence lesion size. However, they also showed that IL-10 expression in the 
aorta was actually increased, possibly suggesting that IL-10 from other sources than 
B cells might compensate for the loss of B cell-derived IL-1012. Additional evidence 
for an atheroprotective role of Bregs was found by the observation that L-selectin 
deficiency decreased the aortic Breg cells and promoted atherosclerosis13. More 
recently, it was shown that induction of IL-10 producing B cells by a synergistic 
effect of BAFF and angiotensin II was associated with atheroprotection33. It has 
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also been shown that in human coronary artery disease Bregs have an impaired 
regulatory function6.
Given the substantial reduction of IL-10+ B cells in atherosclerosis and the immune-
regulating effects found in this study, we believe there is still ample evidence that 
IL-10+ B cells could protect against atherosclerosis. However, the lack of means 
to expand the number of Bregs in vivo still hampers this research. In this study we 
investigated a pure population of IL-10-secreting B cells, however the bidirectional 
effects induced by our culture protocol prevented an atheroprotective effect. In this 
respect, future research focusing on other strategies to induce Bregs in atheroscle-
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Bidirectional effects of IL-10+ regulatory B cells in Ldlr-/- mice
Supplementary Figure S1. Representative gating of IL-10+ B cells. Splenocytes were isolated and 
stimulated with a combination of LPS (50 µg/ml), PMA (50 ng/ml), ionomycin (500 ng/ml) and monen-
sin (2 µM) for 5 hours. Fc receptors were blocked and samples were stained with anti-mouse fluoro-
chrome conjugated antibodies against B220, CD19 and IL-10. After dead cells were excluded, B220+ 
cells were gated followed by gates for IL-10 and CD19 which were set according to unstimulated 
controls or to isotype controls.
Supplementary Figure S2. IL-10+ B cells in the blood and non-draining lymph nodes are not affected 
by Western Type Diet (WTD). Mice were either put on WTD or normal chow diet for 9 weeks after 
which single cell suspensions of blood, mesenteric lymph nodes and Peyer’s patches were stimulated 
with LPS+PMA+Ionomycin and Monensin for 5 hours. Fc receptors were blocked and samples were 
stained with anti-mouse fluorochrome conjugated antibodies against B220, CD19 and IL-10. Gates 
were set according to unstimulated controls or to isotype controls.
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Supplementary Figure S3. Regulatory B cell subsets. Ldlr-/- mice were fed a WTD or normal chow diet 
for 9 weeks after which spleens and lymph nodes were analyzed with flow cytometry to determine 
(A) CD21hiCD23hiCD24hi B cells, (B) TIM-1+ B cells and (C) CD1dhiCD5+ B cells. (D) Single cell suspen-
sions from the peritoneum were analyzed for B2 (CD19+B220+), B1a (CD19+B220–CD5+) and B1b 
(CD19+B220–CD5–) cells.
Supplementary Figure S4. Isolation of pure and viable IL-10+ B cells. B cells were cultured with an 
agonistic CD40 antibody (5 µg/ml) for 72 hours after which they were stimulated with LPS (50 µg/ml), 
PMA (50 ng/ml) and ionomycin (500 ng/ml) to secrete IL-10. Using a specialized IL-10-catching anti-
body, IL-10-secreting B cells were separated from non IL-10-secreting B cells using magnetic beads. 
Flow cytometry analysis of the isolated cells showed that this consistently resulted in a ≥95% purity 
of viable IL-10+ B cells.
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Supplementary Figure S5. Experimental setup of adoptive transfer experiment. Ldlr-/- mice were put 
on a Western type diet for 9 weeks and received either three i.v. injections of PBS, IL-10+ or IL-10– 
B cells (1x106 cells/injection) after which the mice were sacrificed and atherosclerosis was quantified.
Supplementary Figure S6. CD40-stimulation of B cells leads to increased lymphotoxin-alpha and 
LIGHT expression. Isolated CD19+ B cells were stimulated for indicated periods of time with an ago-
nistic CD40 antibody (5 µg/ml) with additional LPS, PMA and ionomycin stimulation where indicated. 
Subsequently, expression of (A) LIGHT and (B) lymphotoxin-alpha (LTα) were measured with flow 
cytometry. (C) IL-10– and IL-10+ CD19+ B cells were isolated after stimulation for 72 hours with an 
agonistic CD40 antibody followed by LPS, PMA and ionomycin stimulation for 5 hours. Subsequently, 
the expression of LIGHT and lymphotoxin-alpha (LTα) were measured with qPCR. Data are shown as 
mean ± SEM (***p<0.001, ****p<.00001).
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Increasing evidence has shown that immune checkpoint molecules of the T-cell im-
munoglobulin and mucin domain (TIM) family are associated with diverse physiologic 
and pathologic processes. Previous studies of the role of TIM-1 in atherosclerosis 
using anti-TIM-1 antibodies have yielded contradictory results. We thus aimed to 
investigate atherosclerosis development in TIM-1 deficient mice. In this study, mice 
with a specific loss of the TIM-1 mucin-domain (TIM-1Δmucin) were used. Introduc-
tion of atherosclerosis in TIM-1Δmucin and C57BL/6 (WT) mice was performed with 
a single injection of a recombinant adeno-associated virus encoding murine PCSK9 
(rAAV2/8-D377Y-mPCSK9). Subsequently mice were fed a Western type diet for 13 
weeks and atherosclerosis development was quantified. TIM-1Δmucin mice developed 
significantly larger lesions in the aortic root and arch compared to WT mice. These 
lesions were composed of significantly more macrophages and showed a trend 
towards a larger necrotic core. The exacerbated atherosclerosis in TIM-1Δmucin mice 
was associated with a significant loss of IL-10+ B cells and regulatory B cell subsets 
compared to WT mice. TIM-1Δmucin mice also showed an increase in splenic and 
circulating leukocytes compared to WT mice, which was caused by an increase in B 
and CD4+ T cells in the spleen, while no specific leukocyte population was changed 
in the circulation. Splenic CD4+ T cell activation was not affected, but TIM-1Δmucin 
mice showed decreased CD4+ T cell differentiation as measured by an increased 
number of naïve CD4+ T cells. TIM-1Δmucin mice also displayed a dramatic reduction in 
Th2-associated immune response compared to controls but no changes in humoral 
immune response. In summary, TIM-1Δmucin mice displayed a profound impairment in 
IL-10+ B cells and an imbalance in the Th1/Th2 ratio, which associated with exacer-
bated atherosclerosis.
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Introduction
Regulation of immune responses represents a promising option for the treatment 
of atherosclerosis1. Activation of the immune system is tightly controlled by im-
mune checkpoint proteins and these molecules comprise an interesting group of 
therapeutic targets2. Immune checkpoint proteins are comprised of a diverse fam-
ily of molecules, each with its own target cells and pathways. In general, immune 
checkpoint proteins are divided into stimulatory or inhibitory coreceptors, which 
are often associated with a proatherogenic and atheroprotective role, respectively2. 
Earlier data show that immune checkpoint molecules of the T-cell immunoglobulin 
and mucin domain (TIM) family are associated with a number of disorders including 
asthma, allergy and autoimmunity3. Eight murine members of the TIM gene family 
have been identified (TIM1-8), while in humans only three orthologues have been 
characterized (TIM1, -3, and -4). Structurally, TIM molecules are composed of an 
immunoglobulin V domain, a mucin-like domain, a transmembrane domain and a 
cytoplasmic tail3. There are distinct ligands for each TIM protein, however, there 
is some overlap between TIM-1 and TIM-4 since both molecules are able to bind 
phosphatidylserine which is expressed by apoptotic cells4. Additionally, it has been 
shown that TIM-4 is able to interact with TIM-1 as a ligand5. The cellular expression 
pattern of TIM proteins is quite broad, including T cells, B cells, macrophages and 
dendritic cells (DCs), highlighting the central role TIM molecules can play in the 
immune response.
We have previously explored the effects of TIM-1, TIM-3 and TIM-4 in atherosclero-
sis6,7 and identified that antibody-mediated blockade of any of these TIM molecules 
results in exacerbated atherosclerosis, indicating a general protective role of TIM-
signaling in atherosclerosis6,7. In contrast, others have recently shown that by using a 
different antibody clone, TIM-1 antagonism resulted in attenuated atherosclerosis8. 
TIM-1 is an immune checkpoint protein which is primarily expressed on CD4+ helper 
type 2 cells9, dendritic cells and regulatory B cells10. Principal studies suggested that 
TIM-1 is a stimulatory coreceptor since it induced T cell proliferation and cytokine 
production9. Later studies, however, showed that TIM-1 has a more complex im-
mune checkpoint function5,11. It has been demonstrated that the administration of 
low doses of a soluble TIM-1 ligand (TIM-4) results in significant T cell inhibition, 
while higher doses increase T cell proliferation5. Additionally, it was shown that dif-
ferential engagement by two TIM-1 antibodies could result in T cell expansion or 
inhibiton11. These data clearly demonstrate that TIM-1 signaling is highly dependent 
on ligand density and the extent of TIM-1 engagement5,11. This could potentially ex-
plain the differential effects of antagonistic TIM-1 antibodies on atherosclerosis6,8. 
Chapter 4
74
Indeed, the anti-TIM-1 antibody used by Hosseini et al. (RMT1-10) has a low binding 
avidity and might be partial agonistic11, while the antibody used in our previous 
experiments (3D10) is described as a non-activating antibody12.
The contradictory results obscure the precise contribution of TIM-1 during 
atherosclerosis development and warrant additional research. To circumvent the 
complexities associated with antibody binding avidity and functionality, we aimed 
to examine the effects of TIM-1 in atherosclerosis using TIM-1-deficient mice. 
Earlier work showed that complete TIM-1 deficiency fails to show any marked 
phenotype13,14. However, others have previously shown that the mucin domain of 
TIM-1 has a crucial biological function in TIM-1 signalling15. Mice with a specific loss 
of the TIM-1 mucin-domain (TIM-1Δmucin) retain the ligand binding IgV structure and 
express TIM-1 at normal levels. These mice do demonstrate a profound defect in 
regulatory B cells with associated development of systemic autoimmunity15. In this 




Female C57BL/6 (WT) and TIM-1-mucin domain-deficient (TIM-1Δmucin) mice15 were 
bred in house and were kept under standard laboratory conditions. TIM-1Δmucin mice 
were provided by Dr. V. Kuchroo (Brigham and Women’s Hospital). Mice were fed 
a Western-type diet (WTD) containing 0.25% cholesterol and 15% cocoa butter 
(Special Diet Services, Witham, Essex, UK). Diet and water were provided ad libitum. 
During the experiments, mice were weighed, and blood samples were obtained by 
tail vein bleeding. At the end of experiments, mice were anaesthetized by a subcuta-
neous injection of a cocktail containing ketamine (40 mg/mL), atropine (50 μg/mL), 
and sedazine (6.25 mg/mL). Mice were exsanguinated by femoral artery transection 
followed by perfusion with PBS through the left cardiac ventricle. All animal work 
was approved by the Leiden University Animal Ethics Committee and the animal 
experiments were performed conform the guidelines from Directive 2010/63/EU of 
the European Parliament on the protection of animals used for scientific purposes.
PCSK9-induced atherosclerosis
To induce atherosclerosis in WT and TIM-1Δmucin mice, 8-9 week old female mice were 
administered a single i.v. injection of rAAV2/8-D377Y-mPCSK9 (5x1011 genome 
copies/mouse)16. This results in the rapid overexpression of proprotein convertase 
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subtilisin/kexin type 9 (PCSK9) and a significant decrease in hepatic low-density 
lipoprotein receptor (LDLR)16. For atherosclerosis development, mice were subse-
quently fed a WTD for 13 weeks before mice were sacrificed and relevant organs 
were harvested for analysis.
Flow cytometry
For the analysis of IL-10+ B cells, single cell suspensions were stimulated for 5 
hours with LPS (50 µg/ml), PMA (50 ng/ml), ionomycin (500 ng/ml) and monensin 
(2 µM). Secretion of cytokines by T cells was induced with stimulation of PMA, 
ionomycin and brefeldin A (5 µg/ml). For flow cytometry analysis, Fc receptors of 
single cell suspensions were blocked with an unconjugated antibody against CD16/
CD32. Samples were then stained with a fixable viability marker (ThermoScientific) 
to select live cells and with anti-mouse fluorochrome-conjugated antibodies (see 
Supplementary Table 1). FACS analysis was performed on a FACSCanto II (Becton 
Dickinson) and the acquired data were analyzed using FlowJo software.
Proliferation assay
To measure T cell proliferation, 2x105 splenocytes were cultured in RPMI medium 
(supplemented with 10% FCS, L-glutamine and streptomycin/penicillin) for 72h. 
Cells were cultured with medium, oxidized low-density lipoprotein (oxLDL, 5 µg/ml) 
or stimulated with anti-CD3 (1.25 µg/ml) and anti-CD28 (1.25 µg/ml). Supernatant 
was harvested for cytokine analysis before splenocytes were pulsed with 3H-thy-
midine (0.5 μCi/well, Perkin Elmer, The Netherlands) for the last 16h. The amount 
of 3H-thymidine incorporation was measured using a liquid scintillation analyzer 
(Tri-Carb 2900R). Responses are expressed as the disintegrations per minute (DPM).
Cytokine determination
Cytokine levels in culture supernatants were measured using a Luminex bead-based 
multiplex assay (ProcartaPlex, Thermo Fisher Scientific) on a Luminex Instrument 
(MAGPIX). Recombinant cytokine standards (Thermo Fisher Scientific) were used to 
calculate cytokine concentrations and data were analyzed using Bio-Rad software.
Blood and serum analyses
During the experiment, blood was collected from the tail vein. After euthanasia, 
orbital blood was collected in EDTA-coated tubes. Whole blood cell counts were 
analyzed using the XT-2000iV hematology analyzer (Sysmex Europe GMBH, Nor-
derstedt, Germany). Serum was acquired by centrifugation and stored at -20°C until 
further use. The total cholesterol levels in serum were determined using enzymatic 
colorimetric procedures (Roche/Hitachi, Mannheim, Germany). Precipath (Roche/
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Hitachi) was used as an internal standard. Total serum titers of IgM, IgG1, IgG2c and 
oxidized LDL-specific antibodies were quantified by ELISA as previously described17. 
Serum levels of PCSK9 were measured by ELISA according to manufactures protocol 
(R&D systems).
Histology
To determine lesion size, cryosections (10 μm) of the aortic root and aortic arch 
were stained with Oil-Red-O and hematoxylin (Sigma-Aldrich). Sections with the 
largest lesion plus four flanking sections were analyzed for lesion size. Collagen 
content in the lesion was assessed with a Masson’s trichrome staining according 
to the manufacturers protocol (Sigma-Aldrich). Corresponding sections on separate 
slides were also stained for monocyte/macrophage content using a monoclonal rat 
IgG2b antibody (MOMA-2, 1:1000, AbD Serotec) followed by a goat anti-rat IgG-
horseradish peroxidase antibody (1:100, Sigma-Aldrich) and color development. All 
slides were analyzed with a Leica DM-RE microscope and LeicaQwin software (Leica 
Imaging Systems).
Statistics
All data are expressed as mean ± SEM. Data were tested for significance using a Stu-
dent’s t-test. Probability values of p < 0.05 were considered significant. All statistical 
analysis was performed using GraphPad Prism 7.0.
Results
TIM-1Δmucin mice display exacerbated atherosclerosis
Since we aimed to investigate the effects of impaired TIM-1 signaling in the context 
of atherosclerosis, we administered TIM-1Δmucin mice a single injection of a recombi-
nant adeno-associated virus encoding for a gain-of-function for PCSK9 (rAAV2/8-
D377Y-mPCSK9)16. This resulted in the rapid induction of circulating PCSK9 (Fig. 
S1A) and cholesterol (Fig. S1B) levels after mice were fed a WTD. Despite a signifi-
cant lower body weight at the time of sacrifice (Fig. S1C), we found that TIM-1Δmucin 
mice showed a considerable increase in lesion development (Fig. 1A). We further 
characterized lesion composition and noticed that the macrophage content was 
significantly increased in lesions from TIM-1Δmucin mice compared to WT mice (Fig. 
1B). Additionally, there were no differences in collagen content, but we found a 
trend towards a larger necrotic core area in lesions of TIM-1Δmucin mice compared 
to WT mice (Fig. 1C). We also analyzed lesion development in the aortic arch and 
found a dramatic increase in lesion size in TIM-1Δmucin mice compared to WT mice 
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(Fig. 1D). These data clearly indicate that TIM-1Δmucin mice developed exacerbated 
atherosclerosis.
Figure 1. TIM-1Δmucin mice display exacerbated atherosclerosis. C57BL/6 (WT) and TIM-1-mucin do-
main-deficient (TIM-1Δmucin) mice were administered a single i.v. injection of rAAV2/8-D377Y-mPCSK9 
and subsequently fed a Western type diet for 13 weeks to induce atherosclerosis. After 13 weeks the 
aortic root was analyzed for (A) lesion size, which was determined with an Oil-Red-O and hematoxylin 
staining, (B) macrophage/monocyte content, which was determined with a MOMA-2 antibody and 
(C) collagen content and necrotic area, which were assessed using a Trichrome staining. (D) The aortic 
arch was analyzed for lesion size, which was determined with an Oil-Red-O and hematoxylin staining. 
Representative pictures are shown. Data are shown as mean ± SEM (**p<0.01), n=12-19/group for 
A-C and n=5-6/group for D.
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TIM-1Δmucin mice show impaired IL-10 production by Bregs
In a previous study, it was demonstrated that the major impairment in TIM-1Δmucin 
mice is defective IL-10 production by B cells15. To assess if reduced IL-10-producing 
B cells (Bregs) could have contributed to the increased lesion development in our 
experiment, we measured circulating IL-10-producing B cells during the experiment. 
As shown in Figure 2A, IL-10+ B cells were reduced in TIM-1Δmucin mice compared to 
WT mice which reached significance at week 3 and 8. Additionally, the area under 
the curve showed that the total presence of circulating Bregs during the experiment 
was significantly reduced in TIM-1Δmucin mice compared to WT mice (Fig. 2B). Sub-
sequently, we found a significant reduction of Breg cells in spleens of TIM-1Δmucin 
mice at sacrifice (Fig. 2C). Furthermore, we determined the level of well-known Breg 
subsets CD1dhiCD5+ B cells18 and CD9+ B cells19,20 and found that these subsets were 
significantly lower in TIM-1Δmucin mice when compared to levels in WT mice (Fig. 2D 
and 2E). Since TIM-1 is also an important Breg marker15,21, we measured the presence 
of TIM-1+ B cells, and found these cells were significantly decreased in TIM-1Δmucin 
mice compared to WT mice (Fig. 2F). These findings highlight that during atheroscle-
rosis development, TIM-1Δmucin mice display an impaired IL-10 production by Bregs.
Figure 2. TIM-1Δmucin mice show impaired IL-10 production by Bregs. C57BL/6 (WT) and TIM-1-mucin 
domain-deficient (TIM-1Δmucin) mice were administered a single i.v. injection of rAAV2/8-D377Y-mPC-
SK9 and subsequently fed a Western type diet for 13 weeks to induce atherosclerosis. (A) During the 
experiment, blood samples were obtained and single cell suspensions of blood leukocytes were stimu-
lated for 5 hours with LPS, PMA, ionomycin and monensin after which the IL-10 positive B cells were 
determined with flow cytometry. (B) Quantification of the area-under-the curve of circulating IL-10+ 
B cells during the experiment. After 13 weeks, the number of (C) IL-10+ B cells, (D) CD1dhiCD5+ B cells, 
(E) CD9+ B cells and (F) TIM-1+ B cells were determined in the spleen with flow cytometry. Data are 
shown as mean ± SEM (*p<0.05, **p<0.01, ****p<0.0001) and n=5-8/group.
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Increased viable leukocytes in TIM-1Δmucin mice
Deficiencies in IL-10-producing B cells have previously been shown to induce an 
activated immune phenotype15. We examined if the development of atherosclero-
sis in TIM-1Δmucin mice led to a similar activation of the immune system. We first 
measured spleen weight (Fig. 3A) and the total number of spleen cells (Fig. 3B) and 
did not find differences between WT and TIM-1Δmucin mice. TIM-1 is involved in the 
recognition of apoptotic cells22 and flow cytometry experiments displayed a consis-
tent increase in the percentage of viable white blood cells both in the spleen and 
circulation of TIM-1Δmucin mice compared to WT mice (Fig. 3C). We further examined 
if specific leukocyte populations were increased, which revealed that the number of 
splenic CD4+ T cells and CD19+ B cells were significantly increased, while CD11b+ 
leukocytes and dendritic cells were markedly decreased in the spleen of TIM-1Δmucin 
mice compared to WT mice (Fig. 3D). Analysis of circulating cells revealed a similar 
phenotype with increased CD19+ B cells and a percentage of circulating monocytes 
(Fig. 3E).
Figure 3. Increased viable leukocytes in TIM-1Δmucin mice. At sacrifice, (A) spleens of C57BL/6 (WT) 
and TIM-1-mucin domain-deficient (TIM-1Δmucin) mice were weighed and (B) the total number of sple-
nocytes were analyzed with a Sysmex hematolyzer. Using flow cytometry the percentage white bloods 
cells negative for Fixable Viability Dye (FVD) were assessed (C). Specific leukocyte populations in the 




CD4+ T cell differentiation but not activation is affected in TIM-1Δmucin mice
To investigate if the increase in splenic CD4+ T cells was due to enhanced CD4+ 
T cell activation, we first assessed the expression of CD69 and the proliferation 
marker Ki-67 in CD4+ T cells. This, however, did not reveal any (statistical significant) 
differences between the different mice phenotypes (Fig. S2). Next, we isolated sple-
nocytes and performed an ex vivo proliferation assay. Irrespective of the stimulus 
used (i.e. oxLDL or anti-CD3/anti-CD28), splenocytes from WT and TIM-1Δmucin 
mice showed a comparable proliferation (Fig. S3). Similarly, levels of IL-2 in the 
supernatants of anti-CD3/anti-CD28 stimulated splenocytes did not differ between 
Figure 4. CD4+ T cell response in TIM-1Δmucin mice. At sacrifice, splenocytes of C57BL/6 (WT) and 
TIM-1-mucin domain-deficient (TIM-1Δmucin) mice were analyzed with flow cytometry to determine 
the number of (A) naïve (CD62l+CD44hi) and effector memory (CD62l–CD44hi) CD4+ T cells and (B) Th1 
(T-bet+), Th2 (Gata-3+), Treg (CD25+FoxP3+), Th17 (RORγt+) CD4+ T cells. (C) Single cell suspensions of 
splenocytes were stimulated for 5 hours with PMA, ionomycin and Brefeldin A after which intracel-
lular IFNγ and IL-4 was measured and the ratio between IFNγ+ and IL-4+ CD4+ T cells was determined. 
(D) Splenocytes were cultured in RPMI medium and stimulated with anti-CD3 (1.25 µg/ml) and anti-
CD28 (1.25 µg/ml). After 72 hours, supernatant was harvested and analyzed with a multiplex assay 
for Th2-associated cytokines. Data are shown as mean ± SEM (*p<0.05, **p<0.01, ***p<0.001) and 
n=5-8/group.
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WT and TIM-1Δmucin mice (Fig. S3). These data suggest that the activation of CD4+ 
T cells in TIM-1Δmucin mice was not affected during atherosclerosis development. We 
subsequently tested whether the differentiation of CD4+ T cells was altered, since 
TIM-1 appears to be primarily involved in Th2 responses6,23. We noticed that spleens 
of TIM-1Δmucin mice contained significantly more naïve CD4+ T cells compared to 
spleens of WT mice (Fig. 4A), while no difference was found in the number of effec-
tor memory CD4+ T cells. More detailed analysis of the CD4+ T cell subsets showed 
that TIM-1Δmucin mice demonstrated a significant decrease in the number of Th1 and 
Th17 cells compared to WT mice, with an even more remarkable decrease in the 
number of Th2 cells (Fig. 4B). Subsequently, we used a five hour ex vivo stimulation 
with PMA and ionomycin to determine cytokine production by CD4+ T cells from 
WT and TIM-1Δmucin mice. While we did not find any differences between TIM-1Δmucin 
and WT mice in IFNγ, IL-4 or IL-10 production with flow cytometry (Fig. S4), we 
noticed a significant shift in the IFNγ/IL-4 ratio indicating a reduced Th2-response 
(Fig. 4C). We wanted to further investigate this effect and measured additional 
cytokines in the culture supernatants of our ex vivo proliferation assay. In line with 
a reduced Th2-response, we did not observe any differences in Th1-, Th17- and 
Treg-associated cytokines in culture supernatants (Fig. S5), however we observed a 
large decrease in the Th2-associated cytokines IL-4 and IL-5 in culture supernatants 
from TIM-1Δmucin splenocytes compared to WT splenocytes (Fig. 4D). These data 
indicate that impaired TIM-1 signaling significantly decreased the differentiation of 
naïve CD4+ T cells towards Th2 cells.
Humoral immunity is unaffected in TIM-1Δmucin mice
Isotype switching of B cells is strongly influenced by local cytokine production and 
given the increased number of splenic B cells and decrease in Th2 cells, we won-
dered if the humoral immunity was altered in TIM-1Δmucin mice. We measured total 
IgG1 (Fig. 5A) and IgG2c (Fig. 5B), which did not reveal any differences between the 
two groups. Given the shift we observed in the Th1/Th2 ratio, we examined the 
IgG2c/IgG1 ratio and found a slight but non-significant trend towards an increased 
ratio (Fig. 5C). Similarly, we did not find any differences in total oxLDL-specific IgG 
levels (Fig. 5D). It has recently been shown that treatment of mice with the RMT1-
10 anti-TIM1 antibody resulted in increased peritoneal B1 cells and a concomitant 
increase in atheroprotective IgM antibodies8. In contrast, defective TIM-1 signaling 
did not influence peritoneal B1 cells numbers (Fig. 5E), total IgM levels (Fig. 5F) 
or oxLDL-specific IgM levels (Fig. 5G). Taken together, these data indicate that the 




TIM-1 has been associated with a broad number of inflammatory disorders. We 
and others have previously investigated the role of TIM-1 in atherosclerosis using 
anti-TIM-1 antibodies6,8. However, due to the complex nature of TIM-1 signaling 
these studies demonstrated contradicting results. It is clear that TIM-1 signaling is 
highly dependent on binding avidity, which varies with different anti-TIM-1 anti-
body clones. Here, we circumvented the antibody-associated difficulties by using 
TIM-1Δmucin mice and now show that TIM-1 has an overall protective effect during 
atherosclerosis development.
A previous study with TIM-1Δmucin mice revealed that up to 6 months of age these 
mice did not develop any overt auto-immune responses, but already showed a mild 
defect in B cell-derived IL-10 production15. With increasing age, or when crossbred 
onto an autoimmune genetic background, the Breg deficiency was exacerbated 
and resulted in concomitant increased numbers of B and T cells15. In this study, we 
show that the development of atherosclerosis in young TIM-1Δmucin mice (<6 months) 
was accompanied by profound impairment in B cell associated IL-10 production. 
Similarly, we observed leukocytosis in the spleen and circulation of TIM-1Δmucin mice, 
with primarily an increase in B cells and CD4+ T cells. A major difference with the 
study of Xiao et al., however, is our observation of increased naïve but not differ-
Figure 5. The humoral immunity is unaffected in TIM-1Δmucin mice. At sacrifice, serum from C57BL/6 
(WT) and TIM-1-mucin domain-deficient (TIM-1Δmucin) mice was analyzed for total (A) IgG1, (B) IgG2c 
and (F) IgM levels. Serum titers of (D) IgG and (G) specific for oxidized low-density lipoprotein (oxLDL) 
were measured. (C) Quantification of the IgG2c/IgG1 ratio. Flow cytometry was used to (E) quantify 
CD19+CD5+ B1 cells in the peritoneal cavity. Data are shown as mean ± SEM and n=5-8/group.
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entiated CD4+ T cells , while they observed increased CD4+ T cell activation and 
differentiation TIM-1Δmucin mice15. They demonstrated that TIM-1Δmucin mice cross-
bred with Fas-mutant lpr mice showed marked autoimmune responses, including 
enlarged lymphoid tissues, and hyperactive B and T cells. A potential reason for this 
contrast is that TIM-1 expression is highly dynamic and depending on the context 
and immune status its resulting effect can be either positive or negative coinhibition. 
Fas-deficient lpr mice on a C57BL/6 background already develop systemic autoim-
munity24, while atherosclerosis induces a much milder autoimmune response. This 
difference in immune status between the disease models could have influenced the 
CD4+ T cell status in response to a lack in TIM-1 signaling. Additionally, we found 
that the number of splenic DCs was significantly reduced in our atherosclerotic 
TIM-1Δmucin mice. TIM-1 is constitutively expressed on DCs and TIM-1 signaling on 
DCs is associated with increased CD4+ T cell effector responses25. Thus the reduced 
number and absence of TIM-1 on DCs could also have contributed to the decreased 
effector CD4+ T cells in this study.
The two previous studies investigating the role of TIM-1 in atherosclerosis demon-
strated contrasting results6,8. While we previously showed that antibody blockade 
of TIM-1 was associated with a shift in the Th1/Th2 balance and exacerbated 
atherosclerosis, Hosseini et al. demonstrated that TIM-1 inhibition resulted in ath-
eroprotective IgM-producing B1a and IL-10+ B cells8. In this study we investigated 
atherosclerosis in TIM-1 deficient mice and found a combination of these effects. It 
has been shown that TIM-1 is predominantly expressed on Th2 cells, while expres-
sion is low on Th1 cells26. In addition, TIM-1 is frequently associated with allergic 
diseases which are mainly Th2-driven3. In line with these findings, we observed a 
strong decrease in Th2 cells and Th2-associated cytokines. In contrast, Th1- and 
Th17-associated cytokines were similar in TIM-1Δmucin and WT mice, resulting in a 
significant switch in the Th1/Th2 balance. While our observation of increased naïve 
CD4+ T cells would be expected to reduce atherosclerosis, atherosclerosis is primar-
ily a Th1-driven disease and skewing towards a Th1-dependent immune response 
in TIM-1Δmucin mice will most likely have significantly contributed to the increased 
atherosclerosis development in these mice. Besides the effects on CD4+ T cells, we 
also observed significant differences in IL-10+ B cells in TIM-1Δmucin mice. It is well-
known that TIM-1 has a prominent role in the maintenance and generation of IL-10+ 
B cells8,10,21. In other auto-immune disorders, IL-10+ B cells have shown great thera-
peutic potential, but their role in atherosclerosis is not clearly defined27,28. The work 
of Hosseini et al., however, showed that increased IL-10+ and TIM-1+ B cells after 
treatment with an partial agonistic TIM-1 antibody was associated with decreased 
atherosclerosis8, indicating that the strong decrease in IL-10+ B cells and Breg 
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subsets we found in TIM-1Δmucin mice could contribute to the exacerbated lesion 
development. Taken together, our work identified that mice completely deficient in 
effective TIM-1 signaling both showed an imbalance in the Th1/Th2 ratio as well as 
impaired numbers of IL-10+ B cells during atherosclerosis development.
There are also some interesting differences between our current study and ear-
lier data. For instance, we previously reported that TIM-1 inhibition resulted in 
increased IgG1 antibodies6 and others demonstrated that TIM-1 inhibition resulted 
in increased IgM production by B1a cells8, while TIM-1Δmucin mice do not display 
any alterations in antibody levels. One explanation for these discrepancies might 
lie in the use of different experimental atherosclerosis models. While we previously 
used low-density lipoprotein receptor-deficient (Ldlr-/-) mice on a WTD, Hosseini 
et al. investigated atherosclerosis development in apolipoprotein E-deficient mice. 
In the current study, we introduced atherosclerosis in TIM-1Δmucin mice by a PCSK9 
adeno-associated virus yielding an Ldlr-/- phenotype. As alluded to above, the ex-
pression and function of TIM-1 is highly dynamic and therefore also susceptible 
for the underlying disease pathology. This is also illustrated by the fact that TIM-1 
does not appear to have one unifying effect in inflammatory disorders29. Hence the 
subtle differences in experimental atherosclerosis models might have added to the 
observed differences found in these three studies.
In summary, this study has shed more light on the role of TIM-1 during athero-
sclerosis development. We show here that TIM-1Δmucin mice display a profound 
impairment of IL-10+ B cells and an imbalance in the Th1/Th2 ratio, which is associ-
ated with exacerbated lesion development. This work, combined with earlier data in 
mice, represents a firm foundation for future studies that could focus on elucidating 
the role of TIM-1 in human cardiovascular disease.
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Figure S1. General characteristics of WT and TIM-1Δmucin mice. C57BL/6 (WT) and TIM-1-mucin do-
main-deficient (TIM-1Δmucin) mice were administered a single i.v. injection of rAAV2/8-D377Y-mPCSK9 
and subsequently fed a Western type diet for 13 weeks to induce atherosclerosis. (A) Circulating 
levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) were measured after 13 weeks. (B) 
Serum cholesterol levels and (C) weight were monitored during the experiment. Data are shown as 
mean ± SEM (***p<0.001).
Figure S2. CD4+ T cell activation is not affected in TIM-1Δmucin mice. C57BL/6 (WT) and TIM-1-mucin 
domain-deficient (TIM-1Δmucin) mice were administered a single i.v. injection of rAAV2/8-D377Y-mPC-
SK9 and subsequently fed a Western type diet for 13 weeks to induce atherosclerosis. After 13 weeks 
single cells suspensions of the spleen were analyzed for CD69+ and Ki-67+ CD4+ T cells. Data are 
shown as mean ± SEM.
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Figure S3. No differences in T cell proliferation in TIM-1Δmucin mice. C57BL/6 (WT) and TIM-1-mucin 
domain-deficient (TIM-1Δmucin) mice were administered a single i.v. injection of rAAV2/8-D377Y-mPC-
SK9 and subsequently fed a Western type diet for 13 weeks to induce atherosclerosis. (A) After 13 
weeks, 2x105 splenocytes were cultured in RPMI medium and stimulated with oxidized low-density 
lipoprotein (oxLDL; 5 µg/ml) or anti-CD3 (1.25 µg/ml) and anti-CD28 (1.25 µg/ml). Cells were pulsed 
with 3H-thymidine (0.5 μCi/well) for the last 16h. The amount of 3H-thymidine incorporation was 
measured and expressed as the disintegrations per minute (DPM). (B) Levels of IL-2 in culture super-
natants of anti-CD3 and anti-CD28. Data are shown as mean ± SEM.
Figure S4. No differences in intracellular cytokines of CD4+ T cells in TIM-1Δmucin mice. C57BL/6 
(WT) and TIM-1-mucin domain-deficient (TIM-1Δmucin) mice were administered a single i.v. injection 
of rAAV2/8-D377Y-mPCSK9 and subsequently fed a Western type diet for 13 weeks to induce ath-
erosclerosis. After 13 weeks, single cell suspensions of splenocytes were stimulated for 5 hours with 
PMA, ionomycin and Brefeldin A after which intracellular IFNγ, IL-4 and IL-10 was determined within 
the CD4+ population. Data are shown as mean ± SEM.
89
TIM-1 mucin domain-mutant mice display exacerbated atherosclerosis
Figure S5. Cytokine production of CD4+ T cells in TIM-1Δmucin mice. C57BL/6 (WT) and TIM-1-mucin 
domain-deficient (TIM-1Δmucin) mice were administered a single i.v. injection of rAAV2/8-D377Y-mPC-
SK9 and subsequently fed a Western type diet for 13 weeks to induce atherosclerosis. After 13 weeks, 
2x105 splenocytes were cultured in RPMI medium and stimulated with anti-CD3 (1.25 µg/ml) and 
anti-CD28 (1.25 µg/ml). After 72 hours, supernatant was harvested and analyzed with a multiplex 
assay for (A) Th-1 associated cytokines, (B) Th17-associated cytoines and (C) IL-10+. Data are shown 
as mean ± SEM.
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B and T cells are interconnected in the T follicular helper – germinal center B cell 
(TFH-GC B cell) axis, which is hyperactive during atherosclerosis development and 
loss of control along this axis results in exacerbated atherosclerosis. Inhibition of the 
TFH – GC B cell axis can be achieved by providing negative co-stimulation to TFH cells 
through the PD-1/PD-L1 pathway. Therefore, we investigated a novel therapeutic 
strategy using PD-L1-expressing B cells to inhibit atherosclerosis. We found that 
IFNγ-stimulated B cells significantly enhanced PD-L1 expression and limited TFH 
cell development. To determine whether IFNγ-B cells can reduce collar-induced 
atherosclerosis, apoE-/- mice fed a Western-type diet were treated with PBS, B cells 
or IFNγ-B cells for a total of 5 weeks following collar placement. IFNγ-B cells 
significantly increased PD-L1hi GC B cells and reduced plasmablasts. Interestingly, 
IFNγ-B cells–treated mice show increased atheroprotective Tregs and T cell-derived 
IL-10. In line with these findings, we observed a significant reduction in total lesion 
volume in carotid arteries of IFNγ-B cells-treated mice compared to PBS-treated 
mice and a similar trend was observed compared to B cell-treated mice. In conclu-
sion, our data show that IFNγ-stimulated B cells strongly upregulate PD-L1, inhibit 
TFH cell responses and protect against atherosclerosis.
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Introduction
Cardiovascular disease (CVD) remains a major global health problem despite great 
developments in diagnosis and treatment. The underlying cause for CVD is athero-
sclerosis, which is a chronic autoimmune-like disease and is characterized by the 
formation of lipid-rich lesions in the arteries. The current available treatments are 
aimed at lipid lowering and lead to a 25-30% relative risk reduction1,2, indicative of 
an urgent need for novel disease-modifying drugs. In the last decade, accumulating 
evidence identified the immune system as a major contributor to the pathology of 
atherosclerosis3. For this reason, considerable effort has been devoted to restore the 
dysregulation of the immune system and inflammatory pathways in atherosclerosis.
B and T-lymphocyte dependent immune responses play a key role in the pathophysi-
ology of atherosclerosis and the role of most B and T cell subsets in atherosclerosis 
is now well-defined. For instance, B1 cells have shown a consistent atheroprotective 
effect4–7, while in multiple studies B2 cells were seen to contribute to atheroscle-
rosis8–11. In addition, the involvement of Th1, Th2 and Treg cells in atherosclerosis 
has also been examined comprehensively (reviewed in3). In contrast, only recently 
the contribution of other leukocyte subpopulations such as follicular (FO) B cells, 
marginal zone (MZ) B cells and follicular helper T cells (TFH) to atherosclerosis have 
been identified. Although FO B cells, MZ B cells and TFH cells are radically different 
cell types, they appear to be interconnected in the TFH – Germinal center B cell 
axis. FO B cells enter germinal centers, subsequently undergo proliferation and iso-
type switching and can differentiate in short-lived plasmablasts, which can further 
differentiate into long-lived plasma cells or memory cells. FO B cells promote the 
recruitment of TFH cells and the generation of germinal centers through expression 
of inducible co-stimulator ligand12. Previously, it has been shown that the TFH – GC 
B cell axis is hyperactivated and promotes lesion formation in both apolipoprotein 
E-deficient (apoE-/-) mice13 and low-density lipoprotein receptor-deficient mice fed a 
hypercholesterolemia-inducing diet14. In addition, both TFH cells and FO B cells are 
proatherogenic and can aggravate atherosclerosis15 16.
The TFH – GC B cell axis can be regulated by the co-inhibitory programmed death-1 
(PD-1)/PD-L1 pathway. TFH cells highly express PD-1 and their accumulation can 
be controlled by MZ B cells which express PD-L1. In response to high cholesterol 
levels, MZ B cells upregulate the expression of PD-L1 and thereby regulate TFH cell 
accumulation which limits an exacerbated adaptive immune response.14 However, 
this mechanism fails to completely arrest disease development. Interestingly, in 
autoimmune encephalomyelitis, it has been shown that adoptive transfer of B cells 
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expressing high levels of PD-L1 limited disease severity17. Whether PD-L1 express-
ing B cells can also be used therapeutically to inhibit atherosclerosis development 
has not yet been reported. In this study, we therefore induced PD-L1-expressing 




All animal work was approved by the Leiden University Animal Ethics Committee 
and the animal experiments were performed conform the guidelines from Direc-
tive 2010/63/EU of the European Parliament on the protection of animals used for 
scientific purposes. Female C57BL/6, B6.SJL-PtprcaPepcb/BoyCrl (also known as 
CD45.1) and apolipoprotein E-deficient (apoE-/-) mice were bred in house and kept 
under standard laboratory conditions. Diet and water were provided ad libitum. All 
injections were administered i.v. to the lateral tail vein in a total volume of 100 µl. 
During the experiments, mice were weighed, and blood samples were obtained by 
tail vein bleeding. At the end of experiments, mice were anaesthetized by a subcuta-
neous injection of a cocktail containing ketamine (40 mg/mL), atropine (50 μg/mL), 
and sedazine (6.25 mg/mL). Mice were bled and perfused with phosphate-buffered 
saline (PBS) through the left cardiac ventricle.
Cell culture
B cells were isolated from splenocytes of C57BL/6 or apoE-/- mice using CD19+ mi-
crobeads (Miltenyi Biotec) and cultured in complete RPMI medium. Isolated B cells 
were cultured with different concentrations of heat killed Staphylococcus aureus (In-
vivogen), B-cell activating factor (BAFF; R&D systems) or interferon-gamma (IFNγ; 
ThermoFisher) for 24 hours. For co-culture experiments, CD4+ T cells were isolated 
from splenocytes of C57BL/6 mice using a CD4+ T cell isolation kit (Miltenyi Biotec). 
For some experiments, the CD4+ T cells were labeled using a CellTrace Violet Cell 
Proliferation kit (ThermoFisher) according to the instructions of the manufacturer. 
B and T cells were co-cultured and stimulated with an agonistic plate-bound CD3 
antibody (5 µg/ml) for 72 hours. For adoptive transfer experiments, B cells were 
isolated from splenocytes of apoE-/- or CD45.1 mice, cultured in RPMI medium and 
stimulated for 24 hours with 20 ng/ml of IFNγ. Subsequently, cells were washed, 
checked for purity using flow cytometry and resuspended for injections with PBS. 
For the injection of untouched B cells, B cells were freshly isolated from splenocytes 
of apoE-/- or CD45.1 mice and directly used for adoptive transfer experiments.
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Real-time quantitative PCR
RNA was extracted from cultured B cells by using Trizol reagent according to manu-
facturer’s instructions (Invitrogen) after which cDNA was generated using RevertAid 
M-MuLV reverse transcriptase according to the instructions of the manufacturer 
(Thermo Scientific). Quantitative gene expression analysis was performed using 
Power SYBR Green Master Mix on a 7500 Fast Real-Time PCR system (Applied 
Biosystems). Gene expression was normalized to housekeeping genes. Primer se-
quences are available in Supplementary table 1.
In vivo experiments
For all in vivo experiments, apoE-/- mice were used. ApoE-/- mice were fed a Western-
type diet containing 0.25% cholesterol and 15% cacao butter (SDS, Sussex, UK). 
For the pilot study, mice were pre-fed a Western-type diet for 2 weeks and were 
subsequently treated with 2x106 freshly isolated or cultured B cells and sacrificed 
after three days. For atherosclerosis experiments, carotid artery plaque formation 
was induced after two weeks of Western-type diet feeding by perivascular collar 
placement in these mice as described previously35. Mice continued to be fed a 
Western-type diet for 5 weeks and during this period received 3 injections with ei-
ther freshly isolated B cells (2x106 cells/injection), B cells stimulated with 20 ng/ml 
IFNγ for 24 hours (2x106 cells/injection) or PBS. To discriminate between adoptively 
transferred cells and endogenous cells, B cells were isolated from CD45.1 mice for 
the last injection. Time between injections was 2 weeks. At the end of experiments, 
mice were sacrificed and relevant organs were harvested for analysis.
Cytokine analysis
Isolated splenocytes from PBS, B cell or IFNγ-B cell treated mice were cultured 
in complete RPMI medium and stimulated for 72 hours with anti-CD3 (1 µg/ml) 
and anti-CD28 (0.5 µg/ml). The levels of cytokines in culture supernatants were 
measured using a Luminex bead-based multiplex assay (ProcartaPlex, Thermo Fisher 
Scientific) on a Luminex Instrument (MAGPIX). Recombinant cytokine standards 
(Thermo Fisher Scientific) were used to calculate cytokine concentrations and data 
were analyzed using Bio-Rad software.
Flow cytometry
For flow cytometry analysis, Fc receptors of single cell suspensions were blocked 
with an unconjugated antibody against CD16/CD32. Samples were then stained 
with a fixable viability marker (ThermoScientific) to select live cells. Next, cells were 
stained with anti-mouse fluorochrome-conjugated antibodies (Supplementary table 
2). Regular flow cytometry was performed on a Cytoflex S (Beckman Coulter) and 
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the acquired data were analyzed using FlowJo software (version 10). Gates were set 
according to isotype or fluorescence minus one controls.
Serum measurements
Serum was acquired by centrifugation and stored at -20°C until further use. Total 
serum titers of IgM, IgG1, IgG2c and oxidized LDL-specific antibodies were quanti-
fied by ELISA as previously described7.
Histology
Carotid arteries and hearts were frozen in OCT compound (TissueTek) and stored 
at -80°C until further use. Transverse cryosections proximal to the collar were col-
lected and mounted on Superfrost adhesion slides (ThermoFisher). To determine 
lesion size, cryosections were stained with hematoxylin and eosin (Sigma-Aldrich). 
Quantification of lesion size was assessed every 100 µm from the first section with 
visible lesion proximal to the collar until no lesion could be observed. Plaque volume 
was determined with lesion size and the total distance of the lesions in the carotid 
artery. Phenotypic analysis of the lesion was performed on sections containing 
the largest three lesions. Collagen content in the lesion was assessed with a Mas-
son’s trichrome staining according to the manufacturers protocol (Sigma-Aldrich). 
Corresponding sections on separate slides were also stained for monocyte/mac-
rophage content using a monoclonal rat IgG2b antibody (MOMA-2, 1:1000, AbD 
Serotec) followed by a goat anti-rat IgG-horseradish peroxidase antibody (1:100, 
Sigma-Aldrich) and color development using the ImmPACT NovaRED substrate 
(Vector Laboratories). All slides were analyzed with a Leica DM-RE microscope and 
LeicaQwin software (Leica Imaging Systems).
Statistics
All data are expressed as mean ± SEM. Data were tested for significance using a Stu-
dent’s t-test for two normally distributed groups. Data from three groups or more 
were analyzed by an ordinary one-way ANOVA test followed by Holm-Sidak post 
hoc test. Probability values of p < 0.05 were considered significant. All statistical 
analyses were performed using GraphPad Prism 7.0.
Results
IFNγ-stimulated B cells express high levels of PD-L1
To investigate the role of PD-L1hi B cells in atherosclerosis, we first aimed to gener-
ate PD-L1hi B cells ex vivo. We explored several stimuli that previously have been 
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shown to control PD-L1 expression18,19 (Fig. S1 and Fig 1) and found that IFNγ 
dose-dependently increased the number of PD-L1+ B cells, with 20.0 ng/ml of IFNγ 
leading to an almost pure population of PD-L1-expressing B cells (Fig. 1A). Using 
qPCR, we also found an almost 8-fold induction of PD-L1 on mRNA level after IFNγ 
stimulation (Fig. 1B). Furthermore, we observed that the majority of IFNγ-stimulated 
B cells expressed very high levels of PD-L1 (Fig. 1C). Previously, it has been shown 
that IFNγ-signaling in B cells drives STAT-1 dependent expression of T-bet and BCL-
6 and switches them towards a GC B cell phenotype with increased IFNγ and IL-6 
production20,21. In line with this, our ex vivo IFNγ-stimulated B cells (IFNγ-B cells) 
showed a similar increase in STAT1, T-bet and BCL-6 (Fig 1D) gene expression. In 
contrast, we observed a trend towards less IL-6 and no difference in IFNγ expres-
sion (Fig 1D). Interestingly, IFNγ stimulation resulted in a strong significant increase 
in TGF-β expression (Fig. 1D). We also investigated the chemokine receptor profile 
of these B cells and found a dose-dependent increase in CCR7 expression, while 
there was no effect on CXCR5 or Ebi-2 (Fig. 1D). This change in chemokine receptor 
expression is typical of B cells that migrate towards the T-B cell border in lymphoid 
tissues in response to the CCL21 gradient22. Hence, these data indicate that IFNγ-
stimulated B cells express high levels of PD-L1 and TGF-β and a chemokine profile 
that homes B cells to the T-B cell border.
IFNγ-stimulated B cells inhibit TFH cells in vitro and in vivo
Next, we explored the functional effects of IFNγ-stimulated B cells on TFH cell 
development using a CD4+ T cell and B cell coculture. We stimulated wild-type 
CD4+ T cells for 72 hours with anti-CD3 in the presence of unstimulated or IFNγ-
stimulated apoE-/- B cells. Although we did not observe any difference in prolifera-
tive capacity of CD4+ T cells (Fig. 2A), we found a remarkable decrease of TFH cells 
when CD4+ T cells were cocultured with IFNγ-stimulated B cells compared to 
unstimulated B cells (Fig 2B). These findings illustrate that IFNγ-B cells are able to 
curb TFH cell development in vitro. We subsequently tested IFNγ-stimulated B cells 
in an in vivo setting by adoptively transferring either freshly isolated B cells or B cells 
stimulated with 20.0 ng/ml of IFNγ for 24 hours into apoE-/- mice. To induce initial 
TFH cell accumulation, mice were fed a Western-type diet for two weeks before they 
received the adoptive transfers (Fig. 2C)14. We observed a remarkable reduction 
in effector CD4+ T cells in mice treated with IFNγ-B cells compared to mice that 
received PBS or B cells (Fig. 2D). Contrary, the number of naïve CD4+ T cells was 
increased in IFNγ-B cells treated mice compared to mice receiving PBS (Fig. 2D). 
Most importantly, treatment of mice with IFNγ-B cells resulted in a strong reduction 
in TFH cells compared to mice that were administered with PBS or B cells (Fig. 2E). 
These data demonstrate that IFNγ-B cells are also able to inhibit TFH cells in vivo.
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Figure 1. Characterization of IFNγ-stimulated B cells. CD19+ B cells were isolated from C57BL/6 
mice and (A) stimulated for 24 hours with different doses interferon-gamma (IFNγ) after which PD-L1 
protein expression was measured with flow cytometry. (B) CD19+ B cells were unstimulated or stimu-
lated with 0.2 ng/ml or 20.0 ng/ml IFNγ for 24 hours, after which mRNA expression of PD-L1 was 
assessed using qPCR. (C) B cells as stimulated in (B) were analyzed for PD-L1lo, PD-L1int and PD-L1hi 
expression with flow cytometry. (D) mRNA expression was analyzed for depicted genes in B cells as 
stimulated in (B). Data are analyzed with a One-Way ANOVA and shown as mean ± SEM (* p<0.05, ** 
p<0.01, ***p<0.001, ****p<.00001). n=3/group.
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Adoptive transfer of IFNγ-B cells during atherosclerosis development 
affects the TFH – GC B cell axis
Given the in vitro and in vivo regulatory effects of IFNγ-B cells on TFH cells, we further 
investigated whether these B cells would be able to restrict TFH cell numbers during 
atherosclerosis development. We fed apoE-/- mice a Western-type diet for 2 weeks 
after which we placed a perivascular collar and started treatment with either PBS, 
B cells or IFNγ-B cells (Fig. 3A). After a total of 3 injections and 7 weeks of Western-
type diet, we harvested the organs and analyzed the immune cells associated with 
the TFH – GC B cell axis. IFNγ-B cell-treated mice showed a trend towards reduced 
FO B cells (Fig. 3B) and a significant increase in MZ B cells compared to mice receiv-
ing PBS (Fig. 3C). Moreover, mice that received IFNγ-B cells showed a significant 
increase in the number of GC B cells compared to mice that were administered 
Figure 2. IFNγ-B cells inhibit T follicular helper cells in vitro and in vivo. Isolated CD19+ B cells were 
unstimulated or stimulated with 0.2 ng/ml or 20.0 ng/ml IFNγ for 24 hours and co-cultured with iso-
lated CD4+ T cells. The coculture was stimulated with anti-CD3 (5 µg/ml) for 72 hours after which (A) 
proliferation of CD4+ T cells was analyzed with CellTrace Violet and (B) the number of follicular CD4+ T 
helper (TFH) cells were analyzed. (C) apoE-/- mice were fed a Western type diet for 2 weeks after which 
they either received PBS, freshly isolated CD19+ B cells (B cells) or CD19+ B cells stimulated with 
20.0 ng/ml IFNγ for 24 hours (IFNγ-B cells). After three days, mice were sacrificed and spleens were 
isolated for flow cytometry analysis for (D) naive (CD62l+CD44–) and effector (CD62l–CD44hi) CD4+ 
T cells and (E) T follicular helper cells (CD4+CD44hiCXCR5+PD-1+). Representative flow charts of the 
CD4+ T cell population are shown. Data are analyzed with a One-Way ANOVA and shown as mean ± 
SEM (* p<0.05, ** p<0.01). n=3/group.
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PBS (Fig 3D and E). By using the CD45 congenic marker system, we showed that 
adoptively transferred IFNγ-B cells indeed reached the germinal center (Fig. 3F) 
and locally increased the number of PD-L1hi B cells (Fig. 3G). As shown in Fig. 3D 
and E, freshly isolated B cells also increased the number of GC B cells, but these 
were not derived from the adoptive transfer (Fig. 3F) and were PD-L1– (Fig. 3H). At 
sacrifice, we did not observe a difference in TFH cells in IFNγ-B cell-treated mice, 
while adoptive transfer of B cells resulted in an increase in TFH cells compared to 
PBS-treated mice (Fig. 3I).
Figure 3. Adoptive transfer of IFNγ-B cells during atherosclerosis development affects the TFH – GC 
B cell axis. (A) ApoE-/- mice were fed a Western type diet for 7 weeks. After 2 weeks they received 
a perivascular collar and were treated with PBS, freshly isolated B cells (B cells) or B cells stimulated 
with 20.0 ng/ml IFNγ for 24 hours (IFNγ-B cells). Mice received a total of three injections and injec-
tions were spaced every two weeks. After 7 weeks, mice were sacrificed and spleens were analyzed 
with flow cytometry. Flow cytometry quantification of (B) follicular (FO) B cells, (C) marginal zone 
(MZ) B cells, (D) extracellular staining of germinal center B cells, (E) intracellular staining of germinal 
center B cells, (F) CD45.1+ germinal center B cells, (G) PD-L1hi germinal center B cells, (H) PD-L1– 
germinal center B cells and (I) flow charts and quantification of follicular helper T cells (CD44hiPD-
1+CXCR5+ICOS+). Data are analyzed with a One-Way ANOVA and shown as mean ± SEM (* p<0.05, ** 
p<0.01, *** p<0.001). n=10-12/group.
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Next, we assessed the number of plasmablasts and plasma cells and found a signifi-
cant reduction in plasmablasts when mice received IFNγ-B cells compared to mice 
receiving PBS (Fig. 4A). Mice that received B cells showed a similar trend towards 
less plasmablasts and also a significant increase in plasma cells compared to PBS- 
and IFNγ-B cells-treated mice. Since BLIMP-1 is the driving transcription factor for 
plasma cell generation23, we also measured BLIMP-1 expression which revealed a 
significant increase in BLIMP-1+ cells in mice that received B cells compared to mice 
receiving PBS or IFNγ-B cells (Fig. 4B). Since plasmablasts and plasma cells are re-
sponsible for the humoral immunity, we measured circulating antibodies. However, 
neither B cell treatments led to a significant difference in circulating antibodies (Fig. 
4C).
Figure 4. Effects of adoptive transfer of IFNγ-B cells on the humoral immunity. ApoE-/- mice were fed 
a Western type diet for 7 weeks. After 2 weeks they received a perivascular collar and were treated 
with PBS, freshly isolated B cells (B cells) or B cells stimulated with 20.0 ng/ml IFNγ for 24 hours 
(IFNγ-B cells). Mice received a total of three injections and injections were spaced every two weeks. 
After 7 weeks, mice were sacrificed and spleens were analyzed with flow cytometry. (A) Flow charts 
and quantification of plasmablasts (B220+CD138+) and plasma cells (B220loCD138hi). (B) Flow charts 
and quantification of CD19loBLIMP-1+ plasma cells. (C) Serum was analyzed for circulating antibod-
ies by ELISA. Spleens were analyzed with flow cytometry for (D) Th17 cells (RORyt+) or (E) Treg cells 
(FoxP3+). (F) Splenocytes were isolated and stimulated with anti-CD3 (1 µg/ml) and anti-CD28 (0.5 
µg/ml) for 72 hours after which supernatant was collected and analyzed for cytokine expression with 
a multiplex analysis. Quantification of IL-10 concentration is shown. Data are analyzed with a One-
Way ANOVA and shown as mean ± SEM (* p<0.05, ** p<0.01). n=10-12/group.
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Adoptive transfer of IFNγ-B cells promotes an anti-inflammatory CD4+ T 
cell response
The CD4+ T cell response is also highly involved in the pathogenesis of atheroscle-
rosis and PD-L1hi B cells have previously shown to restrict CD4+ T cell differentia-
tion17. While we did not observe any differences in Th1 or Th2 CD4+ T cells between 
mice treated with IFNγ-B cells, B cells or PBS in our study (Fig. S2), we observed a 
significant decrease in Th17 cells (Fig. 4D) and a significant increase in atheropro-
tective regulatory T cells (Fig. 4E; Tregs) in mice treated with IFNγ-B cells. We next 
measured cytokine levels of ex vivo anti-CD3 and anti-CD28 stimulated splenocytes 
for 72 hours with a multiplex assay. In line with the increase in Tregs, we observed 
a significant increase in IL-10 production by splenocytes from IFNγ-B cells treated 
mice compared to splenocytes from mice treated with PBS or B cells (Fig. 4F).
Adoptive transfer of IFNγ-B protects against lesion formation
Given the immune-regulating effects of IFNγ-B cells, we subsequently assessed 
whether adoptive transfer of these IFNγ-B cells was able to reduce collar-induced 
atherosclerosis in apoE-/- mice. We quantified lesion development in the carotid 
arteries and found a significant reduction in total lesion volume when mice were 
treated with IFNγ-B cells compared to PBS and a similar trend was found when 
compared to B cell-treated mice (Fig. 5A). Media size did not differ between the 
treatment groups (Fig. 5B). Furthermore, there were no differences in weight gain 
and serum cholesterol levels (Fig. S3A and S3B). We also assessed lesion phenotype 
at the site of the maximal lesion. This revealed that mice treated with IFNγ-B cells 
showed an early lesion phenotype with relatively more macrophages than collagen 
compared to mice that received B cells or PBS (Fig. 5C and 5D), suggesting that 
adoptive transfer of IFNγ-B cells inhibited atherosclerotic lesion progression to-
wards more advanced lesions.
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Discussion
Up to date, three groups have reported the proatherogenic role of the TFH – GC B 
cell axis13–15. Direct depletion of TFH cells in Ldlr-/- mice resulted in a reduction of 
atherosclerosis15, and loss of control on the TFH – GC B axis by depletion of MZ 
B cells14 or CD8+ regulatory T cells13 aggravated atherosclerosis. We now show that 
adoptive transfer of PD-L1 expressing B cells inhibit TFH cell responses both in vitro 
and in vivo and protect against atherosclerosis.
Figure 5. Adoptive transfer of IFNγ-B protects against atherosclerosis. ApoE-/- mice were fed a West-
ern type diet for 7 weeks. After 2 weeks they received a perivascular collar and were treated with PBS, 
freshly isolated B cells (B cells) or B cells stimulated with 20.0 ng/ml IFNγ for 24 hours (IFNγ-B cells). 
Mice received a total of three injections and injections were spaced every two weeks. After 7 weeks, 
mice were sacrificed and (A) total lesion volume and (B) media size was determined in the right carotid 
artery with a hematoxylin and eosin staining. Lesion phenotype was determined in sections contain-
ing the largest lesions. (C) Macrophage content was analyzed using a MOMA-2 staining. (D) Collagen 
content was quantified with a Trichrome staining. Data are analyzed with a One-Way ANOVA and 
shown as mean ± SEM (* p<0.05, ** p<0.01). n=8-12/group.
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Using ex vivo stimulation of B cells with IFNγ we rapidly provided a large and almost 
pure population of PD-L1-expressing B cells. IFNγ is an extensively investigated 
cytokine with a broad range of immune actions. Interestingly, while we show here 
that IFNγ stimulation of B cells results in a regulatory phenotype that reduces the 
number of TFH cells, earlier work identified a role for IFNγ in the generation of spon-
taneous germinal centers and B cell autoreactivity20,24. These previous data were, 
however, mainly acquired in the context of autoimmunity, where B cells receive 
a multitude of different signals and IFNγ signaling seems primarily to synergize 
with BCR-, CD40- and TLR-mediated stimuli to induce spontaneous germinal 
centers24. Under these circumstances, IFNγ signaling in B cells results in increased 
IL-6 and IFNγ production which drives auto-immunity20,21. In contrast, our ex vivo 
stimulated B cells lacked additional stimuli and upregulated expression of PD-L1 
and TGF-β, while we did not see any effects on IL-6 and IFNγ. We further showed 
that IFNγ-B cells express high levels of CCR7 with minimal changes in CXCR5 and 
Ebi-2. This expression profile is in line with a previous study that demonstrated 
that MZ B cells from Ldlr-/- mice interact with pre-TFH cells at the T-B cell border in 
response to a high-cholesterol diet14. During our atherosclerosis study, we indeed 
found that adoptively transferred IFNγ-B cells showed the characteristics of B cells 
that reside in or near the germinal center.
Similar to flow-sorted PD-L1hi B cells17, we next showed that IFNγ-B cells were 
able to inhibit TFH cell numbers in vitro and in vivo. This study further demonstrated 
that IFNγ-B cells were able to promote anti-inflammatory CD4+ T cells. This corre-
sponds with the effects found in experimental autoimmune encephalomyelitis using 
PD-L1hi B cells, which restricted Th1 and Th17 differentiation17. Along this line, we 
found that IFNγ-B cells resulted in decreased Th17 cells and a significant increase in 
atheroprotective Tregs and IL-10 production of CD4+ T cells.
Furthermore, we demonstrated atheroprotective effects of IFNγ-B cells that ex-
press high levels of PD-L1, which is in line with a general protective role of the 
PD-L1/PD-1 axis in atherosclerosis. Mice deficient in both PD-L1 and PD-L2 show 
increased atherosclerosis32. Similarly, PD-1 knockout mice or mice treated with a 
PD-1 blocking antibody developed exacerbated atherosclerosis33,34. Our data is 
further supported by previous studies that demonstrated the proatherogenic role of 
TFH cells13–15. However, due to the pleiotropic nature of IFNγ, other factors besides 
PD-L1 could also have contributed to our findings. Indeed, the observed increase in 
TGF-β expression could have contributed to both the TFH inhibition and Treg induc-
tion, since TGF-β signaling is known to prevent TFH cell accumulation and B cell au-
toreactivity25. In addition, there have been a large number of studies with adoptive 
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transfer of B cells expressing TGF-β that reported immune tolerance in autoimmune 
mouse models26–29. The majority of these studies reported Treg induction, which is in 
line with our findings of increased Tregs and IL-10 production after adoptive transfer 
of IFNγ-B cells. PD-L1 is also known to be essential for the induction of Treg cells30, 
the Treg accumulation could thus be a combined effect of increased TGF-β and PD-
L1 expression by IFNγ-B cells. Since the atheroprotective effects of Treg cells is 
well characterized31, the observed Treg induction undoubtedly contributed to the 
reduced atherosclerosis found with adoptive transfer of IFNγ-B cells.
In conclusion, this study uncovers a new role for ex vivo stimulation of B cells with 
IFNγ for the induction of atheroprotective B cells. IFNγ-B cells show the genetic 
makeup of GC B cells with increased expression of PD-L1 and TGF-β and effectively 
inhibit TFH cells in vitro and in vivo and ameliorate atherosclerosis development in 
apoE-/- mice. These results further emphasize the proatherogenic role of the TFH – 
GC B axis and provide a novel way to regulate this axis.
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Supplementary Figure 1. PD-L1 expression of stimulated B cells. CD19+ B cells were isolated from 
C57BL/6 mice and stimulated for 24 hours with different doses of (A) heat killed S. Aureus (HK-SA) or 
(B) B cell activating factor (BAFF) after which PD-L1 expression was measured with flow cytometry. 
Data are analyzed with a One-Way ANOVA and shown as mean ± SEM (** p<0.01, ****p<.00001). 
n=3/group.
Supplementary Figure 2. Effects of adoptive transfer of IFNγ-B cells on Th1 and Th2 cells. ApoE-/- 
mice were fed a Western type diet for 7 weeks. After 2 weeks they received a perivascular collar and 
were treated with PBS, freshly isolated B cells (B cells) or B cells stimulated with 20.0 ng/ml IFNγ for 
24 hours (IFNγ-B cells). Mice received a total of three injections and injections were spaced every two 
weeks. After 7 weeks, mice were sacrificed and spleens were analyzed with flow cytometry for (A) Th1 
cells (T-bet+) and (B) Th2 cells (Gata-3+). Data are shown as mean ± SEM. n=10-12/group.
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Supplementary Figure 3. ApoE-/- mice were fed a Western type diet for 7 weeks. After 2 weeks they 
received a perivascular collar and were treated with PBS, freshly isolated B cells (B cells) or B cells 
stimulated with 20.0 ng/ml IFNγ for 24 hours (IFNγ-B cells). Mice received a total of three injections 
and injections were spaced every two weeks. (A)Weight was assessed during the experiment and (B) 
and cholesterol serum levels were analyzed at the end of the experiment.
Table 1
Target Accession # Forward primer Reverse primer
CD274 (CD274 antigen, PD-L1) NM_021893 ggactacaagcgaatcacgctg tcatgctcagaagtggctggat
Tbx21 (T-box 21, Tbet) NM_019507 agtgactgcctaccagaacgcagag ccaggtggcgaggggacact
Bcl6 (B cell leukemia/lymphoma 6) NM_009744 ctgcaacgaatgtgactgccgtttc ccgattgaactgcgctccacaaatg
Il6 (interleukin 6) NM_031168 agacaaagccagagtccttcagaga ggagagcattggaaattggggtagg
infg (interferon gamma) NM_008337 ccttcttcagcaacagcaaggcga gcgctggacctgtgggttgt
TGF-(b) (transforming growth factor, 
beta 1, Tgfb1) NM_011577 agggctaccatgccaacttct gcaaggaccttgctgtactgtgt
CCR7 (chemokine (C-C motif) receptor 
7, EBI-1) NM_007719 cgtgctggtggtggctctcct accgtggtattctcgccgatgtagtc
Cxcr5 (chemokine (C-X-C motif) 
receptor 5) NM_007551 cgagctgagtggctatctctct agaggtcactgcggaactttac
Gpr183 (G protein-coupled receptor 
183; EBI-2) NM_183031 ggacgcctgctcgatcactcttaaa acgttgccagtggggtagtgaaatt
B-actin (actin, beta, Actb) NM_007393 cttctttgcagctccttcgttgccg aatacagcccggggagcatcgtc
Rpl27 (Ribosomal protein L27) NM_011289 cgccaagcgatccaagatcaagtcc agctgggtccctgaacacatccttg
Rplp0 (ribosomal protein, large, P0, 
36B4) NM_007475 ctgagtacaccttcccacttactga cgactcttcctttgcttcagcttt
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Table 2
Antigen Clone Fluorochrome Supplier
B220 RA3-6B2 PerCP-Cy5.5 ThermoFisher
B220 RA3-6B2 Alexa fluor 700 ThermoFisher
BCL-6 K112-91 Brilliant Violet 421 BD Biosciences
Blimp-1 5E7 Alexa fluor 647 Biolegend
CD138 281-2 Brilliant Violet 421 Biolegend
CD19 6D5 Brilliant Violet 605 Biolegend
CD21 7G6 Brilliant Violet 421 Biolegend
CD23 B3B4 PE ThermoFisher
CD279 (PD1) J43 FITC ThermoFisher
CD4 RM4-5 FITC ThermoFisher
CD4 RM4-5 PerCP ThermoFisher
CD44 IM7 APC ThermoFisher
CD44 IM7 BV510 Biolegend
CD45.1 A20 PE ThermoFisher
CD5 53-7.3 FITC BD Biosciences
CD62L MEL-14 FITC Biolegend
CD8a 53-6.7 FITC ThermoFisher
CD8a 53-6.7 Alexa fluor 700 Biolegend
CD93 AA4.1 PE-Cy7 ThermoFisher
CD95 Jo2 PE-Cy7 ThermoFisher
CXCR5 L138D7 PE Biolegend
Fixable Viability Dye APC-efluor 780 ThermoFisher
FoxP3 FJK-16s Pacific Blue ThermoFisher
Gata-3 TWAJ PE ThermoFisher
GL7 GL-7 efluor 450 ThermoFisher
ICOS 7E.17G9 PE-Cy7 ThermoFisher
IgD 11-26 APC ThermoFisher
NK1.1 PK136 FITC BD Biosciences
PD-L1 10F.9G2 PE-Dazzle 594 Biolegend
PNA FITC Vectorlabs
RORyt Q31-378 Brilliant Violet 650 BD Biosciences
T-bet eBio4B10 PE-Cy7 ThermoFisher
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Aims: The immune system is strongly involved in atherosclerosis and immune regu-
lation generally leads to attenuated atherosclerosis. B and T lymphocyte attenuator 
(BTLA) is a novel co-receptor that negatively regulates the activation of B and T cells, 
however, there have been no reports of BTLA and its function in atherosclerosis or 
cardiovascular disease (CVD). We aimed to assess the dominant BTLA expressing 
leukocyte in CVD patients and to investigate whether BTLA has a functional role in 
experimental atherosclerosis.
Methods and results: We show that BTLA is primarily expressed on B cells in CVD 
patients and follicular B2 cells in low-density lipoprotein receptor-deficient (Ldlr-/-) 
mice. We treated Ldlr-/- mice that were fed a Western-type diet (WTD) with PBS, an 
isotype antibody or an agonistic BTLA antibody (3C10) for 6 weeks. We report here 
that the agonistic BTLA antibody significantly attenuated atherosclerosis. This was 
associated with a strong reduction in follicular B2 cells, while regulatory B and T cells 
were increased. The BTLA antibody showed similar immunomodulating effects in a 
progression study in which Ldlr-/- mice were fed a WTD for 10 weeks before receiving 
antibody treatment. Most importantly, BTLA stimulation stabilized preexisting lesions.
Conclusion: Stimulation of the BTLA pathway in Ldlr-/- mice reduces initial lesion 
development and increases stability of established lesions, presumably by shifting 
the balance between atherogenic follicular B cells and atheroprotective B cells and 
directing CD4+ T cells towards regulatory T cells. We provide the first evidence that 
BTLA is a very promising target for the treatment of atherosclerosis.
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Introduction
Inflammation is a key process in the development of atherosclerosis1. Components 
of both the innate and adaptive immune system contribute significantly to the pa-
thology of atherosclerosis. The connection between these two arms of the immune 
system is provided by professional antigen presenting cells (APCs). Dendritic cells 
and macrophages are well known APCs, but nowadays the role of B cells as potent 
APCs is also increasingly recognized. Next to processing and presenting antigens to 
lymphocytes, these cells provide additional stimuli in the form of co-receptors. In 
fact, the activation of T cells and B cells is tightly controlled by these immune check-
point proteins 2. APCs have a wide-ranging variety of both stimulatory and inhibitory 
immune checkpoint proteins. In general, stimulatory co-receptors are found to be 
atherogenic, while inhibitory proteins attenuate atherosclerosis 2.
B- and T-lymphocyte attenuator (BTLA, also known as CD272) is a relatively 
recently described co-inhibitory receptor belonging to the immunoglobulin super-
family. It was originally identified in search for a T helper type 1 (Th1) marker 3 
and it has been demonstrated that BTLA interacts with herpesvirus entry mediator 
(HVEM) 4. HVEM is part of the tumor necrosis factor receptor superfamily and the 




checkpoint proteins of both superfamilies. Ligation of HVEM to BTLA generates an 
inhibitory signal which is supported by the fact that BTLA-deficient T and B cells are 
hyperresponsive 3,5,6. In addition, BTLA-deficient mice show a marked phenotype of 
auto-immunity with increased levels of auto-antibodies, spontaneous development 
of autoimmune-like hepatitis 7 and increased susceptibility towards experimental 
autoimmune encephalomyelitis 3. In humans, BTLA seems to function similarly since 
BTLA cross-linking on human T cells leads to suppressed proliferation and cytokine 
production 8. Moreover, in patients with rheumatoid arthritis 9 and type 1 diabetes 
10 functional polymorphisms or altered expression levels of BTLA have been found.
Hence, since its discovery as an inhibitory co-receptor, BTLA has attracted a lot of 
attention as a potential target for immunotherapy. While in oncology novel ways to 
block BTLA are explored 11, it has been shown that in autoimmune or inflammatory 
disorders stimulation of BTLA is a more promising option. For instance, agonistic 
antibodies for BTLA have been used in experimental models of Behcet’s disease 
12, cerebral malaria 13, graft-versus-host disease 14 and cardiac allograft rejection 
15. These data clearly indicate that the BTLA pathway is a potent option for the 
treatment of autoimmune disorders. Up to date there have been no reports of BTLA 
and if it is involved in atherosclerosis or CVD.
In the present study, we therefore aimed to characterize BTLA-expressing leuko-
cytes in CVD patients and to investigate whether BTLA has a functional role in 
atherosclerosis by using a non-depleting agonistic BTLA antibody.
Methods
Human samples
Eleven anonymous atherosclerotic plaques and blood were collected post-opera-
tively from carotid or femoral arteries endarterectomy surgeries performed in 2017 
and 2018 at the Haaglanden Medical Center (HMC), Westeinde, The Hague, The 
Netherlands. The collection of samples was performed conform the declaration of 
Helsinki regarding ethical principles for medical research involving human subjects 
(METC registration number 17-046). All atherosclerotic samples were processed to 
single cell suspensions as described previously16. In short, cell suspensions from 
human atherosclerotic plaques were obtained upon digestion with collagenase IV 
(Gibco) and DNase (Sigma) for 30 minutes at 37°C prior to single-cell separation 
through a 70μm cell strainer. Red blood cells in blood samples were lysed using 
ACK lysis buffer. All human white blood cell populations were characterized by 
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flow cytometry based on the expression of the pan-leukocyte marker CD45. Gating 
strategies are shown where appropriate.
Animals
Female low-density lipoprotein receptor-deficient mice (Ldlr-/-) were bred in house 
and kept under standard laboratory conditions. Mice were fed a Western-type diet 
(WTD) containing 0.25% cholesterol and 15% cocoa butter (Special Diet Services, 
Witham, Essex, UK). Diet and water were provided ad libitum. All injections were 
administered i.p. in a total volume of 100 µl. During the experiments, mice were 
weighed, and blood samples were obtained by tail vein bleeding. At the end of 
experiments, mice were anaesthetized by a subcutaneous injection of a cocktail 
containing ketamine (40 mg/mL), atropine (50 μg/mL), and sedazine (6.25 mg/
mL). Mice were bled by femoral artery transection followed by perfusion with 
phosphate-buffered saline (PBS) through the left cardiac ventricle. All animal work 
was approved by the Leiden University Animal Ethics Committee and the animal 
experiments were performed conform the guidelines from Directive 2010/63/EU of 
the European Parliament on the protection of animals used for scientific purposes.
In vivo experiments
Two separate diet-induced atherosclerosis experiments were performed in this 
study; an atherosclerosis initiation and an atherosclerosis progression experiment. 
For the initiation experiment, female Ldlr-/- mice (n=11-12/group) were fed a WTD 
for 6 weeks while either receiving an i.p. injection of PBS, an appropriate Armenian 
hamster isotype antibody (Innovative Research, Novi, MI; 100 µg/injection) or a 
non-depleting agonistic BTLA antibody15 (3C10; 100 µg/injection) twice a week. 
For the progression experiment, female Ldlr-/- mice (n=11-12/group) were first fed a 
WTD for 10 weeks before initiating the same treatment with an isotype antibody or 
an agonistic BTLA antibody for 6 weeks. At the start of the treatment, one group of 
mice was sacrificed as a baseline group. A third in vivo experiment was performed to 
investigate the direct effect of BTLA blockade on T cells. Female Ldlr-/- mice (n=5-6/
group) were fed a WTD for 2 weeks while, similarly as described above, receiving i.p. 
injections of either PBS, isotype control, BTLA, or receiving once a week anti-CD20 
(Genentech, clone 5D2; 250 µg/injection) to deplete B cells, or a combination of 
BTLA and anti-CD20.
Flow cytometry
For flow cytometry analysis, Fc receptors of single cell suspensions of the mediastinal 
lymph node, spleen, blood or peritoneum were blocked with an unconjugated anti-
body against CD16/CD32. Samples were then stained with a fixable viability marker 
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(ThermoScientific) to select live cells and anti-mouse fluorochrome-conjugated 
antibodies (see Online Supplementary Table 1).
For the analysis of IL-10+ B cells, single cell suspensions were stimulated for 5 hours 
with LPS (50 µg/ml), PMA (50 ng/ml), ionomycin (500 ng/ml) and monensin (2 µM). 
FACS analysis was performed on a FACSCanto II (Becton Dickinson) or a Cytoflex 
S (Beckman Coulter) and the acquired data were analyzed using FlowJo software. 
Gates were set according to unstimulated controls (only treated with monensin) or 
to isotype and fluorescence minus one controls.
Serum measurements
After euthanasia, orbital blood was collected in EDTA-coated tubes. Whole blood 
cell counts were analyzed using the XT-2000iV hematology analyzer (Sysmex Europe 
GMBH, Norderstedt, Germany). Serum was acquired by centrifugation and stored 
at −20°C until further use. The total cholesterol levels in serum were determined 
using enzymatic colorimetric procedures (Roche/Hitachi, Mannheim, Germany). 
Precipath (Roche/Hitachi) was used as an internal standard. Total serum titers of 
IgM, IgG1, IgG2c and antigen-specific antibodies were quantified by ELISA as previ-
ously described 17.
B cell culture
B cells were isolated from female Ldlr-/- mice using CD19+ microbeads (Miltenyi 
Biotec) and cultured in complete RPMI medium in the presence of different con-
centrations of the agonistic BTLA antibody or recombinant murine HVEM Fc (R&D 
systems). After 24 hours cells were harvested and either stained using an Annexin-V 
Apoptosis detection kit (ThermoFisher) or used for routine flow cytometry.
B cells were also isolated from mice treated with PBS or the BTLA agonistic anti-
body for 2 weeks. Isolated B cells were co-cultured with isolated CD4+ T cells from 
OT-II mice in the presence of OVA323 peptide (1 µg/ml). After 72 hours, cells were 
harvested and analyzed with flow cytometry.
Histology
To determine plaque size, cryosections (10 μm) of the aortic root were stained with 
Oil-Red-O and hematoxylin (Sigma-Aldrich). Sections with the largest lesion plus four 
flanking sections were analyzed for lesion size and two flanking sections for lesion 
composition. Collagen content in the lesion was assessed with a Masson’s trichrome 
staining according to the manufacturers protocol (Sigma-Aldrich). Corresponding 
sections on separate slides were also stained for monocyte/macrophage with a 
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MOMA-2 antibody (1:1000, AbD Serotec) followed by a goat anti-rat IgG-alkaline 
phosphatase antibody (1:100, Sigma-Aldrich). Color development was achieved 
using nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate as enzyme 
substrates. The relative amount of collagen and percentage of macrophages in the 
lesions is expressed as the ratio between the collagen- or MOMA-2-positive and 
the total lesion surface area. Smooth muscle cells were stained with an α-smooth 
muscle cell-actin (αSMA) antibody (clone 1A4, Sigma-Aldrich) and SMC positive 
areas were related to the total intima surface area. The necrotic core was defined as 
the a-cellular, debris-rich plaque area as percentage of total plaque area. CD4+ T cell 
(RM4-5, 1:90, ThermoFisher) and B cell (RA3-6B2, 1:100, BD Biosciences) analysis 
in the lesion was assessed using a rat monoclonal antibody and a secondary rabbit 
anti-rat antibody (BA-4001, Vector). Followed by the Vectastain ABC kit (PK-4000, 
Vector) and color was developed using the ImmPact Novared kit (Vector). Sections 
where no primary antibody was used were taken as negative controls. All slides were 
analyzed with a Leica DM-RE microscope and LeicaQwin software (Leica Imaging 
Systems).
For fluorescent histology, cryosections (10 μm) of the spleen were stained with 
anti-mouse antibodies against CD3 (SP7) and B220 (RA3-6B2). Subsequently, 
sections were stained with secondary goat-anti rabbit and goat-anti rat antibodies 
conjugated to Alexa fluor 647 and Alexa fluor 488 (Abcam). Nuclei were visualized 
using the Fluoroshield mounting medium containing DAPI. Sections were captured 
using a Nikon TiE 2000 confocal microscope with a 20x plan apochromat objective 
and analyzed with Nis Elements version 4.3.
Statistics
All data are expressed as mean ± SEM. Data were tested for significance using a 
Student’s t-test for two normally distributed groups. Data from three groups or 
more were analyzed by an ordinary one-way ANOVA test followed by a Holm-Sidak 
post hoc test. Data from experiments with 2 or more variables were analyzed by 
a two-way ANOVA test followed by a Sidak post hoc test. Probability values of 





B cells from CVD patients display strong BTLA expression
There is currently no data available regarding BTLA in patients with CVD. Hence, 
we obtained blood and lesions from patients that underwent an endarterectomy 
to assess the expression of BTLA on leukocytes. We found that almost 90% of the 
circulating CD19+CD20+ B cells expressed high levels of BTLA, while CD3+ T cells 
(8.5%) and monocytes (5.2%) showed a much more moderate expression and 
granulocytes expressed only minimal levels of BTLA (Online Figure I, Figure 1A and 
B). Within the lesion, the greater majority of leukocytes, including B cells, do not 
express BTLA. This is partly caused by a difference in B cell subsets that reside in 
the lesion compared to blood (Figure 1B). The circulating B cell population is mostly 
composed of naïve B cells that express the highest levels of BTLA, whereas in the 
lesion we mainly found effector B cell subtypes that have lower BTLA expression. 
These data suggest that BTLA is most abundantly expressed on circulating B cells in 
patients with CVD, while this expression seems to be lost on B cells that are present 
in the lesion.
Figure 1. B cells from CVD patients display strong BTLA expression
Flow cytometry was applied on blood and lesions from CVD patients to identify BTLA expression on 
major leukocyte populations. (A) Flow charts of BTLA expression by major leukocyte populations. (B) 
Quantification of BTLA expression by leukocyte populations and B cell subsets. A two-way ANOVA 
followed by a Sidak post hoc test was performed. Data are shown as mean ± SEM, n=11 (* p<0.05, 
***p<0.001, **** p<0.0001 vs. isotype).
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BTLA is predominantly expressed by follicular B2 cells in Ldlr-/- mice
Given the high expression of BTLA on peripheral B cells from CVD patients and its 
inhibitory role, we wanted to further explore the potential of BTLA as a therapeutic 
target to treat atherosclerosis. First, we characterized the expression profile of 
BTLA on immune cells using spleens from low-density lipoprotein receptor-deficient 
(Ldlr-/-) mice. Similar to human leukocytes, we found that BTLA was predominantly 
expressed on B cells, with relatively low expression on CD4+ T cells, CD8+ T cells 
and innate immune cells (Figure 2A and Online Figure II-A). Moreover, we did not 
find any differences in BTLA expression between CD4+ T helper cell subsets in 
contrast to previous work 3 (Online Figure II-B). Interestingly, we again discovered a 
significant difference in BTLA expression between B cell subsets, with conventional 
follicular B2 cells being the most dominant BTLA-expressing leukocyte (Figure 2B).
BTLA activation reduces initial atherosclerosis
The role of B cells in atherosclerosis has been quite controversial and seems to 
be highly dependent on the B cell subset 18. Previously, it has been reported that 
Figure 2. Activation of BTLA reduces initial atherosclerosis.
(A) Flow overlays and quantification of BTLA expression in leukocyte populations and (B) specific B 
cell subsets of female Ldlr-/- mice; follicular (CD21intCD23+); marginal zone (CD21hiCD23–) and newly 
formed (CD23loCD21lo). (C) Female Ldlr-/- mice were treated twice a week intraperitoneally with PBS, 
an isotype antibody or an agonistic BTLA antibody for 6 weeks while being fed a Western-type diet. 
(D) Mice were weighed and (E) serum cholesterol levels were determined. (F) Oil-Red-O and hema-
toxylin staining in aortic root sections and lesion size quantification. Scale bars are 100 µm. An ordi-
nary one-way ANOVA test followed by a Holm-Sidak post hoc test was performed. Data are shown as 
mean ± SEM, n=3 (A/B) and n=9/12 (C-F) (** p<0.01, **** p<0.0001).
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follicular B cells aggravate atherosclerosis 19–21. Since BTLA was most abundantly 
expressed on follicular B cells, we hypothesized that an agonistic BTLA antibody 
could inhibit follicular B cells in Ldlr-/- mice, leading to attenuated atherosclerosis. 
We therefore treated female Ldlr-/- mice twice a week with either PBS, an isotype 
control antibody or an agonistic BTLA antibody (3C10) for 6 weeks while being fed 
a Western-type diet (WTD) (Figure 2C). The 3C10 antibody has previously been 
described as a non-depleting agonistic BTLA antibody 15. Treatment with the BTLA 
antibody did not affect body weight or total serum cholesterol levels (Figure 2D 
and E). Stimulation/agonism of BTLA resulted in a significant 43% reduction in le-
sion size in the aortic root compared to PBS-treated mice and a significant 37% 
reduction compared to isotype-treated mice (Figure 2F). Correspondingly, we found 
that lesions from mice treated with the BTLA antibody predominantly consisted of 
macrophages and relatively low amounts of collagen (Online Figure III), illustrating 
an early lesion phenotype. In contrast, lesions from mice treated with PBS or the 
isotype control, showed a more advanced phenotype with relatively more collagen 
and less macrophage content (Online Figure III).
Activation of BTLA leads to strong follicular B2 cell reduction
To assess whether the reduced atherosclerosis could be attributed to altered im-
mune functions, we analyzed circulating leukocytes. We found a major reduction 
in total white blood cells in mice treated with the BTLA antibody compared to 
PBS- or isotype-treated mice (Online Figure IV). This was primarily due to a major 
decrease in lymphocytes and a smaller decrease in monocytes. Since monocytes 
and macrophages contribute significantly to initial lesion formation, we measured 
monocytes and monocyte subsets with flow cytometry but we could not identify 
a difference between BTLA-treated mice and PBS- or isotype-treated mice (Online 
Figure V). The strong lymphocyte reduction was primarily due to a sharp decrease 
in B cells in the blood and a similar effect was found in the spleen, lymph node 
and peritoneum (Figure 3A, Online Figure VI-A). Moreover, analysis of the B cell 
lineages showed that BTLA agonism particularly led to a reduction in B2 cells and a 
relative increase in the percentage of B1 cells (Figure 3B, Online Figure VI-B). More 
specifically, we found that the percentage of follicular B2 cells decreased, while 
marginal zone B cells increased in mice treated with the BTLA antibody compared 
to mice treated with PBS or isotype control (Figure 3C, Online Figure VI-C). In line 
with these findings, fluorescent immunohistology on spleen cryosections revealed 
that BTLA stimulation led to a decrease of B cells immediately surrounding the T cell 
areas, which corresponds to a reduction in follicular B cells (Figure 3D).
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Figure 3. Activation of BTLA leads to strong follicular B2 cell reduction.
Female Ldlr-/- mice were treated twice a week with PBS, an isotype antibody or an agonistic BTLA 
antibody and fed a WTD for 6 weeks. (A) Flow charts of splenocytes and quantifications of B cells 
(CD19+B220+) in different organs. (B) Flow charts of splenocytes and quantification of B1 cells 
(CD19+CD11b+B220lo) and B2 cells (CD19+CD11b–B220+) in the spleen. (C) Flow charts of spleno-
cytes and quantification of follicular (CD21intCD23+), marginal zone (CD21hiCD23–) and newly formed 
(CD23loCD21lo) B cells in the spleen. (D) Representative images of spleen sections stained for CD3 
(red), B220 (green) and DAPI (blue). Regions of interest are visualized as depicted at higher magnifi-
cations. Scale bars are 100 µm and 500 µm. An ordinary one-way ANOVA test followed by a Holm-




Mechanistically, we show that BTLA agonism, similarly as BTLA-HVEM signaling, in-
creased apoptosis and reduced activation in follicular B cells (Online Figure VII). Since 
follicular B cells are often involved in the humoral immunity, we next determined 
whether BTLA treatment reduced atherosclerosis by altering antibody responses. 
However, we did not find relevant differences in either total or malondialdehyde-
LDL and oxidized-LDL-specific serum titer levels that could explain the ameliorated 
atherosclerosis (Online Figure VIII).
Activation of BTLA leads to increased regulatory B cells
Besides the conventional B1 and B2 cells, we nowadays know that there are many 
novel B cell subsets that can regulate the immune response 18. Although most of 
these regulatory B cells (Bregs) ultimately act via interleukin-10 (IL-10), they can be 
identified by different extracellular markers 22, such as CD1dhiCD5+ expression 23, 
and T-cell immunoglobulin and mucin domain 1 (TIM-1) 24. We found that BTLA was 
expressed on all of these Breg subsets (Online Figure II-C). Accordingly, Ldlr-/- mice 
treated with agonstic BTLA showed a very strong increase in B10 cells and TIM-1+ 
B cells in the spleen, lymph nodes and blood when compared to treatment with 
PBS or isotype control (Figure 4A and B). In addition, we measured the direct secre-
tion of IL-10 by B cells and found that BTLA stimulation significantly increased the 
percentage of B cells that secreted IL-10 compared to the PBS or isotype control 
groups (Figure 4C).
Activation of BTLA leads to a protective T cell response
Treatment with the BTLA antibody resulted in a B cell pool that is highly enriched in 
marginal zone B cells and Breg cells, which can both inhibit the CD4+ T cell response 
22,25. Hence, we assessed the number of lesional CD4+ T cells and found a marked 
reduction in infiltrating CD4+ T cells in BTLA-treated mice compared to PBS- or 
isotype-treated mice (Figure 5A). Corroborating with earlier data 21, we did not find 
any relevant numbers of B cells in the lesion at this stage (Online Figure IX). We thus 
reasoned that the CD4+ T cell regulation had taken place peripherally as shown in 
earlier reports 21. Although we did not find a difference in total splenic CD4+ T cells, 
we found that BTLA-treated mice contained more effector and less naïve T cells than 
PBS- or isotype-treated mice (Figure 5B). More specifically, we observed an increase 
in regulatory (Treg) and Th17 cells in BTLA-treated mice, while no effects were found 
for Th1 or Th2 cells (Figure 5C). It is widely recognized that Tregs are atheroprotec-
tive 26 and Th17 cells have also been shown to protect against atherosclerosis in a 
setting with reduced B cells 21. This indicates that treatment with the BTLA antibody 
polarized the CD4+ T cell response in vivo towards a more atheroprotective reponse. 
The reduced activation of CD4+ T cells in BTLA-treated mice was not dependent 
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on changes in DCs, as we did not find differences in total DCs or regulatory DCs 
(DEC-205+CD8+) between PBS-, isotype- or BTLA-treated mice (Online Figure X). 
To test if the altered CD4+ T cell response after BTLA treatment was a direct effect 
of a different B cell pool, we cultured OT-II CD4+ T cells with B cells from mice 
treated with PBS or the BTLA antibody. We found that after 72 hours of stimulation 
with OVA323 peptide, OT-II CD4+ T cells cultured in the presence of BTLA-treated 
B cells, showed a marked increase in Tregs (Figure 5D). Moreover, CD4+ T cells from 
co-cultures with BTLA-treated B cells showed a significant decrease in TNFα secre-
tion, while IL-5 secretion was increased compared to T cells from co-cultures with 
PBS-treated B cells (Figure 5E). Finally, we show that the anti-inflammatory T cell 
response seen with BTLA agonism was not exclusively caused by changes seen in 
B cells, as BTLA treatment in B cell depleted mice also inhibits TNFα secretion by 
CD4+ T cells (Online Figure XI).
Taken together, these data strongly indicate that the BTLA antibody reduced the 
peripheral activation of CD4+ T cells, both indirectly by altering the APC function of 
B cells and by directly polarizing CD4+ T cells, resulting in reduced lesional CD4+ T cells.
Figure 4. Activation of BTLA leads to increased regulatory B cells.
Female Ldlr-/- mice were treated twice a week with PBS, an isotype antibody or an agonistic BTLA 
antibody and fed a WTD for 6 weeks. Flow charts for splenocytes and quantifications of regulatory 
B cells are shown for (A) B10 cells (CD19+CD1dhiCD5+), (B) TIM-1+ B cells (CD19+TIM-1+) and (C) IL-
10 secreting B cells (CD19+IL-10+). An ordinary one-way ANOVA test followed by a Holm-Sidak post 




Activation of BTLA leads to increased stability in established lesions
Since most CVD patients that require medication already have well-established ath-
erosclerosis, we also investigated the effects of the BTLA antibody on pre-existing 
lesions. Therefore, we fed Ldlr-/- mice a WTD for 10 weeks, after which we started 
the agonistic BTLA or isotype treatment for 6 weeks (Figure 6A). In line with our 
initial atherosclerosis study, we found a highly significant reduction in total B cells 
in all relevant organs (Figure 6B) caused by a strong decrease in follicular B cells 
(Figure 6C). In contrast, IL-10+ B cells (Figure 6D) and Tregs were increased (Online 
Figure 5. Activation of BTLA leads to decreased T cell infiltration and activation. Female Ldlr-/- mice 
were treated twice a week intraperitoneally with PBS, an isotype antibody or an agonistic BTLA an-
tibody for 6 weeks while being fed a Western type diet. (A) Representative images of aortic root 
sections stained for CD4 (arrows) and hematoxyline and cell number quantification. Scale bars are 
100 µm. (B) Flow charts and quantifications of total CD4+ T cells, naive CD4+ T cells (CD62l+CD44–), 
effector CD4+ T cells (CD62l–CD44+) and effector memory CD4 T cells (CD62l+CD44+) in splenocytes. 
(C) Flow cytometry quantifications of regulatory T cells (FoxP3+), Th17 (RORyt+), Th1 (T-bet+), and Th2 
(Gata-3+) cells in splenocytes. (D) B cells from mice treated with PBS or an agonistic BTLA antibody 
for 2 weeks were co-cultured with isolated CD4+ T cells from OTII mice in the presence of OVA323 
peptide (1 µg/ml). CD4+ T cells were harvested after 72 hours and assessed with flow cytometry for 
regulatory T cells (FoxP3+), Th17 (RORyt+), Th1 (T-bet+), and Th2 (Gata-3+) cells and (E) for cytokine 
production. An ordinary one-way ANOVA test followed by a Holm-Sidak post hoc test was performed. 
Data are shown as mean ± SEM, n=9/12 (*p<0.05, ** p<0.01, ***p<0.001, ****p<.00001). Tregs; regu-
latory T cells, Th; T helper cell.
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Figure XII). Although we did not find differences in lesion size between isotype- or 
BTLA-treated mice (Figure 6E), we did observe that lesions of mice treated with the 
BTLA antibody contained significantly more collagen than lesions of mice treated 
with the isotype control (Figure 6F). Furthermore, lesional macrophages, smooth 
muscle cell content and necrotic core area was determined (Online Figure XIII). This 
shows that BTLA stimulation increased the stability of already established lesions 
in Ldlr-/- mice.
Figure 6. Activation of BTLA leads to increased stability in established lesions.
(A) Female Ldlr-/- mice were fed a WTD for 10 weeks after wich one group was sacrificed (baseline), 
while other mice were treated twice a week intraperitoneally with an isotype antibody or an agonistic 
BTLA antibody for 6 weeks. (B) Flow cytometry quantification of B cells (CD19+) in different organs. 
(C) Flow charts of splenocytes and quantification of follicular (CD21intCD23+), marginal zone (CD-
21hiCD23–) and newly formed (CD23loCD21lo) B cells in the spleen. (D) Flow cytometry quantification 
of regulatory B cells (CD19+IL-10+) in spleen and lymph node. (E) Oil-Red-O and hematoxylin staining 
in aortic root sections and lesion size quantification. (F) Trichrome staining in aortic root sections and 
collagen quantification. Scale bars are 100 µm. A Student’s t-test was performed for two groups or an 
ordinary one-way ANOVA test followed by a Holm-Sidak post hoc test for multiple groups. Data are 




The discovery of immune checkpoint proteins has been a tremendous support in 
finding targets for immunomodulatory drugs 2. For many of these co-receptors, 
therapeutic antibodies or small molecules are now being tested in experimental 
animal models or in clinical trials. For the treatment of atherosclerosis and CVD 
we still lack potent agents that target pathways other than cholesterol metabolism. 
There is an urgent need for such treatments, since the residual risk of CVD is still 
considerable even after effective cholesterol management 27. Moreover, the recent 
CANTOS trial demonstrated that anti-inflammatory therapy can significantly reduce 
the risk of cardiovascular events 28. In this study, we provide the first evidence that 
one of the newest additions to the co-receptor family, BTLA, is a very promising 
target for the treatment of atherosclerosis.
Up to date, most research in relation to BTLA has focused on T cells, while it is most 
abundantly expressed on B cells 3,6,29,30. One apparent reason for this discrepancy 
could be that many inflammatory disorders are thought to be mainly T cell driven. 
However, with the recognition of novel B cell subsets, we gained significantly more 
insight into the actual contribution of B cells to inflammatory disorders. In athero-
sclerosis, we now know that B1 cells 19,31, marginal zone B cells 25 and regulatory 
B cells 32 can exert protective functions, contrary to follicular B cells that aggravate 
atherosclerosis 20,21. Since follicular B cells are in the majority, complete B2 cell 
depletion has resulted in attenuated atherosclerosis 20,21. Yet, these treatments 
deplete the complete B2 cell population which includes atheroprotective Bregs 
and marginal zone B cells 20,21,33. In a side-to-side comparison study, we show that 
whereas anti-CD20 treatment depletes all B cells, BTLA specifically targets follicu-
lar B2 cells and can directly inhibit pro-inflammatory CD4+ T cells. Secondly, the 
humoral immunity is compromised with complete B2 cell depletion, illustrated by 
reductions in both total and antigen-specific IgG and IgM antibodies 20,21. In this 
study, we now describe that an agonistic antibody for BTLA specifically reduced, 
but not ablated, the atherogenic follicular B cells, while the atheroprotective B cell 
subsets were increased. Although B cell depleting antibodies are already in clinical 
use for other autoimmune diseases such as rheumatoid arthritis34, we believe that 
BTLA stimulation might be superior to total B cell depletion in CVD.
Additionally, we have found that the humoral immunity was not affected since both 
total and antigen-specific IgG1, IgG2 and IgM levels remained the same. This is in 
line with others that showed that blockade of the HVEM/BTLA pathway also did not 
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alter the humoral effect following transplantation 35. This highlights the potential 
benefits of using an agonistic BTLA antibody for the treatment of atherosclerosis.
Besides reducing atherogenic follicular B2 cells, we found that BTLA activation re-
sulted in a splenic B cell population enriched in atheroprotective marginal zone B cells 
and Bregs. Bregs have shown great protective potential in autoimmune disorders 
such as collagen-induced arthritis and experimental autoimmune encephalomyelitis, 
primarily through their production of IL-10 22. Studies investigating the role of Bregs 
in atherosclerosis show conflicting results 18,32,36. However, recently we found a very 
strong inverse correlation between atherosclerosis severity and the frequency of IL-
10+ B cells, and adoptive transfer of IL-10+ B cells strongly reduced circulating leu-
kocyte numbers and inflammatory monocytes in Ldlr-/- mice37 Moreover, blockade of 
TIM-1, another immune checkpoint protein strongly associated with increased IL-10 
producing B cells 24, leads to aggravated atherosclerosis, potentially via the blockade 
of TIM-1+ B cells 38. Since BTLA agonism strongly increased B10 cells and TIM-1+ 
B cells, we believe this contributed to the reduction of atherosclerosis.
In the last years, it has been increasingly recognized that B cells have an important 
cellular function independent of antibody production. We found that the altered B 
cell population led to strongly decreased T cell activation. In addition, we showed 
that in both studies BTLA activation resulted in increased Tregs. During many au-
toimmune disorders, including atherosclerosis, Tregs become dysfunctional and are 
unable to curb disease 26. Restoration of this function or expansion of Tregs has been 
protective in atherosclerosis 26. Interestingly, it has previously been demonstrated 
that in experimental autoimmune encephalomyelitis, Bregs are able to recover the 
inhibitory activity of Tregs in a BTLA-dependent manner 39. Enhanced inhibitory 
activity of Tregs, could also explain the decrease in T cell activation found in this 
study. Furthermore, we show that the BTLA antibody also directly inhibits pro-
inflammatory T cells under hypercholesterolemic conditions. Overall, the expansion 
of Bregs and Tregs could have greatly contributed to the atheroprotective effects 
found with BTLA activation.
Nowadays, tremendous efforts are undertaken in the clinic to identify and treat 
vulnerable lesions that are prone to rupture 40. By stimulating the BTLA pathway 
we were able to both reduce lesion size in an initiation study and also stabilize le-
sions during progression of atherosclerosis. The latter underscores that modulating 
the BTLA pathway presents a very promising option for clinical use. In addition, we 
found that in CVD patients almost 90% of all circulating B cells still express high 
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levels of BTLA. Despite our limited sample number, this suggests that BTLA is also 
an interesting and accessible target in CVD patients.
In summary, treatment with an agonistic BTLA antibody prevents atherosclerosis 
and stabilizes already established lesions by favorably shifting the balance between 
atherogenic follicular B cells and atheroprotective B cells and directing CD4+ T cells 
towards Tregs. Our data strongly indicate that BTLA activation may be considered 
for the treatment of atherosclerosis.
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Online Figure I. Gating strategy leukocyte population blood and lesion CVD patients.
Flow cytometry was applied on blood and lesions from CVD patients to identify BTLA expression on 
major leukocyte populations. Cells were analyzed for a live/dead marker after which the indicated 
gating strategies were applied. B cells were also assessed for CD19 expression before subtypes were 
identified.
Online Figure II. BTLA expression of CD4+ T cell subsets in Ldlr‑/‑ mice.
(A) Quantification of BTLA expression in leukocyte populations; dendritic cells 
(CD19–SSCloCD11c+CD11b+), granulocytes (SSChiCD11b+), neutrophils (CD11b+Ly-6G+). (B) Quantifi-
cation of BTLA expression in effector CD4+ T cell subsets; Th1 (T-bet+), Th2 (Gata-3+), Th17 (RORyt+) 
and Tregs (FoxP3+). (C) Quantification of BTLA expression in regulatory B cell subsets. Data are shown 
as mean ± SEM, n=3. Tregs; regulatory T cells, Th; T helper cell. Data are shown as mean ± SEM. An 
ordinary one-way ANOVA test followed by a Holm-Sidak post hoc test was performed. (** p<0.01, 
***p<0.001, **** p<0.0001 vs. isotype).
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Online Figure III. Activation of BTLA leads to an early lesion phenotype.
Female Ldlr-/- mice were treated twice a week intraperitoneally with PBS, an isotype antibody or an 
agonistic BTLA antibody for 6 weeks while being fed a Western type diet. (A) MOMA-2 staining in 
aortic root sections with total and relative macrophage area quantification. (B) Trichrome staining in 
aortic root sections with total and relative collagen area quantification. Scale bars are 100 μm. Data 
are shown as mean ± SEM. An ordinary one-way ANOVA test followed by a Holm-Sidak post hoc test 
was performed. (*p<0.05, ** p<0.01).
Online Figure IV. Activation of BTLA leads to a strong reduction in circulation lymphocytes.
Female Ldlr-/- mice were treated twice a week intraperitoneally with PBS, an isotype antibody or an 
agonistic BTLA antibody for 6 weeks while being fed a Western type diet. After sacrifice, circulat-
ing levels of total white blood cells (WBC), lymphocytes, neutrophils or monocytes were measured 
in full blood using a hematology analyzer. Data are shown as mean ± SEM. An ordinary one-way 




Online Figure V. Activation of BTLA does not lead to changes in monocytes. Female Ldlr-/- mice were 
treated twice a week intraperitoneally with PBS, an isotype antibody or an agonistic BTLA antibody 
for 6 weeks while being fed a Western type diet. Cirulating monocytes (B220–NK1.1–CD11b+SSCintLy-
6GloCD115+) and inflammatory monocytes (B220–NK1.1–CD11b+SSCintLy-6GloCD115+Ly-6Chi) were 
measured with flow cytometry. Data are shown as mean ± SEM.
Online Figure VI. Activation of BTLA leads to a strong reduction in abolute numbers of follicular 
B2 cells in the spleen. Female Ldlr-/- mice were treated twice a week intraperitoneally with PBS, an 
isotype antibody or an agonistic BTLA antibody for 6 weeks while being fed a Western type diet. (A) 
Quantification of absolute number of B cells (CD19+) in th spleen. (B) Quantification of absolute num-
ber of B1 cells (CD19+CD11b+B220lo) and B2 cells (CD19+CD11b–B220+) in the spleen. (C) Quantifica-
tion of absolute number of follicular (CD21intCD23+), marginal zone (CD21hiCD23–) and newly formed 
(CD23loCD21lo) B cells in the spleen. Data are shown as mean ± SEM. An ordinary one-way ANOVA 
test followed by a Holm-Sidak post hoc test was performed. (*p<0.05, ** p<0.01).
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Online Figure VII. Activation of BTLA leads increased cell death and reduced activation in B cells.
Splenic B cells were isolated from female Ldlr-/- mice with CD19+ microbeads and stimulated with dif-
ferent concentrations of an agonistic BTLA antibody or recombinant murine HVEM Fc for 24h. (A) Cell 
death was measured with propidium iodide and Annexin-V staining. B cell activation was measured 
using CD40 (B) or CD86 (C). Data are shown as mean ± SEM. An ordinary one-way ANOVA test fol-
lowed by a Holm-Sidak post hoc test was performed. (*p<0.05, ***p<0.001, ****p<0.0001 BTLA ab vs 
0 and ##p<0.01, ####p<0.0001 HVEM Fc vs 0).
Online Figure VIII. BTLA activation does not affect the humoral immune response. Female Ldlr-/- mice 
were treated twice a week intraperitoneally with PBS, an isotype antibody or an agonistic BTLA an-
tibody for 6 weeks while being fed a Western type diet. At euthanasia, serum of mice was collected 
in which total and antigen-specific antibodies for atherosclerosis-related antigens were determined 
using ELISA. Data are shown as mean ± SEM. An ordinary one-way ANOVA test followed by a Holm-
Sidak post hoc test was performed. (** p<0.01). oxLDL, oxidized low-density lipoprotein; MDA-LDL, 




Online Figure IX. Absence of B220+ cells in the aortic root. Female Ldlr-/- mice were treated twice a 
week intraperitoneally with PBS, an isotype antibody or an agonistic BTLA antibody for 6 weeks while 
being fed a Western type diet. Representative images of aortic root sections stained for B220 (brown) 
and hematoxylin (blue) are shown. No B220+ cells were observed. Scale bars are 100 μm.
Online Figure X. Activation of BTLA does not lead to changes in dendritic cells. Female Ldlr-/- mice 
were treated twice a week intraperitoneally with PBS, an isotype antibody or an agonistic BTLA anti-
body for 6 weeks while being fed a Western type diet. Dendritic cells (CD19–CD11c+MHC-IIhi), regula-
tory dendritic cels (CD19–CD11c+MHC-IIhiCD8+DEC-205+) and BTLA+ regulatory dendritic cells were 
measured with flow cytometry. Data are shown as mean ± SEM.
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Online Figure XI. Female Ldlr-/- mice (n=5-6/group) were fed a WTD for 2 weeks while receiving intra-
peritoneal injections with PBS, an isotype antibody, an agonistic BTLA antibody, anti-CD20 or anti-
CD20+BTLA. (A) Flow cytometry quantifications of total CD19+ T cells. (B) Flow cytometry quanti-
fications of follicular B cells (CD21intCD23+), marginal zone B cells (CD21hiCD23–) and new B cells 
(CD21–CD23–) within the CD19+ population. (C) Flow cytometry quantifications of co-receptor ex-
pression on CD19+ B cells. (D) Flow cytometry quantification of CD4+ T cells and (E) of TNFα+ CD4+ 




Online Figure XII. BTLA activation leads to changes in CD4 T cells. Female Ldlr-/- mice were fed a 
WTD for 10 weeks after wich one group was sacrificed (baseline) and other mice were treated twice 
a week intraperitoneally with an isotype antibody or an agonistic BTLA antibody for 6 weeks (A) 
Flow cytometry quantifications of total CD4+ T cells, naive CD4+ T cells (CD62l+CD44–), effector CD4+ 
T cells (CD62l–CD44+) and effector memory CD4 T cells (CD62l+CD44+) in splenocytes. (B) Flow cy-
tometry quantifications of regulatory T cells (FoxP3+), Th17 (RORyt+), Th1 (T-bet+), and Th2 (Gata-3+) 
cells in splenocytes. (C) Data are shown as mean ± SEM. A Student’s t-test was performed (*p<0.05, 
** p<0.01). Tregs; regulatory T cells, Th; T helper cell.
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Online Figure XIII. Activation of BTLA promotes plaque stabilization. Female Ldlr-/- mice were fed a 
WTD for 10 weeks after wich one group was sacrificed (baseline) and other mice were treated twice 
a week intraperitoneally with an isotype antibody or an agonistic BTLA antibody for 6 weeks. (A) 
Representative pictures and quantification of necrotic core analysis from Masson’s Trichrome stained 
sections. (B) Representative pictures of MOMA-2 staining in aortic root sections with macrophage 
quantification. (C) Representative pictures of alpha-smooth muscle staining in aortic root sections 
with smooth muscle cell quantification. Scale bars are 100 μm. Data are shown as mean ± SEM. A 




Atherosclerosis initiation study (acquired on FACS canto II)
 Treg/Th17
Antigen Label Clone Supplier
Dead/Live APC-Cy7 n/a Thermo Fisher
CD4 PerCP RM4-5 BD Biosciences
CD25 APC PC61.5 Thermo Fisher
CD44 FITC IM7 Thermo Fisher
FoxP3 Pacific Blue FJK-16s Thermo Fisher
RORyt PE AFKJS-9 Thermo Fisher
Th1/Th2
Dead/Live APC-Cy7 n/a Thermo Fisher
CD8 Alexa fluor 700 53-6.7 Biolegend
CD4 PerCP RM4-5 BD Biosciences
CD62l FITC MEL-14 Thermo Fisher
CD44 Pe-Cy7 IM7 Thermo Fisher
T-bet Alexa fluor 647 4B10 Thermo Fisher
Gata-3 PE TWAJ Thermo Fisher
B1/B2 cells
Dead/Live APC-Cy7 n/a Thermo Fisher
CD19 PeCy7 1D3 Thermo Fisher
B220 FITC RA3-6B2 Thermo Fisher
CD5 BV421 53-7.3 BD Biosciences
CD11b APC M1/70 Thermo Fisher
B2 cell subsets
Dead/Live APC-Cy7 n/a Thermo Fisher
CD19 PeCy7 1D3 Thermo Fisher
CD21 BV421 7G6 Thermo Fisher
CD23 PE B3B4 Thermo Fisher
CD93 PerCP-Cy 5.5 AA4.1 Thermo Fisher
IgD APC 11-26 Thermo Fisher
IgM FITC II/41 Thermo Fisher
Regulatory B cells
Dead/Live APC-Cy7 n/a Thermo Fisher
CD19 PeCy7 1D3 Thermo Fisher
CD5 BV421 53-7.3 BD Biosciences
CD1d PerCP-Cy 5.5 1B1 Thermo Fisher
TIM-1 PE RMT1-4 Biolegend
CD9 FITC KMC8 Thermo Fisher
IL-10 APC JES5-16E3 eBioscience
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BTLA expression in human tissue
B cell subsets
Antigen Label Clone Supplier
Dead/Live APC-efluor 780 n/a Thermo Fisher
CD19 PercP-Cy5.5 HIB19 Thermo Fisher
CD20 FITC 2H7 Thermo Fisher
CD27 Brilliant Violet 605 O323 Biolegend
CD45 APC 5B1 Miltenyi Biotec
BTLA Pe-Dazzle MIH-26 Biolegend
CD3 eFluor 450 OKT3 Thermo Fisher
IgD Alexa fluor 700 IA6-2 Biolegend
Atherosclerosis progression study (acquired on Cytoflex S)
B cell subsets
Antigen Label Clone Supplier
Dead/Live APC-efluor 780 n/a Thermo Fisher
CD93 PE-Cy7 AA4.1 Thermo Fisher
CD19 BV605 6D5 Biolegend
CD43 APC S11 Biolegend
CD5 FITC 53-7.3 Thermo Fisher
CD21 BV421 7E9 Biolegend
CD23 PE B3B4 Thermo Fisher
B220 PerCP-Cy5.5 RA3-6B2 Thermo Fisher
T cell subsets
Dead/Live APC-efluor 780 n/a Thermo Fisher
CD4 PerCP RM4-5 BD Biosciences
CD8a Alexa fluor 700 53-6.7 Biolegend
CD44 BV510 IM7 Biolegend
CD62L FITC MEL-14 Thermo Fisher
CD25 APC PC61.5 Thermo Fisher
FoxP3 Pacific blue FJK-16s Thermo Fisher
T-bet PE-Cy7 eBio4B10 Thermo Fisher
RORyt BV650 Q31-378 BD Biosciences
Gata-3 PE TWAJ Thermo Fisher
Regulatory B cells
Dead/Live APC-Cy7 n/a Thermo Fisher
CD19 BV605 6D5 Biolegend
CD5 BV421 53-7.3 BD Biosciences
CD1d PerCP-Cy 5.5 1B1 Thermo Fisher
TIM-1 PE RMT1-4 Biolegend
IL-10 APC JES5-16E3 eBioscience
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BTLA expresion in LDLRKO mice (acquired on Cytoflex S)
B cell subsets
Antigen Label Clone Supplier
Dead/Live APC-efluor 780 n/a Thermo Fisher
CD93 PE-Cy7 AA4.1 Thermo Fisher
CD19 BV605 6D5 Biolegend
BTLA APC 8F4 Biolegend
CD5 FITC 53-7.3 Thermo Fisher
CD21 BV421 7E9 Biolegend
CD23 PE B3B4 Thermo Fisher
B220 PerCP-Cy5.5 RA3-6B2 Thermo Fisher
T cell subsets
Dead/Live APC-efluor 780 n/a Thermo Fisher
CD4 PerCP RM4-5 BD Biosciences
CD8a Alexa fluor 700 53-6.7 Biolegend
CD44 BV510 IM7 Biolegend
CD62L FITC MEL-14 Thermo Fisher
BTLA APC 8F4 Thermo Fisher
FoxP3 Pacific blue FJK-16s Thermo Fisher
T-bet PE-Cy7 eBio4B10 Thermo Fisher
RORyt BV650 Q31-378 BD Biosciences
Gata-3 PE TWAJ Thermo Fisher
T cell subsets
Dead/Live APC-efluor 780 n/a Thermo Fisher
CD8a APC-efluor 700 53-6.7 Biolegend
CD19 PE-Cy7 1D3 Thermo Fisher
CD4 PerCP RM4-5 BD Biosciences
CD11c FITC N418 Thermo Fisher
CD11b BV421 M1/70 Thermo Fisher
LY-6G PE 1A8 BD Biosciences
F4/80 Brilliant Violet 650 T45-2342 BD Biosciences









Atherosclerosis is the main underlying cause for cardiovascular disease (CVD). Ath-
erosclerosis is characterized by the build-up of cholesterol in the artery wall. For this 
reason, cholesterol and lipid metabolism have been studied extensively in the patho-
genesis of atherosclerosis during the 20th century. This has led to advancements in 
treatment options including the use of statins that block the rate-limiting enzyme in 
the cholesterol synthesis. Statins significantly lower cholesterol levels and are able 
to reduce cardiovascular relative risk by 25-30%. More novel approaches to lower 
cholesterol levels include the use of PCSK9 inhibitors, which have also shown to 
significantly reduce the relative risk of cardiovascular events1. Despite these lipid-
lowering drugs, CVD remains a central health care problem in the Western world, 
with large numbers of patients and CVD-related deaths2. We nowadays know that 
besides lipid metabolism, the immune system is a major contributor during all stages 
of atherosclerosis.
The first paper that suggested an active immune-inflammatory pathway during ath-
erosclerosis development appeared in 19853. This paper demonstrated that a large 
number of cells present in carotid artery plaques expressed MHCII molecules, which 
suggested that antigen presentation to and activation of CD4+ T cells could be part 
of the atherosclerosis pathophysiology. Interestingly, the same paper also demon-
strated that 30% of all cells present in the lesion expressed Fc-receptors, indicating 
that the humoral immunity might also be an important process in atherosclerosis3. 
This latter fact, however, did not receive the same attention as the first one and 
we can see in Figure 1 that in the years after this initial publication, the number of 
studies investigating CD4+ T cells and atherosclerosis grew exponentially, while the 
number of publications about B cells and atherosclerosis did not increase that much. 
A potential reason for this discrepancy could be that for most antigens, antibody 
production by B cells requires an effective CD4+ T cell response. Thus research into 
CD4+ T cells indirectly also investigated the humoral immunity. Nowadays, we know 
that many antigens can elicit a T cell-independent B cell response. Additionally, 
more and more antibody-independent functions of B cells have been discovered 





in this thesis, we aimed to explore and modulate the B cell response during athero-
sclerosis. In chapter 2 we provide an overview of the current knowledge regarding 
the role of B cells in atherosclerosis. In general, B cells can be divided in two main 
lineages; B1 and B2 cells (Fig. 2). These B cells are different in origin and func-
tion which is also resembled by their differential effects in atherosclerosis. B1 cells 
form a minor B cell population and thought to be atheroprotective, while B2 cells 
comprise the majority of B cells and have a proatherogenic role. The distinction 
between B1 and B2 cells is, however, a simplified representation and both B1 and 
B2 cells can be further divided into B cell subsets. For example, it has recently been 
shown that marginal zone B2 cells have a protective role during atherosclerosis4. 
On the other hand, the majority of B2 cells are of the follicular phenotype which 
are known to aggravate atherosclerosis5. In chapter 6 we targeted these follicular 
B cells with an agonistic BTLA antibody. Besides these classical B cell subsets, novel 
B cell subsets that are characterized by specific functional properties have now 
been identified. For instance, in chapter 3 we examined the role of IL-10-producing 
B cells. Similarly, in chapter 4 we used TIM-1Δmucin mice that show a clear impairment 
in IL-10 secretion by B cells. Finally, in chapter 5 we focused on B cells that express 
PD-L1 through which they can inhibit T follicular helper (TFH) cells. In these chapters 
Figure 1. Number of indexed articles in Pubmed. A basic Pubmed search for “CD4” or “B cells” to-
gether with “atherosclerosis” was performed (24/10/18). The number of resulting publications are 
plotted (y-axis) versus the year of publication (x-axis).
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we used two main methods to modulate the B cell response; (1) through adoptive 
transfer of B cell subsets and (2) by modulation of co-receptors.
Cellular therapy by B cell adoptive transfers
The main rationale of anti-inflammatory therapy for atherosclerosis is to limit the 
local and systemic immune response. We hypothesized that cellular therapy with 
regulatory B cells would lead to immune cell inhibition and reduced atherosclerosis. 
Regulatory B cells form a family of different B cell subsets that are able to limit the 
immune response.
In chapter 3 we focused on B cells that produce the anti-inflammatory cytokine 
IL-10. These are the most extensively studied regulatory B cells in autoimmune 
disorders6, but the role of IL-10+ B cells in atherosclerosis was still controversial7–11. 
For this reason, we first set out to examine the dynamics of IL-10+ B cells during ath-
erosclerosis development. This showed that during disease progression, the number 
of IL-10+ B cells gradually decreased. We also found a strong inverse correlation 
between IL-10+ B cells and lesion size. We thus reasoned that adoptive transfer of 
IL-10+ B cells would represent a beneficial treatment of atherosclerosis. The main 
Figure 2. Overview of the main B cell subsets and their known and putative effects on atherosclerosis. 
Orange highlighted sections indicate the investigated B cell subsets in this thesis.
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hurdle however with IL-10+ B cells is that they are a relatively rare population and 
they cannot be flow-sorted with general procedures. Earlier work in other auto-
immune disorders mainly resolved these problems by using specific B cell subsets 
in which IL-10+ B cells are enriched (e.g. CD1dhiCD5+ B cells)7. Although enriched, 
the majority of these B cells are still IL-10– B cells. Therefore, we opted for a dif-
ferent strategy in which we stimulated ex vivo cultured B cells with anti-CD40 and 
subsequently used a specialized isolation kit to isolate pure IL-10+ and IL-10– B cells. 
After adoptive transfer of IL-10+ B cells we observed that they indeed reduced the 
inflammation as measured by circulating leukocytes and CD4+ T cell activation, while 
adoptive transfer of IL-10– B cells did not result in any noticeable immune response 
limitation. Moreover, we found a significant increase in IL-10+ CD4+ T cells when 
mice were treated with IL-10+ B cells. Unexpectedly, the immune regulation by IL-
10+ B cells did not result in reduced lesion formation, while IL-10– B cells strongly 
exacerbated atherosclerosis. To explain the lack of effect on lesion size by adoptive 
transfer of IL-10+ B cells, we assessed other factors that could have influenced 
the development of atherosclerosis. This revealed that adoptive transfer of both 
IL-10– and IL-10+ B cells resulted in hepatic steatosis. Both treatments increased 
the hepatic and circulating lipid levels, which are known to have very strong correla-
tions with lesion size. Interestingly, this correlation was not present in mice treated 
with IL-10+ B cells, suggesting that the anti-inflammatory effects had negated the 
lipid effects. In an effort to explain the increased lipid levels after B cell adoptive 
transfer, we investigated the expression of LIGHT and lymphotoxin-alpha on anti-
CD40 stimulated B cells. We observed a very marked increase in both molecules, 
which have previously been shown to increase cholesterol levels. This could be the 
reason that both B cell treatments resulted in hepatic steatosis. Nonetheless, this 
study showed that IL-10+ B cells were able to regulate the immune response during 
atherosclerosis development. For this reason, we believe that there is still ample 
evidence that other strategies which increase IL-10+ B cells without affecting lipid 
metabolism, could ameliorate atherosclerosis.
In chapter 5, we performed another B cell adoptive transfer in which we specifically 
investigated B cells that express high levels of PD-L1, since it was demonstrated 
that these cells are able to inhibit CD4+ T follicular helper (TFH) cells12. Earlier stud-
ies already demonstrated a proatherogenic role of TFH cells but did not report a 
therapeutic strategy to inhibit these cells and ameliorate atherosclerosis4,13,14. We 
first investigated the ratio of PD-L1hi B cells and TFH cells in young ApoE-/- mice with 
minimal lesions and in old atherosclerotic ApoE-/- mice with established lesions. We 
observed that the ratio was significantly increased, with relatively more TFH cells than 
PD-L1hi B cells in older ApoE-/- mice. Hence, we hypothesized that adoptive transfer 
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of PD-L1hi B cells could be able to reduce atherosclerosis. Our first approach was 
to flow-sort PD-L1hi B cells and adoptively transfer these to ApoE-/- mice. However, 
this did not result in significant TFH restriction. We subsequently tried to optimize an 
ex vivo culture protocol to generate a large and pure population of PD-L1 expressing 
B cells. We showed that 24-hour stimulation of B cells with IFNγ resulted in very 
strong upregulation of PD-L1 on almost all B cells. Functionally, these IFNγ-B cells 
were able to inhibit TFH cells both in vitro and in vivo. We thus adoptively transferred 
IFNγ-B cells to ApoE-/- mice in which we initiated lesion formation by placement 
of a perivascular collar. This led to an increase in PD-L1hi germinal center B cells, 
plasmablast inhibition, increased regulatory T cells and a concomitant reduction in 
total lesion volume. This indicates that ex vivo stimulation of B cells with IFNγ, leads 
to a regulatory phenotype which is able to reduce atherosclerosis.
Taken together, these two chapters have shown the potential of cellular B cell 
therapy for the treatment of atherosclerosis. It is of particular interest that splenic 
B cells are mostly comprised of follicular B cells, which are known to be athero-
genic5. Here, we have shown two ex vivo methods to generate and isolate protective 
B cell subsets from this general pool of atherogenic splenic B cells. The protective 
effects of our anti-CD40 generated IL-10+ B cells were, however, negated by their 
bidirectional effect which also induced increased cholesterol levels. The adoptive 
transfer of IFNγ-B cells or freshly isolated B cells, which were used as a control 
treatment in chapter 5, did not influence lipid metabolism. This further supports the 
notion that the increased cholesterol levels we observed in chapter 3 were due to 
our ex vivo protocol of anti-CD40 stimulation.
Although we have used a cellular adoptive transfer in chapter 5, PD-L1 is a well-
known co-receptor and essentially this chapter could also have been categorized as 
modulation of co-receptors, which will be described below.
Modulation of co-receptors
A second approach through which we influenced the B cell response is by co-receptor 
modulation. Co-receptors are molecules which are mainly expressed by antigen-
presenting cells and are key proteins in the immune response15. Co-receptors or 
immune-checkpoint proteins provide additional signals for a B or T cell which has 
recognized antigen. These signals can either be inhibiting or stimulating, resulting in 
a diminished or enhanced immune response respectively. Given their central role in 
the immune response, co-receptors are frequently targeted in auto-immune disor-
ders. In atherosclerosis, stimulating coreceptors generally aggravate atherosclerosis, 
while inhibiting coreceptors are frequently atheroprotective15. In this thesis, we 
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have investigated the effects of TIM-1 deficiency in chapter 4 and of an agonistic 
antibody for BTLA in chapter 6.
T-cell immunoglobulin and mucin domain 1 (TIM-1) is part of a larger family of TIM 
molecules with a total of four functional active TIM proteins. TIM-1 has been linked 
to a number of inflammatory and autoimmune disorders16. Our research group had 
initially identified a protective role for TIM-1, since administration of mice with 
a TIM-1 inhibiting antibody resulted in exacerbated atherosclerosis17. After this 
publication, others showed that TIM-1 was also an important protein for the induc-
tion and maintenance of IL-10+ B cells18–20. Moreover, it was shown that a different 
inhibiting TIM-1 antibody resulted in increased regulatory B cells and attenuated 
atherosclerosis, suggesting a proatherogenic role for TIM-121. These discrepancies 
were later clarified when it was demonstrated that depending on antibody affinity or 
ligand density, TIM-1 could act both as an inhibitory and as a stimulatory coreceptor. 
This led us to investigate atherosclerosis development in a mouse model in which 
TIM-1 signaling was impaired. We describe in chapter 4 that compared to wild-type 
mice, these TIM-1Δmucin mice show a strong deficit in IL-10 production by B cells, 
which was associated with a significant increase in viable leukocytes. Furthermore, 
a specific reduction in Th2 cells and Th2-associated cytokines caused a significant 
shift towards a more Th1-dependent immune response in TIM-1Δmucin mice. Taken 
together, these immune effects resulted in exacerbated atherosclerosis both in the 
aortic root and the aortic arch. This work identified that the general contribution 
of TIM-1 during atherosclerosis development is protective, potentially due to its 
importance for regulatory B cells.
In chapter 6 we targeted another coreceptor, B- and T-lymphocyte attenuator 
(BTLA). As the name implies, BTLA is an inhibitory coreceptor which is expressed 
on both B and T cells. Our work, however, identified that BTLA is predominantly 
expressed on B cells in atherosclerotic patients and mice. Moreover, we noticed that 
BTLA was most abundantly expressed on a particular B cell subset, the follicular B2 
cells. Given the proatherogenic role of these follicular B2 cells and the inhibitory 
function of BTLA, we aimed to treat atherosclerosis with an agonistic BTLA antibody. 
This resulted in a drastic reduction of follicular B2 cells in mice treated with the 
BTLA agonist. We further investigated the B cell population and found that BTLA 
stimulation led to a significant increase in the number of regulatory B cell subsets 
and IL-10+ B cells. Similarly, other atheroprotective subsets such as marginal zone 
B cells and B1 cells were also increased in mice that received the BTLA antibody. 
Furthermore, the CD4+ T cells response was skewed towards a regulatory pheno-
type. These strong immune effects eventually resulted in a significant decrease in 
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lesion formation in mice treated with the BTLA antibody. We further investigated 
whether BTLA agonism also affected established lesions and found that treatment 
with the BTLA antibody increased lesion stability.
In conclusion, the data described in chapter 4 and 6 underline the central role of co-
receptors in the immune system and atherosclerosis. Co-receptors are extensively 
investigated but often in relation to T cells or dendritic cells. We have shown here 
that modulation of co-receptors on B cells can also greatly influence atherosclerosis.
Future perspectives
Since the initial proposition of the inflammation theory in atherosclerosis, the re-
search community has made big strides forward. At this point, we are at the onset 
of clinical use of anti-inflammatory therapy in cardiovascular disease. The recent 
CANTOS trial showed that antibody-mediated inhibition of interleukin 1β signifi-
cantly lowered cardiovascular risk independent of lipid-level lowering22. This proved 
the inflammation theory and might pave the way for future clinical trials focusing on 
anti-inflammatory therapy in cardiovascular disease.
There are many hurdles that have to be overcome before preclinical targets can be 
validated clinically for their therapeutic effect in atherosclerosis. Hence, it is likely 
that B cell modulating therapies that are already accepted for the treatment of other 
disorders will be the first options for clinical use in atherosclerosis. Rituximab, a 
monoclonal antibody against CD20, depletes B cells and is already registered for 
clinical use for the treatment of rheumatoid arthritis (RA). Given that CD20-mediated 
B cell depletion in pre-clinical models of atherosclerosis results in reduced disease23, 
rituximab could potentially also be used in atherosclerosis patients. Patients with 
RA have an increased risk of cardiovascular events, hence, some pilot studies have 
already investigated the effect of rituximab treatment in RA patients on cardiovas-
cular parameters. In general, short term treatments with rituximab led to decreased 
carotid intima-media thickness and an overall improvement of cardiovascular param-
eters, suggesting that this indeed could be a beneficial treatment for atherosclerosis 
patients24,25. Another B cell-depleting therapy, belimumab, blocks B cell activating 
factor (BAFF) and is now accepted for the use in patients with systemic lupus ery-
thematosus (SLE). Mice deficient for the receptor for BAFF (BAFFR) or treatment 
of mice with a BAFFR blocking antibody results in attenuated atherosclerosis26–28, 
suggesting that blockade of the BAFF/BAFFR pathway is indeed a potential target 
for the treatment of atherosclerosis. However, a recent study showed that antibody 
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blockade of BAFF actually exacerbated atherosclerosis29. Although the authors also 
show that this was due to B cell independent protective effects of BAFF, these 
data do indicate that a more cautious approach is necessary when exploring BAFF 
blockade in clinical cardiovascular settings. Other B cell modulating therapies that 
are currently being tested in clinical trials include the use of CD19-mediated B cell 
depletion. In contrast to CD20, CD19 is also expressed on some antibody-producing 
plasma cells30. Since increased autoantibodies are a detrimental characteristic in 
many auto-immune disorders, anti-CD19 antibodies represent an interesting option 
for these disorders. In atherosclerosis, however, the role of IgG antibodies remains 
controversial and anti-CD19 could also reduce atheroprotective IgM titers. All of 
these clinically available options are aimed to reduce the total B cell population, 
which might lead to potential adverse effects, such as increased susceptibility to 
infections or reduced vaccination efficacy. Additionally, as discussed before, there is 
a large diversity in the effects of different B cell subsets on atherosclerosis.
Ideally, therapies should focus on specifically reducing atherogenic subsets and/or 
expansion of atheroprotective subsets. In this thesis we have shown four potential 
B cell options for the treatment of atherosclerosis which could potentially achieve 
these effects. For instance, we have shown that an agonistic BTLA antibody specifi-
cally reduced B2 cells, while leaving atheroprotective B cell subsets unaffected. We 
also showed that in cardiovascular patients, the BTLA expression is similar to that 
of atherosclerotic mice. We have compared the effects of our BTLA antibody with 
CD20-mediated B cell depletion and found the BTLA antibody superior in terms of 
influencing the CD4+ T cell response. Hence, the positive results found with ritux-
imab on cardiovascular parameters, could potentially be improved with the use of 
a humanized agonistic antibody for BTLA. Another target that we discussed in this 
thesis and that could be targeted with the use of an antibody is TIM-1. We previously 
showed that a blocking TIM-1 antibody resulted in exacerbated atherosclerosis17, 
which is in line with increased lesion development in TIM-1Δmucin mice. Therefore, an 
agonistic TIM-1 antibody should be considered for the treatment of atherosclerosis, 
which indeed resulted in increased IL-10+ B cells and ameliorated atherosclerosis in 
a preclinical mouse model21.
Most novel biological treatments are based on antibodies, however nowadays, 
cellular therapy is also an increasingly used option for the treatment of a number 
of disorders. For instance, there are multiple ongoing clinical trials with regulatory 
T (Treg) cell therapy in organ transplantation surgeries31. They have been able to 
isolate and generate human Tregs under GMP conditions with similar isolation (mi-
crobeads) and culture methods as described in our studies. Our work with IL-10+ or 
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PD-L1hi B cells describe preclinical proof-of-concepts but it could be envisioned that 
experiments focusing on translational aspects, may lead to the actual clinical use of 
regulatory B cell therapy. For instance, it has recently been shown that patients with 
atherosclerosis have a lower frequency of circulating IL-10+ B cells32. Such clinical 
studies strengthen the rationale for therapies aimed to increase these regulatory 
B cells and remain of great interest. Furthermore, as we demonstrated in our BTLA 
study, to increase the clinical relevance of adoptive regulatory B cell transfers it 
would be interesting to investigate if we could induce plaque regression or induce 
plaque stabilization with such treatments.
Taken together, in the chapters presented here we have shown that each approach 
to modulate the B cell response had significant effects on other immune pathways 
in particular on CD4+ T cells, without significant impact on the antibody-producing 
capacities of B cells. This supports the notion that B cells have many antibody-inde-
pendent effects and that these processes can strongly influence atherosclerosis. As 
depicted in figure 1, B cell research in the context of atherosclerosis is still lagging 
behind research into CD4+ T cells, however it seems like the research community is 
catching up and the therapeutic value of modulation of B cell responses in athero-
sclerosis receives increasingly more attention nowadays. The work presented in this 
thesis is proof of that sentiment and provides a foundation for further research into 
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Cardiovasculaire aandoeningen of hart- en vaatziekten zijn de overkoepelende cate-
gorie waaronder welbekende complicaties zoals een hartaanval, beroerte of hartrit-
mestoornissen behoren. De grote maatschappelijke impact die hart- en vaatziekten 
hebben volgt onder meer uit de schatting van de Wereldgezondheidsorganisatie 
dat jaarlijks meer dan 15 miljoen mensen overlijden aan het gevolg van dergelijke 
aandoeningen. Nederlandse cijfers laten zien dat het ook in ons eigen land nog 
steeds een groot probleem vormt. Volgens de Hartstichting zijn er in Nederland ruim 
1.4 miljoen patiënten met enige vorm van hart- en vaatziekten en wat wellicht nog 
meer tot de verbeelding spreekt, is dat er geschat wordt dat er dagelijks zo’n 100 
mensen sterven aan een cardiovasculaire aandoening in Nederland. Niettemin is dit 
aantal tussen 1980 en 2016 al sterk gedaald doordat we beter zijn geworden in het 
managen van de onderliggende oorzaak; slagaderverkalking.
Atherosclerose
Slagaderverkalking of atherosclerose is een aandoening waarbij er verdikkingen 
plaatsvinden in de vaatwand, deze worden over het algemeen laesies of plaques 
genoemd. In eerste instantie wordt een dergelijke laesie veroorzaakt door schade 
aan de vaatwand, wat door meerdere risicofactoren verergert of versneld kan wor-
den, bijvoorbeeld alcoholgebruik, roken, overgewicht en hoge bloeddruk. Schade 
aan de vaatwand in combinatie met een hoog cholesterolgehalte leidt ertoe dat het 
cholesterol zich gaat ophopen binnen de vaatwand. Vaak spreekt men hier wel over 
het slechte cholesterol genaamd lage-dichtheids lipoproteïne, oftewel LDL. Het LDL 
wat zich binnen de vaatwand bevindt zorgt ervoor dat de cellen die de vaatwand 
bekleden, endotheelcellen, geactiveerd raken. Deze cellen brengen vervolgens 
bepaalde signaaleiwitten tot expressie die immuun cellen vanuit de bloedbaan de 
vaatwand in kunnen trekken. In eerste instantie zijn dit voornamelijk monocyten, 
die onder invloed van verschillende factoren binnenin het weefsel verder ontwik-
kelen tot macrofaag. Ondertussen ondergaat het cholesterol binnen in de vaatwand 
verschillende veranderingen waardoor het cholesterol verandert in geoxideerd 
cholesterol of oxLDL. Deze verandering van het LDL tot oxLDL leidt ertoe dat het 
immuunsysteem dit cholesterol gaat beschouwen als lichaamsvreemde stof. Het is 
geen toeval dat het immuunsysteem als eerste reageert via macrofagen. De letterlijke 
vertaling vanuit het oude Grieks voor deze macrofagen is namelijk veelvraten. Deze 
naam gaat gepaard met hun functie, namelijk het opeten of fagocyteren van externe 
stoffen. Dit is exact wat de macrofagen in de vaatwand doen, zij fagocyteren het 
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schadelijk oxLDL en ruimen op deze manier het bloedvat op. Macrofagen die grote 
hoeveelheden vetten zoals cholesterol gefagocyteerd hebben, hebben onder de mi-
croscoop een “schuimig” uiterlijk en worden daarom ook wel schuimcellen genoemd. 
In deze fase van atherosclerose is de verdikking van de vaatwand nog minimaal en 
over het algemeen compleet zonder symptomen voor de patiënt. Dit soort laesies, 
in deze fase fatty streaks genoemd, komen vaak ook al voor in jongvolwassenen en 
horen in zeker zin tot een normaal ouderdomsverloop.
Echter, zolang de patiënt geen actie onderneemt om het hoge cholesterolgehalte te 
verminderen, blijft het zich ophopen in de vaatwand, wat ertoe leidt dat de macro-
fagen niet meer om kunnen gaan met de grote hoeveelheid oxLDL. Vanaf dit punt 
wordt het initieel beschermende karakter van de immuunreactie meer en meer een 
schadelijk proces. Het begint bij de macrofagen die uiteindelijk zo vol zitten met ox-
LDL, dat ze hierdoor afsterven via een proces genaamd apoptose. Cellen die sterven 
geven allerlei stoffen af die zich normaal gesproken exclusief binnen een cel bevin-
den. Zodra deze stoffen buiten een cel komen, herkennen immuun cellen dit als een 
schadelijk en lichaamsvreemd proces en sturen ze extra immuun cellen hierop af. De 
schuimcellen zelf en de endotheelcellen scheiden ondertussen ook signaalstoffen 
uit om extra hulp in te roepen van het immuunsysteem. Het immuunsysteem is dan 
al niet meer in staat om de ophoping van oxLDL tegen te gaan en juist door de komst 
van andere immuun cellen zoals, neutrofielen, dendritische cellen, B cellen en T 
cellen, neemt de verdikking van de vaatwand alsmaar toe. Door de heftige immuun-
reactie raken ook de omliggende gladde spiercellen van de vaatwand geactiveerd. 
Deze cellen migreren richting de laesie en vormen een beschermende laag over de 
ophoping van vetten en immuun cellen, zodat dit niet blootgesteld kan worden aan 
het bloed. Ze produceren daarnaast ook collageen strengen die er voor zorgen dat al 
het geaccumuleerde materiaal op zijn plek blijft. Deze gladde spiercellen zorgen in 
eerste instantie dus voor stabilisatie van de laesie. Stabiele laesies leiden vaak nog 
niet tot grote complicaties, maar de vernauwing van het bloedvat (stenose) kan op 
zichzelf al leiden tot problemen. Een dergelijke stenose kan dusdanig ernstig worden 
dat het weefsel achter de vernauwing onvoldoende doorbloed raakt of ischemisch 
wordt. In minder zware vormen kan dit leiden tot druk op de borst (angina pectoris) 
of bijvoorbeeld kortademigheid.
Zwaardere complicaties zijn vaak het gevolg van een instabiel geraakte laesie, wat 
veroorzaakt wordt door meerdere processen. Ten eerste ontstaat er zodra er meer 
en meer immuun cellen in de vaatwand sterven een zogenaamde necrotische kern. 
De aanwezigheid van deze ophoping van kapotte cellen en afvalstoffen draagt bij 
aan het instabiel worden van de laesie. Ten tweede wijzen veel wetenschappelijke 
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studies er op dat de gladde spiercellen hun stabiliserende functie langzamerhand 
verliezen doordat de beschermende laag en de collageen strengen weer worden 
afgebroken. Dit alles kan leiden tot het scheuren van de laesie waarbij de inhoud aan 
het bloed bloot gesteld wordt. Hierbij vormt zich dan een stolsel of trombus dat de 
bloedtoevoer naar het achterliggende weefsel compleet kan afsluiten. Afhankelijk 
van de locatie kan dit leiden tot bijvoorbeeld een hart- of herseninfarct.
Bij acute complicaties zijn er verschillende opties om de bloedtoevoer te herstellen. 
Eén daarvan is om te dotteren. Hierbij wordt er gebruik gemaakt van een soort 
ballon die opgepompt wordt binnen het bloedvat om zodanig weer voldoende 
bloed naar het achterliggende weefsel toe te laten. In veel gevallen wordt er dan 
ook gebruik gemaakt van een stent (een soort veertje) dat in het bloedvat wordt 
geplaatst dat voorkomt dat het vat zich weer sluit na het dotteren. Indien de slag-
ader ernstig vernauwd of compleet afgesloten is, kan er ook gekozen worden voor 
een zogenaamde bypass operatie. Hierbij wordt een ader uit een ander deel van 
het lichaam verwijderd en wordt hiermee een omleiding van de bloedtoevoer naar 
het afgesloten weefsel gemaakt. Een andere operatieve behandeling houdt in dat 
de complete laesie verwijderd wordt door middel van een endarterectomie. Al deze 
invasieve methoden hebben als nadeel dat ze vaak door de chirurgische handelin-
gen ook schade aan het bloedvat leveren. Deze schade heeft weer ten gevolg dat de 
kans op een nieuwe vernauwing, restenose, zeer groot is. Hierom en vanwege de niet 
geringe risico’s die gepaard gaan met deze ingrepen, blijft het voorkomen van acute 
cardiovasculaire complicaties van zeer groot belang.
Hiertoe is een verandering in levensstijl is vaak een eerste optie, gezien veel 
patiënten in de huidige Westerse maatschappij blootgesteld zijn aan een groot 
aantal risicofactoren (alcoholgebruik, roken, sedimentaire levensstijl, overgewicht). 
Ten tweede wordt er vaak gebruikt gemaakt van cholesterol verlagende middelen, 
meestal in de vorm van statines. Statines remmen de aanmaak van cholesterol in 
de lever en zijn de reden dat er een sterke afname in cardiovasculair-gerelateerde 
sterfgevallen zijn sinds de jaren 80. Er is gebleken dat ze het risico op hart- en 
vaatziekten met circa 25% verminderen. Vrij recent zijn er nieuwe middelen op de 
markt gekomen die cholesterol niveaus kunnen verminderen via het remmen van 
PCKS9. Dit eiwit zorgt voor de afbraak van de receptor voor het slechte cholesterol, 
de LDL receptor. Door dit eiwit te blokkeren, zijn er meer LDL receptoren die LDL 
wegvangen uit de bloedsomloop en waardoor de cholesterol concentratie wordt 
verlaagd. Ondanks de grote successen die behaald zijn met cholesterol verlagende 
middelen, hebben ze als groot nadeel dat ze bestaande laesies niet of nauwelijks 
beïnvloeden. Over het algemeen krijgen patiënten pas symptomen (en dus behan-
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deling) op het moment dat de laesies al vrij groot zijn geworden en er al een heftige 
immuunrespons plaatsvindt binnen het bloedvat. Naast de cholesterolverlagende 
middelden is het immuunsysteem daarom een tweede belangrijke pijler waarop men 
therapeutisch in kan grijpen bij aderverkalking. Deze ontstekingstheorie heeft in de 
afgelopen decennia veel aandacht gekregen in de onderzoekswereld. Een belangri-
jke mijlpaal werd vrij onlangs bereikt toen een grote klinische studie aantoonde dat 
het remmen van de ontstekingsfactor interleukine-1β resulteerde in 15% minder 
sterfgevallen als gevolg van een cardiovasculaire complicatie. Dit onderzoek bewees 
dat de ontstekingstheorie van aderverkalking ook daadwerkelijk succesvol vertaald 
kon worden naar een klinische therapie. Echter, vergeleken met het onderzoek naar 
cholesterolverlagende middelen, staat het onderzoek naar het immuunsysteem voor 
de behandeling van hart- en vaatziekten nog in de kinderschoenen en valt er nog 
veel winst te boeken. Dit onderstreept duidelijk het belang van verder onderzoek 
naar de invloed van specifieke immuun cellen en ontstekingsfactoren op de ontwik-
keling van atherosclerose.
Het immuunsysteem
Het immuunsysteem is de belangrijkste verdediging van het lichaam tegen externe 
en interne ziekteverwekkers of schadelijke processen. Een van de belangrijkste 
taken hierbij is om onderscheid te kunnen maken tussen lichaamseigen en niet-
lichaamseigen cellen en moleculen. De wijze waarop immuun cellen dit onderscheid 
kunnen maken verdeelt het immuunsysteem grofweg in twee takken: aangeboren of 
aspecifieke immuniteit en verworven of specifieke immuniteit.
Vrijwel alle organismen bezitten een vorm van het aangeboren immuunsysteem. 
Deze aspecifieke immuniteit herkent met behulp van speciale receptoren patronen 
en structuren die vaak voorkomen op bacteriën en/of virussen, maar kan hierbij 
geen onderscheid maken tussen specifieke pathogenen. Het grote voordeel van 
een dergelijk afweersysteem is dat het snel kan reageren op potentieel gevaar. De 
monocyten en macrofagen die al eerder benoemd waren zijn onderdeel van het 
aangeboren immuunsysteem, evenals de dendritische cel. Zowel macrofagen als 
dendritische cellen controleren de extracellulaire ruimtes en kunnen moleculen die 
niet in het lichaam thuis horen fagocyteren en zijn op die manier onderdeel van de 
eerstelijnsafweer. Daarnaast hebben zij nog een tweede zeer belangrijke functie, 
namelijk verbinding maken met cellen van de verworven immuniteit. Nadat een 
macrofaag of dendritische cel een bepaald niet-lichaamseigen molecuul heeft gefa-
gocyteerd, zorgt deze cel ervoor dat (gedeeltes van) dit molecuul aan de buitenkant 
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van zijn celmembraan op een herkenbare manier gepresenteerd worden aan cellen 
van de specifieke afweer. Daarom worden macrofagen en dendritische cellen ook 
wel antigeen-presenterende cellen genoemd.
Immuun cellen van de specifieke afweerreactie hebben over het algemeen hulp 
nodig van antigeen-presenterende cellen en deze reactie komt daarom ook lang-
zamer op gang dan de aangeboren afweer. De belangrijkste cellen van deze tak 
van het immuunsysteem zijn B- en T-lymfocyten. Deze B en T cellen zijn zeer 
gespecialiseerde ontstekingscellen zodat elk van deze cellen maar één specifiek 
molecuul kan herkennen. In de ontwikkeling van deze cellen wordt elke B of T cel 
die een lichaamseigen molecuul herkent verwijderd, waardoor er alleen B en T 
cellen overblijven die lichaamsvreemde antigenen herkennen. Zodra een antigeen-
presenterende cel moleculen presenteert op de buitenkant van zijn celmembraan 
en een B of T cel dat specifieke antigeen herkent, raakt de cel geactiveerd. Deze 
activatie leidt er voornamelijk toe dat de cel zich veelvuldig gaat delen, zodat er een 
grote populatie aan immuun cellen ontstaat dat dit antigeen herkent. Geactiveerde 
T cellen zorgen voornamelijk voor de afweer tegen pathogenen die zich binnenin 
cellen bevindt door ontstekingsfactoren uit te scheiden of door geïnfecteerde cellen 
direct kapot te maken.
B cellen daarentegen scheiden antistoffen uit die in het bloed circuleren en het 
specifieke antigeen kunnen neutraliseren. Nadat alle gevaarlijke antigen opgeruimd 
zijn door het immuunsysteem differentieert een kleine groep van specifieke B en T 
cellen zich tot geheugencellen. Deze populatie van geheugencellen kan zeer lang 
overleven in het lichaam en zorgt ervoor dat bij een volgende infectie met dit anti-
geen de specifieke afweerreactie veel sneller en sterker zal zijn. Dit geheugen van 
het specifieke afweersysteem vormt de basis van vaccinaties, waarbij een klein, niet 
gevaarlijk, gedeelte van een pathogeen wordt geïnjecteerd. De patiënt raakt hier 
niet ziek van, maar creëert wel een populatie geheugencellen zodat bij een daad-
werkelijke infectie, de patiënt beschermd is door een effectieve immuunreactie.
Dit proefschrift
Centraal in deze thesis staat de ontstekingstheorie van atherosclerose, waarbij er-
van uit gegaan wordt dat het remmen van de immuunreactie een gunstig effect zal 
hebben op het ziekte verloop. Het belangrijkste celtype dat dit proefschrift daarbij 
behandeld is de B cel. Het klassieke kenmerk van B cellen is zogezegd de productie 
van antistoffen of antilichamen. In de laatste decennia is de niet-klassieke rol van B 
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cellen desalniettemin steeds duidelijker geworden. Zo zijn B cellen bijvoorbeeld ook 
zeer goed antigeen-presenterende cellen en kunnen ze een grote verscheidenheid 
aan ontstekingsmediatoren uitscheiden. Daarnaast zijn er ook nieuwe type B cellen 
gevonden, waarvan het onbekend was welke rol deze speelden in de pathofysiologie 
van aderverkalking. In dit proefschrift is geprobeerd op verschillende manieren B 
cellen te beïnvloeden waarbij we ons geconcentreerd hebben op de nieuwe type B 
cellen en niet-klassikale functies om te onderzoeken wat hiervan het effect zou zijn 
op aderverkalking,
In hoofdstuk 2 hebben we het laatste onderzoek naar de rol van B cellen bij 
aderverkalking samengevat en zijn we specifiek ingegaan op potentiele functies 
van nieuwe type B cellen. B cellen kunnen over het algemeen in twee verschil-
lende types onderscheiden worden: B1 en B2 cellen. B2 cellen komen veruit het 
meeste voor en ontwikkelen zich in het beenmerg en circuleren vervolgens in het 
bloed en lymfoïde organen, zoals de milt. Hier ontwikkelen de meeste B2 cellen 
zich verder tot folliculaire B cellen, terwijl een kleinere populatie differentieert in 
marginale zone B cellen. Deze verschillende type B2 cellen reageren op andere 
stimuli en hebben ook een verschillend effect op aderverkalking. Alle B cellen bezit-
ten een specifieke receptor die grotendeels bestaat uit een antistof dat zich in het 
celmembraan bevindt. Wanneer deze receptor zijn specifieke antigeen herkent en 
bindt, is dat het eerste activatiesignaal voor een B cel. De B cellen fagocyteren ver-
volgens het gebonden antigeen en presenteren gedeeltes ervan aan de buitenkant 
van het celmembraan. Voor de activatie van folliculaire B cellen is het noodzakelijk 
dat een naburige T cel ook het gepresenteerde antigeen herkent. Deze T cel zal 
vervolgens ook geactiveerd raken en een verscheidenheid aan mediatoren en stof-
fen uitscheiden die het tweede activatiesignaal vormen voor de B cel. De B cellen 
zullen vervolgens gaan delen en via complexe selectieprocedure, waarbij T cellen 
wederom een belangrijke rol spelen, ontstaat er een populatie van B cellen met een 
receptor die zeer specifiek en met een hoge affiniteit aan het antigeen kan binden. 
Deze populatie ondergaat vervolgens een verandering waarbij het grootste gedeelte 
differentieer in plasma cellen, wat feitelijk cellen zijn die zeer grote hoeveelheden 
antistoffen uitscheiden om het antigeen te neutraliseren. De overige B cellen zullen 
differentiëren in geheugen B cellen. In aderverkalking nog niet volledig bekend wel 
antigeen verantwoordelijk is voor de immuunreactie. Er wordt vaak aangenomen 
dat het belangrijkste eiwit in LDL, het ApoB100 eiwit, het meest bijdraagt aan de 
immuunreactie. Onderzoek heeft uitgewezen dat er inderdaad antistoffen tegen 
ApoB100 gemaakt kunnen worden, maar er is nog geen duidelijke consensus of dat 
deze antistoffen bijdragen aan verslechtering van de ziekte. Dit komt mede doordat 
er een grote verscheidenheid aan verschillende type antilichamen zijn. Folliculaire B 
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cellen scheiden met name antilichamen uit van het IgG type. Alhoewel hier ook nog 
geen sluitend bewijs voor is, wijst de meeste data er op dat deze type antistoffen 
atherosclerose verergeren. In ieder geval is het vanuit onderzoek wel duidelijk dat 
folliculaire B cellen bijdragen aan de ontwikkeling van aderverkalking, aangezien 
verwijdering van deze B cellen leidt minder aderverkalking optreedt. Niettemin is 
het exacte mechanisme hierachter nog niet geheel duidelijk.
Terwijl folliculaire B cellen afhankelijk zijn van de hulp van T cellen, kunnen marginale 
zone B cellen ook reageren op antigeen zonder T cellen. Onlangs is gebleken dat 
deze marginale zone B cellen juist beschermend werken bij aderverkalking. Ditzelfde 
geldt voor de B1 cellen. Deze B1 cellen ontwikkelen zich niet vanuit het beenmerg 
zoals B2 cellen, maar vanuit de lever van de foetus. Een belangrijke eigenschap van 
B1 cellen is dat ze ook zonder antigeen grote hoeveelheden antistoffen uitscheiden 
van het type IgM. Deze antilichamen kunnen een groot scala aan antigenen binden, 
waaronder oxLDL. Onderzoek wijst uit dat neutralisatie van oxLDL door deze na-
tuurlijke antilichamen een groot onderdeel is van de beschermende functie achter 
B1 cellen.
Naast deze indeling in B1 en B2 cellen zijn we in hoofdstuk 2 ingegaan op nieuwe 
subsets van B cellen, die vaak niet geheel binnen deze B1/B2 classificatie vallen. 
Het belangrijkste subtype wat wij hier behandeld hebben is de zogenaamde regu-
latoire B cel. Het immuunsysteem heeft bepaalde mechanismen ingebouwd waarbij 
het zichzelf kan reguleren in het geval het gevaar geweken is of indien er geen 
actieve immuunrespons gewenst is. Het meest bekend en veruit het meest intensief 
onderzochte type cel in dit aspect is de regulatoire T cel. Dit type T cel kan door 
bijvoorbeeld de secretie van de remmende mediatoren zoals interleukine-10 de 
activatie van overige immuun cellen remmen. In de afgelopen jaren heeft onderzoek 
aangetoond dat er binnen de B cellen ook een dergelijk type B cel bestaat dat het 
immuunsysteem kan remmen. Er zijn verscheidene manieren waarop deze B cellen 
functioneren, maar de bijdrage van deze verschillende functies en type B cellen aan 
de ontwikkeling van aderverkalking was nog geheel onbekend.
In hoofdstuk 3 zijn wij daarom gaan onderzoeken wat het effect is van B cellen 
die interleukine-10 kunnen uitscheiden op de ontwikkeling van atherosclerose. 
Gezien het overtuigende bewijs dat regulatoire T cellen die interleukine-10 aan-
maken beschermend zijn, was onze hypothese dat deze regulatoire B cellen dat 
ook zouden zijn. Ons eerste experiment bestond uit het observeren van het aantal 
interleukine-10 producerende B cellen in gezonde en atherosclerotische muizen. 
We vonden dat de zieke muizen significant minder van deze B cellen hadden dan 
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gezonde muizen. Omdat dit uitwees dat bij het ontwikkelen van aderverkalking 
de populatie regulatoire B cellen afnam, besloten wij om te proberen om deze 
populatie in stand te houden tijdens een tweede experiment. Hiertoe ontwikkelden 
we een kweekprotocol waarmee we in vitro aan grote hoeveelheden van interleu-
kine-10 producerende B cellen konden komen. Deze injecteerden we tijdens de 
loop van het experiment een aantal keer in één groep muizen. Aan het einde van 
het experiment vergeleken we het immuunsysteem van deze muizen, met het im-
muunsysteem van muizen die ofwel geen B cellen hadden gekregen of B cellen die 
geen interleukine-10 kunnen produceren. De eerste resultaten waren veelbelovend; 
het immuunsysteem in de muizen die interleukine-10 producerende B cellen kregen 
was duidelijk geremd. We zagen een afname in het aantal ontstekingscellen, een 
afname in de T cel activatie en juist een toename in het aantal regulatoire T cellen. 
Toen we echter de mate van aderverkalking bepaalden zagen we dat dit uiteindelijk 
niet het volledig gewenste effect had bewerkstelligd. De muizen die waren geïnjec-
teerd met B cellen die geen interleukine-10 kunnen uitscheiden, hadden een sterke 
verergering van aderverkalking. Deze observatie was nog volgens de hypothese, 
aangezien deze niet-interleukine 10 producerende B cellen feitelijk folliculaire B cel-
len zijn. Niettemin zagen we dat de muizen die de interleukine-10 producerende B 
cellen hadden ontvangen geen extra bescherming hadden ondervonden; zij toonden 
dezelfde mate van aderverkalking als muizen die geen B cellen hadden gekregen. 
Verdere analyse vertoonde tot onze initiële verbazing dat zowel de muizen die de 
niet-interleukine 10 producerende B cellen als wel de muizen die de interleukine 10 
producerende B cellen hadden gekregen, een significante verhoging van cholesterol 
hadden. Zoals besproken is cholesterol een zeer belangrijke determinant voor de 
mate van aderverkalking, dus deze bevinding zou kunnen verklaren waarom we 
ondanks de remming van het afweersysteem geen effect op aderverkalking zagen 
met de interleukine-10 producerende B cellen. Verdere experimenten suggereerden 
dat dit effect op cholesterol mogelijk door ons kweekprotocol zou kunnen komen. 
Uit het gehele hoofdstuk kunnen we concluderen dat interleukine-10 producerende 
B cellen minder aanwezig zijn in atherosclerotische muizen en dat injectie van deze 
cellen leidt tot remming van het afweersysteem. Niettemin had dit geen effect op 
aderverkalking, wellicht doordat deze effecten gemaskeerd werden door een verho-
ging in cholesterol.
In hoofdstuk 4 hebben we op een andere manier geprobeerd om interleukine-10 
producerende B cellen te beïnvloeden. Eerder onderzoek had aangetoond dat 
een specifiek eiwit genaamd TIM-1 erg belangrijk was voor de ontwikkeling van 
B cellen tot regulatoire B cellen. Muizen die dit eiwit missen hebben vrijwel geen 
interleukine-10 producerende B cellen. Via een speciale virusinjectie hebben wij de 
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ontwikkeling van aderverkalking in deze muizen die TIM-1 missen (TIM1–) kunnen 
vergelijken met normale wild-type (WT) muizen. We observeerden inderdaad dat 
deze TIM1– muizen een verminderd aantal regulatoire B cellen hadden ten opzichte 
van WT muizen. Dit ging ook gepaard met een toename van B en T cellen in de milt. 
Ook de immuunreactie van de T cellen was opgeschoven naar een meer schadelijke 
response. Gezamenlijk leidde dit uiteindelijk tot een sterke toename van aderver-
kalking in TIM1– muizen ten opzichte van WT muizen. Het TIM-1 eiwit bevindt zich 
niet alleen op B cellen en de verwijdering van TIM-1 in deze muizen kan ook ef-
fecten hebben gehad op andere cel populaties. Evengoed suggereert deze data dat 
TIM-1 een belangrijk eiwit is bij de ontwikkeling van aderverkalking en dat dit effect 
gemedieerd wordt via regulatoire B cellen.
Een andere regulatoire B cel populatie hebben we in hoofdstuk 5 onderzocht. Hier 
hebben we ons geconcentreerd op B cellen die het eiwit PD-L1 hoog tot expres-
sie brengen. Dit eiwit kan binden aan PD-1 op T cellen, wat er vervolgens voort 
zorgt dat deze T cel geremd wordt in zijn functie. De meeste T cellen die PD-1 tot 
expressie brengen zijn zogenaamde folliculaire T helper cellen, die hulp bieden aan 
folliculaire B cellen bij het ontwikkelen tot plasma cellen. Aangezien het bekend 
is dat deze folliculaire B cellen aderverkalking verergeren, stelden wij dat B cellen 
met hoge PD-L1 expressie wellicht zouden kunnen leiden tot een vermindering van 
aderverkalking. Deze PD-L1hi B cellen komen vrij weinig voor daarom zijn wij op 
zoek gegaan naar een methode om PD-L1 op meer B cellen tot expressie te bren-
gen. Wij vonden dat wanneer B cellen vierentwintig uur werden gestimuleerd met 
de stof interferon-gamma, dat vrijwel alle B cellen PD-L1 gingen aanmaken en dat 
het overgrote gedeelte zeer veel PD-L1 tot expressie bracht. Deze cellen hebben 
we vervolgens zowel in vitro als in vivo getest om te onderzoeken of ze inderdaad 
folliculaire helper T cellen konden remmen en in beide situaties ondervonden we dat 
deze cellen zeer effectief waren hierin. Vervolgens hebben deze cellen geïnjecteerd 
in muizen om het effect hiervan op aderverkalking te evalueren. Wij zagen toen 
dat de totale verdikking in de aderen van muizen die de interferon-gamma gesti-
muleerde B cellen hadden gekregen significant minder was dan muizen die deze 
B cellen niet hadden gekregen. Vergeleken met muizen die niet-gestimuleerde B 
cellen hadden gekregen was het verschil net niet statistisch significant, maar ook 
duidelijk aanwezig. Kortom, stimulatie van B cellen met de stof interferon-gamma 
resulteerde in hoge expressie van PD-L1 waarmee folliculaire helper T cellen konden 
worden geremd en aderverkalking werd verminderd.
In hoofdstuk 6 hebben we een andere manier gebruikt om de B cel reactie te mo-
duleren. Activatie van B en T cellen vereist naast het antigeen vaak nog een twee 
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signaal via co-receptoren. Dit signaal komt vaak van antigeen-presenterende cellen 
en kan zowel stimulerend als remmend werken. Een redelijk recent beschreven co-
receptor is BTLA (B- and T-lymphocyte attenuator) dat een remmende functie heeft. 
Deze remmende co-receptoren zijn interessant voor de mogelijke behandeling van 
aderverkalking, omdat wanneer het lukt deze remmende functie te versterken, het 
immuunsysteem wordt gedempt en aderverkalking wellicht afneemt. In de eerste 
experimenten gingen wij onderzoeken op welk type cellen BTLA tot expressie kwam. 
We zagen zowel in de mens als de muis dat BTLA voornamelijk op B cellen voor-
kwam en specifiek op de folliculaire B cellen. Daarom kozen wij ervoor om muizen 
te behandelen met een antilichaam dat bindt aan BTLA en de remmende werking 
van BTLA in gang zet. Behandeling van muizen met dit specifieke antilichaam zorgde 
ervoor dat de folliculaire B cellen zeer sterk afnamen, terwijl beschermende B cel 
populaties zoals de B1 cellen en interleukine-10 producerende B cellen in aantallen 
niet afnamen. Dit resulteerde feitelijk in dat de B cel populatie overwegend uit be-
schermende B cellen bestond in de behandelde muizen. Verdere analyse toonde aan 
dat de gehele immuunrespons en met name de T cel reactie verschoof richting een 
meer beschermend karakter. Evaluatie van aderverkalking wees uit dat het gebruikte 
BTLA antilichaam aderverkalking had geremd ten opzichte van geen behandeling of 
behandeling met een controle antilichaam. In een andere proef bekeken we ook het 
effect van dit BTLA antilichaam op al bestaande laesies. We ondervonden dat de 
laesies niet kleiner werden, maar wel stabieler wat evengoed een zeer belangrijke 
parameter is. In dit hoofdstuk konden we concluderen dat stimulatie van BTLA met 
een antilichaam er voor zorgt dat folliculaire B cellen worden geremd en dat dit een 
gunstig effect heeft op de ontwikkeling van aderverkalking.
In hoofdstuk 7 hebben wij een overkoepelende discussie geschreven over het totale 
werk wat in dit proefschrift aan bod komt. In het kort, concluderen wij hierin dat het 
onderzoek naar B cellen en aderverkalking enigszins is achtergebleven in de afge-
lopen jaren, terwijl er alle redenen toe zijn om dit onderzoek juist wel uit te voeren. 
De beschreven experimenten in dit proefschrift tonen namelijk aan dat B cellen een 
belangrijke rol spelen in de immuunreactie die optreedt tijdens aderverkalking en 
dat wanneer deze rol wordt gemoduleerd er duidelijke effecten optreden. Het bewijs 
dat hiervoor is aangevoerd in dit proefschrift is overwegend uitgevoerd in muizen 
en van een observerend karakter. Om deze resultaten te kunnen vertalen naar 
daadwerkelijke klinische toepassingen zal er in eerste instantie verder onderzoek 
gedaan moeten worden in kleine patiënt groepen of op humaan weefsel. Dat type 
onderzoek vergt vaak ook dat er nog meer mechanistische studies in muizen worden 
gedaan die dieper ingaan op de achterliggende werking van eventuele therapieën. 
Op dit moment zijn er al middelen voorhanden die B cellen kunnen depleteren of 
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verwijderen in mensen. Deze worden al toegepast voor de behandeling van met 
name reuma, maar nog niet voor cardiovasculaire ziekten. Wel zijn er al preliminaire 
aanwijzingen gevonden dat reuma patiënten die behandeld zijn met een dergelijk 
middel, minder risico lopen op hart- en vaatziekten. Het is aannemelijk dat deze mid-
delen die alle B cellen remmen of verwijderen als eerste toegepast zullen worden in 
de klinische setting voor hart- en vaatziekten. Echter laat het bewijs uit de literatuur 
en in dit proefschrift zien dat het van essentieel belang is om specifieke subsets te 
remmen dan wel te stimuleren. Daarnaast hebben alle experimenten in deze thesis 
de B cel reactie beïnvloedt, maar niet of nauwelijks de antilichaam productie van B 
cellen. Dit benadrukt de grote invloed van niet-klassikale functies van B cellen in het 
algemeen en in de context van atherosclerose.
Het doet me deugd om te zien dat er tijdens het werken aan deze thesis langzamer-
hand weer meer en meer publicaties verschijnen die eenzelfde invalshoek hebben 
als het werk in dit proefschrift. Dit geeft aan dat de rol van B cellen in aderverkalking 
in de onderzoek community meer aandacht krijgt en de experimenten in dit proef-










Douna, Hidde, Jacob Amersfoort, Frank H. Schaftenaar, Sanne Kroon, Gijs H. M. van 
Puijvelde, Johan Kuiper, en Amanda C. Foks. 2019. “Bidirectional effects of IL-10+ 
regulatory B cells in Ldlr−/− mice”. Atherosclerosis 280 (januari): 118–25. https://doi.
org/10.1016/j.atherosclerosis.2018.11.019.
Douna, Hidde, en Johan Kuiper. 2016. “Novel B-Cell Subsets in Atheroscle-
rosis”: Current Opinion in Lipidology 27 (5): 493–98. https://doi.org/10.1097/
MOL.0000000000000335. (Review)
Douna, Hidde, B. M. Bavelaar, H. Pellikaan, B. Olivier, en T. Pieters. 2012. “Neuro-
protection in Parkinson’s Disease: A Systematic Review of the Preclinical Data.” The 
Open Pharmacology Journal 6: 12–26. (Review)
Amersfoort, J., F. H. Schaftenaar, Hidde Douna, P. J. van Santbrink, M. J. Kröner, G. 
H. M. van Puijvelde, P. H. A. Quax, J. Kuiper, en I. Bot. 2018. “Lipocalin-2 Contributes 
to Experimental Atherosclerosis in a Stage-Dependent Manner”. Atherosclerosis 275 
(augustus): 214–24. https://doi.org/10.1016/j.atherosclerosis.2018.06.015.
Amersfoort, Jacob, Hidde Douna, Frank H. Schaftenaar, Amanda C. Foks, Mara J. 
Kröner, Peter J. van Santbrink, Gijs H. M. van Puijvelde, Ilze Bot, en Johan Kuiper. 
2018. “Defective Autophagy in T Cells Impairs the Development of Diet-Induced 
Hepatic Steatosis and Atherosclerosis”. Frontiers in Immunology 9: 2937. https://doi.
org/10.3389/fimmu.2018.02937.
Perez-Pardo, Paula, Hemraj B. Dodiya, Laus M. Broersen, Hidde Douna, Nick van 
Wijk, Sofia Lopes da Silva, Johan Garssen, Ali Keshavarzian, en Aletta D. Kraneveld. 
2018. “Gut-Brain and Brain-Gut Axis in Parkinson’s Disease Models: Effects of a 
Uridine and Fish Oil Diet”. Nutritional Neuroscience 21 (6): 391–402. https://doi.org/
10.1080/1028415X.2017.1294555.
Douna, Hidde, Jacob Amersfoort, Frank Schaftenaar, Mate Kiss, Bianca Suur, Mara 
Kroner, Christoph Binder, Ilze Bot, Gijs van Puijvelde, Johan Kuiper en Amanda 




Douna, Hidde, V. Smit, G.H.M. van Puijvelde, M. J. Kröner, T. van der Heijden, M. G. 
Kiss, C. J. Binder, I. Bot, V. Kuchroo, A.H. Lichtman, J. Kuiper, A.C. Foks. TIM-1 mucin 
domain-mutant mice display exacerbated atherosclerosis. Manuscript submitted.
Douna, Hidde, J. Amersfoort, F. H. Schaftenaar, M. J. Kröner, M. B. Kiss, B. Slütter, 
M. A. C. Depuydt, A. Wezel, H. Smeets, H. Yagita, C. J. Binder, I. Bot, G.H.M. van 
Puijvelde, J. Kuiper, A.C. Foks. BTLA stimulation protects against atherosclerosis by 
regulating follicular B cells. Manuscript submitted.
Amersfoort J, Douna H, Schaftenaar FH, van Santbrink PJ, van Puijvelde GHM, Slüt-
ter B, Foks AC, Harms A, Moreno-Gordaliza E, Wang Y, Hankemeier T, Bot I, Chi H, 
Kuiper J. Diet-induced dyslipidemia induces metabolic and migratory adaptations in 
regulatory T cells. Manuscript submitted.
Published abstracts
Douna, Hidde, Jacob Amersfoort, Frank Schaftenaar, Gijs van Puijvelde, Johan 
Kuiper, en Amanda Foks. 2018. “Stimulation of the Co-Inhibitory BTLA Pathway 
Protects Against Atherosclerosis by Selectively Reducing Atherogenic B Cells”. 
Atherosclerosis Supplements 32 (juni): 89. https://doi.org/10.1016/j.atherosclerosis-
sup.2018.04.272.
Perez-Pardo, Paula, Hidde Douna, Tom Wijnands, Sofia Lopes da Silva, Christopher 
B. Forsyth, Hemraj B. Dodiya, Johan Garssen, Berend Olivier, Ali Keshavarzian, en 
Aletta D. Kraneveld. 2014. “247 The Role of Toll-Like Receptor-4 in Gut-Brain Cross 
Talk in a Murine Model of Parkinson’s Disease”. Gastroenterology 146 (5): S-59. 
https://doi.org/10.1016/S0016-5085(14)60206-7.
Schaftenaar, Frank, Jacob Amersfoort, Hidde Douna, Mara Kröner, Bram Slütter, 
Ilze Bot, Gijs van Puijvelde, en Johan Kuiper. 2018. “Vaccination with ApoB100 
Derived HLA-A2 Restricted CD8 T Cell Epitopes Did Not Reduce Atherosclerosis in 






2015 LACDR Data management course
2015 On being a scientist (ethics in science)
2014 Introduction to teaching and supervision
2014 Communication in Science
2014 PhD Introductory course on drug research
Presentations
2018 International Symposium on Atherosclerosis, Toronto, Canada
2018 Scandinavian Society for Atherosclerosis Research, Humblebæk, Denemarken
2018 LACDR spring symposium, Leiden, Nederland
2017 Scandinavian Society for Atherosclerosis Research, Humblebæk, Denemarken
2017 LACDR spring symposium, Leiden, Nederland
2017 Rembrandt symposium, Noordwijkerhout, Nederland
2016 LACDR spring symposium, Leiden, Nederland
2016 Scandinavian Society for Atherosclerosis Research, Humblebæk, Denemarken
2015 Rembrandt symposium, Noordwijkerhout, Nederland
2015 LACDR spring symposium, Leiden, Nederland
2014 Rembrandt symposium, Noordwijkerhout, Nederland
2014 LACDR spring symposium, Leiden, Nederland
Teaching
2018 Supervision of MSc internship – Sanne kroon
2017 BSc course Therapeutic modulation of atherosclerosis
2017 Supervision of BSc internships – Emma Pool and Tamar Woudenberg
2017 Supervision of MSc internship – Lars Koeken
2016 BSc course Therapeutic modulation of atherosclerosis
2016 BSc course Geneesmiddel Toediening en afgifte
2016  Supervision of BSc internships – Louise Tambyrajah and Mallory van den 
Heuvel
2016 Supervision of MSc internship – Bianca Suur
2015 Supervision of BSc internships – Bianca Suur and Arlette Quaedvlieg
2015 BSc course Therapeutic modulation of atherosclerosis
2015 BSc course Geneesmiddel Toediening en afgifte
2014 Supervision of BSc internship – Rianne de Zwart
2014 BSc course Geneesmiddel Toediening en afgifte





Hidde Douna werd geboren op 16 december 1988 in Hoorn. In juni 2007 behaalde 
hij zijn gymnasium diploma cum laude aan het Stedelijk Gymnasium te Leiden. In dat-
zelfde jaar begon hij aan de studie Natuurwetenschappen & Innovatiemanagement 
aan de Universiteit Utrecht. Hij behaalde zijn propedeuse in 2008 en besloot toen 
verder te gaan met de bachelor Farmacie, eveneens aan de Universiteit Utrecht. 
Hij behaalde de Bachelor of Science graad cum laude in juli 2011 en vervolgde zijn 
opleiding met de master Drug Innovation. Van januari tot september 2012 deed hij 
zijn eerste masterstage bij het Utrecht Institute for Pharmaceutical Sciences onder 
begeleiding van dr. C. Rietveld en prof. dr. A. Kraneveld. Deze stage werd afgesloten 
met een verslag getiteld: “Emerging concepts of the enteric nervous system: Toll-like 
receptors and Parkinson’s disease”. Van januari 2013 tot juli 2013 voerde hij een 
tweede wetenschappelijke stage uit waarvan drie maanden bij het Rush University 
Medical Center in Chicago. De titel van het onderzoeksproject was: “Rotenone in 
Parkinson’s Disease: from gut to brain and back again” en heeft geleid tot een publi-
catie in het blad Nutritional Neuroscience. Zijn thesis heeft hij onder begeleiding van 
prof. dr. J. Kuiper uitgevoerd aan de Universiteit Leiden getiteld: “Current state and 
optimizations for peptide-based vaccines against atherosclerosis”. De wetenschap-
pelijke stages en thesis hebben geleid tot het behalen van de Master of Science 
graad cum laude in maart 2014.
Van 2008 tot 2014 heeft hij eveneens deelgenomen aan het honours programme 
vanuit de studie Farmacie. In het kader hiervan heeft hij onder andere in samen-
werking met de Parkinson Vereniging een wetenschappelijke studie uitgevoerd dat 
geleid heeft tot een publicatie in het blad The Open Pharmacology Journal.
Van februari 2014 tot oktober 2018 was hij als promovendus werkzaam bij de 
afdeling BioTherapeutics van het Leiden Academic Centre for Drug Research onder 
begeleiding van dr. A.C. Foks, dr. G.H.M. van Puijvelde en prof. dr. J. Kuiper. Voor 
het presenteren van zijn onderzoek ontving Hidde in 2017 zowel de prijs voor beste 
orale presentatie op het Rembrandt Symposium als de prijs voor beste wetenschap-
pelijke poster op de Annual Meeting van de Scandinavian Society for Atherosclerosis 
Research.
Sinds 15 maart 2019 is hij in dienst van Novartis Pharma B.V. en werkzaam in het 
cardio-metabolic team als Medical Scientific Liaison.
